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QUOTATIONS 
 
“Modern science is founded on the belief that knowledge, as it progresses, accumulated new and 
improved concepts driving out the old and the fallible. It prides itself on being objective and 
rigorous; yet it fails to recognize that there can be other systems of thought. Phytotherapy, or 
herbal medicine, believes in the harmonious view that ‘the whole plant is greater than the sum of 
its parts’. Some of the wonder drugs of modern medicine have their roots in indigenous 
medicine.” 
 
 
   by Dr. U Ko Ko, 1991 
        Regional Direction        
        World Health Organization 
 
 
 
“The principal ingredient of the plant or herb is a substance that provides the main therapeutic 
thrust, the other ingredients enhance or assist the therapeutic actions of the first.” 
      
       
by Yuan & Lin, 2000 
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QUOTATIONS 
 
“Modern science is founded on the belief that knowledge, as it progresses, accumulated new and 
improved concepts driving out the old and the fallible. It prides itself on being objective and 
rigorous; yet it fails to recognize that there can be other systems of thought. Phytotherapy, or 
herbal medicine, believes in the harmonious view that ‘the whole plant is greater than the sum of 
its parts’. Some of the wonder drugs of modern medicine have their roots in indigenous 
medicine.” 
 
 
   by Dr. U Ko Ko, 1991 
        Regional Direction        
        World Health Organization 
 
 
 
“The principal ingredient of the plant or herb is a substance that provides the main therapeutic 
thrust, the other ingredients enhance or assist the therapeutic actions of the first.” 
      
       
by Yuan & Lin, 2000 
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Summary 
 
Traditional and alternative medicines which are derived from wide range of plants, animals and 
minerals are used in the treatment of many disease conditions. Numerous studies have 
demonstrated that natural products are a rich source of novel compounds. There is a renewed 
interest in conducting studies to identify novel compounds with the potential to be developed 
into therapeutic agents. 
 
This thesis provides an insight into the key issues in TM/CAM which remains a big challenge for 
Brunei Darussalam. As a worldwide scenario, the regulatory and legislative control of TM/CAM 
varies from country to country. In most developed countries, well established systems are in 
place, whereas in others they are regarded as food or nutrition and often their therapeutic claims 
are not permissible by the regulatory authorities of the countries concerned. However, the 
communities of most developing countries often have a wide ranging numbers of traditionally 
used herbal medicines and folk-knowledge about them from generations to generations. It is also 
highlighted that the three criteria required to legislating a pharmaceutical into the market through 
a legal framework of registration are quality, safety and efficacy. Recent development in 
TM/CAM harmonization and collaborative processes also spearhead into promoting these 
important criteria on TM/CAM towards achieving safe delivery of health for all.  
 
There is an estimated 5,000 native species found in the tropical rain forests of Brunei 
Darussalam. Many medicinal plant species such as Andrographis paniculata (AP) have been 
long used by the local communities for the treatment of various disease conditions. However, so 
far little research has been done on the constituents or bioactivities of the native tropical 
 xxxix 
medicinal plants of Brunei Darussalam. It is likely that certain medicinal plants in Brunei 
Darussalam may have unique characteristics of secondary metabolites which are potential 
sources of therapeutic drugs. Therefore, prioritized research into these valuable medicinal plants 
in order to obtain valuable scientific information about the plants profile is necessary as they 
usually consist of many chemical constituents with highly complex pharmacological effects on 
the body. 
 
Therefore, the main aims of this project are focused on two challenges. The first challenge was to 
develop the strategic framework on TM/CAM for Brunei Darussalam and the second challenge 
was that an interdisciplinary and systematic approach has been undertaken to investigate the 
genetic diversity, phytochemical profile, bioactivities and pharmacological actions of the tropical 
native medicinal plant Andrographis paniculata (Burm. f.) Nees (HDM 15) of Brunei 
Darussalam.  
 
Firstly, the genetic diversity of Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam 
was determined by Random Amplified Polymorphic DNA (RAPD) and Restriction Fragment 
Length Polymorphism (RFLP) analyses. The genetic tree dendrogram was constructed based on 
the genetic variations generated by UPGMA followed by cluster analysis of two main clusters 
between the genotypes at maximum dissimilarity of 10%. Results indicated that the nine 
accessions from the three districts namely Brunei/Muara (Brunei AP), Kuala Belait (K.B.), 
Temburong (T) of Brunei Darussalam analysed in this study were found to be closely related to 
each other with only moderate variations. RAPD analysis demonstrated that it could be used 
effectively to survey the genetic variation of Andrographis species or varieties which will be 
beneficial in the characterisation and authentication of this tropical medicinal native plant of 
Brunei Darussalam. 
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Secondly the major phytochemical constituents Andrographolide (A) and 
Dehydroandrographolide (D) of Andrographis paniculata were determined by analytical High 
Performance Thin Layer Chromatography (HPTLC) and High Performance Liquid 
Chromatography (HPLC). The herbal samples collected from three districts namely 
Brunei/Muara (Brunei AP), Kuala Belait (KB), Temburong (T) of Brunei Darussalam compared 
with the Chinese Reference Sample herb (CRS) and Chuan Xin Lian (CXL) from China using 
the A and D reference standards to determine the levels of content of A and D respectively. 
Difference in the contents of A and D in these samples were observed. The content of A (%w/w) 
in Temburong and Brunei AP samples were higher than those from CXL, K.B. and Chinese 
Reference samples. On the contrary, the content of D (%w/w) in Temburong and Brunei AP 
samples were lower than that in CXL, K.B. and Chinese Reference samples. When combining A 
and D contents, the ranking order were Temburong, CXL, Brunei AP, Kuala Belait (KB) and 
Chinese Reference Sample. 
 
Thirdly, the pharmacological effects of different extracts of Andrographis paniculata (Burm. f.) 
Nees of Brunei Darussalam were studied in vitro. These include studies on their anti-oxidant, 
anti-tumour, anti-hepatotoxicity activities, as well as their effects against compound 48/80-
induced histamine release in rat peritoneal mast cells, and iNOS mediated smooth muscle 
relaxations in rat aorta tissues. Results showed that the aqueous (We), ethanol (Ee), methanol 
(Me) extracts of Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam exhibited some 
significant scavenging activities towards 1,1-diphenyl-2-picryhydrazyl (DPPH), hydroxyl 
radical, hydrogen peroxide and nitric oxide in the cell-free systems with the exception of the 
aqueous extract which did not show any significant DPPH scavenging activity. In rat peritoneal 
mast cells, the extracts only significantly inhibited the compound 48/80-induced histamine 
release at a higher level of 1mg/ml which suggests that the mast cells were less responsive to 
 xli 
Andrographis paniculata. In functional studies of the rat aortic rings treated with LPS, 
Andrographolide and Dehydroandrographolide, the diterpenoid lactones of Andrographis 
paniculata, the ethanol extracts of Andrographis paniculata (Burm. f.) Nees of Brunei 
Darussalam exhibited a significant inhibition of the iNOS mediated relaxations. However, the 
aqueous extracts did not significantly inhibit iNOS responses. There is a correlation between the 
A and D contents and the inhibitory effects on iNOS responses in these extracts, indicating the 
important role of A and D in mediating the inhibitory actions of Andrographis paniculata on 
iNOS-mediated responses.  
 
The tumouricidal activity was assessed against six tumour cell lines including mouse 
lymphoblastic parental PAR (P388), ADR, WEHI-164, K562 (Human Tumour cells), P815 
(Mast cells), Yac-1 (T-Lymphoblastic) tumour cells. The general cytotoxicity against rat 
hepatocytes was assessed in freshly isolated rat hepatocytes.  
 
Andrographolide (Std A) has the most potent anti-tumourigenic activity which inhibited the 
growth of all the six tumour cells by 50%, the IC50 at a concentration range of 6-10µg/ml for 
P388, ADR, WEHI-164, K562, Yac-1 with the exception of the cell line P815 which showed less 
sensitivity to Std A, has a higher IC50 value of 100µg/ml. The other extract fractions tested 
indicated that some Andrographis paniculata fractions inhibited the growth of tumour cell lines 
with varying potency.  
 
It may suggest that the P815 cell line and the rat peritoneal mast cells are both derived from mast 
cells origin which was found to be less sensitive to Andrographis paniculata extract treatment. 
Possibly due to the fact that mast cells in general are less responsive to the treatment of 
Andrographis paniculata.  
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The general cytoxicity of the extract fractions were evaluated by assessing the viability of the rat 
hepatocytes in the presence of two reference standards namely Andrographolide (A), 
Dehydroandrographolide (D) and seven Andrographis paniculata crude extract fractions. Results 
showed that significant toxicity was observed in all fractions but at varying degrees of 
cytotoxicity potency of the tested extract concentration at 100µg/ml. The most cytotoxic of all 
the fraction extracts was Std A which has IC50 value of 60µg/ml at 50% inhibition of rat 
hepatocyte viability. At the concentration of 100µg/ml, the reference Std A, reducing rat 
hepatocyte viability by 68.78% ± 0.84%. At the concentrations tested indicated that all the 
fractions are moderately and relatively non cytotoxic. 
 
This result suggests that Andrographis paniculata leaves may contain other active constituents 
other than Andrographolide with varying levels of %w/w content which may account for its 
varying potency of the anti-tumourigenic and cytotoxic activities. Preliminary results indicated 
that further cytotoxicity tests on Andrographis paniculata is warranted which is required to be 
elucidated in the future studies.  
 
This finding offers support to the validity of the traditional medicine uses of this plant in which 
Andrographolide (A), the major active constituent of the extract of Andrographis paniculata 
(Burm. f.) Nees is a potential anti-cancer therapeutic agent. 
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In conclusion, the findings from the present project have demonstrated that Andrographis 
paniculata from Brunei Darussalam exhibited a distinctive genetic profile than the Andrographis 
paniculata from China. It has a wide range of anti-oxidant activities, pharmacological actions 
including anti-inflammatory and anti-tumour effects. Some of the pharmacological actions of 
Andrographis paniculata correlated with the active constituents Andrographolide (A) and 
Dehydroandrographolide (D). The findings have provided the first experimental evidence for this 
tropical medicinal native plant of Brunei Darussalam.
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1.1 Background 
 
Traditional medicine (TM) has a very long history. These remedies mostly discovered from 
generations of practice and use,  through trial and error, or simply by accident, had provided 
mankind with rich knowledge in plants, animals and minerals (Tyler, 1993) that has become part 
and parcel of life in many communities. It is also well documented that the world’s population 
relies upon natural products such as plants, animals and minerals based materials as the primary 
source of medicines for the treatment of disease conditions for many centuries. As officially 
endorsed by World Health Organization (WHO/EDM/TRM), ‘traditional medicine is the sum of 
total of the knowledge, skills and practices based on the theories, beliefs and experiences 
indigenous to different cultures, whether explicable or not, used in the maintenance of health, as 
well as in the prevention, diagnosis, improvement or treatment of physical and mental illnesses. 
The terms complementary/alternative/non-conventional medicine are used inter-changeably with 
traditional medicine in some countries.’  
  
The World Health Organization (WHO) estimated in 2003 that the global market of traditional, 
complementary and alternative medicine (TM/CAM) usage was approximately US$60 billion 
and is on a rapid increasing trend (Robson, 2003). Herbs or medicinal plants or other natural 
products are now becoming one of the world’s most important commodities that are used with 
the intention to diagnose, treat, prevent or cure diseases, by all means are defined as drugs. 
Therefore, like any other drugs, they must be administered in proper doses for the appropriate 
duration of time and the intended purposes based on advice from the qualified health 
professionals. To ensure that TM/CAM practices are developed in the directions towards 
safeguarding public health, the development of strategic framework on TM/CAM remains an 
important challenge to many countries including Brunei Darussalam.  
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1.1.1 Definition of TM/CAM  
 
In most developed countries, the term ‘complementary and alternative medicine’ (CAM) is 
usually used in the context where the dominant health care system is based on allopathic 
medicine, or where TM has not been incorporated into the national health care system. CAM has 
been recognised by many professionals and also non professionals in connection with health care 
needs. As a result of the paradigm shift, the term is used interchangeably as ‘traditional’, 
‘complementary’, ‘alternative’, ‘non conventional’, ‘contemporary’, ‘herbal’, ‘natural’, 
‘holistic’, ‘spiritual’ medicines with one common goal, that is to provide care to the patients, 
consumers and public at large. In the Bruneian context, the term TM/CAM encompass all the 
terms that are used on the basis of holistic approach.for the enhancement of health and quality of 
life of the communities. 
 
1.2 Use of traditional, complementary and alternative medicines (TM/CAM) 
  
More than 80% of the world population use botanical preparations as medicines, and herbalism 
is experiencing an unprecedented acceptance (Atherton, 1994; Haper, 1994). This is supported 
by the increasing economic scales such as in the U.S. market amounts to about $1.5 billion per 
year (Marwick, 1995) and thrice as much as this was spent in the European market (Brevoort, 
1996). In the developing world, similar trend was reported, such as in Malaysia, the annual 
market value of traditional remedies is about two billion ringgit which is twice as much as the 
amount spent on the pharmaceuticals (Balasubramaniam, 1998). The estimated national cost for 
both CAM preparations and practitioner visits were about one billion dollars when extrapolated 
to the Australian population and the increasing usage of CAM in the global market is 
overwhelming (Eisenberg et al., 1998; MacLennan et al., 1996; MacLennan et al., 2002). In the 
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recent national survey on the current usages of complementary medicines in Australia, 69% of 
the population used at least one of 17 forms of CAM in the last 12 months and for those used 
CAM, 64% of which consulted a CAM practitioner (Xue et al., 2005). The fact that China 
became a member of the World Trade Organization (WTO), had boosted the use of Chinese 
herbal medicines worldwide with a projected market value of $400 billion by 2010 (Zhen & Jun, 
2002).  
 
The use of TM/CAM in the primary health care of the world’s population is accounting for up to 
80% of the low and middle income countries. Among the higher income countries, TM/CAM has 
gained its popularity with up to 65% of the population reporting that they have been exposed to 
the utilization of TM/CAM (Ernst, 2000; WHO, 2002b). Table 1.1 illustrated the % of 
population used CAM in the selected developed countries as reported by World Health 
Organization. The current fusion processes involved in the harmonious approach towards 
achieving common goal in the maintenance of health for all by parties concerned is very 
encouraging. Therefore, by embracing the concept of traditional medicine, perhaps one can meet 
the challenges of the health care needs of the public at present and the future. As far as Brunei 
Darussalam is concerned, this concept remains the mainstay of traditional medicine in the 
country, alike many developing countries as illustrated in table 1.2 (WHO, 2002a). 
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Table 1.1 Percentage of population used TM/CAM at least once in selected developed 
countries (Source: WHO Traditional medicine Strategy 2002-2005) 
 
Developed Countries % of population  
Belgium 31% 
USA 42% 
Australia 48% 
France  49% 
Canada 70% 
 
 
Table 1.2 Percentage of population use of TM in Primary Health Care in selected 
developing countries (Source: TM-Growing Needs and Potential, WHO 
Policy Perspectives on Medicines, No. 2, May, 2002 Geneva)  
 
Developing Countries % of population  
Uganda 60% 
Tanzania 60% 
Rwanda 70% 
India 70% 
Benin 70% 
Ethiopia 90% 
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The increasing global popularity of TM/CAM has drawn much attention from government 
bodies, academia and health care professionals with their keen interest to better understand the 
quality, efficacy and safety of TM/CAM. Despite the economic momentum and the wide use of 
TM/CAM, the better informed public of today are also interested in the safe use of TM/CAM. 
Many international, regional and national conferences, symposiums, meetings, discussions were 
conducted to share important updated information, research and development on the 
harmonisation of TM/CAM and modern medicines. As TM/CAM is being used in tandem with 
western medicine globally, a better understanding between the both worlds of practices would 
bring us closer to provide better health care to the communities. 
 
1.3        Perception of TM/CAM 
 
TM/CAM is commonly recommended to relieve minor ailments and illnesses. They are usually 
considered to be natural and generally safe (Koh & Woo, 2000) from the consumer’s perspective 
but many people do not perceive them in the same way as they take allopathic medicines. Like 
any other medications, the medical practitioner’s advice is for the public to treat TM/CAM with 
respect (Botting & Cook, 2000) and they are needed to be used with care because they may not 
be suitable for others as there is ‘no one size fits all’ and individualised therapy approach to 
optimise the medical condition of the patient is to be advocated. Obviously, they are not free of 
side effects and can also interact with western medicines in either a synergistic or antagonistic 
manner and may result in compromising the medical conditions of patients.  
 
With the advancement in technology, the mass media promotion of TM/CAM has prompted the 
attention of health professionals on the benefit/risk ratio for patients. Young et al., (2001) 
examined the ethical and legal implications of the TM/CAM as requested to be used in the 
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mainstream intensive care practice by the better informed patients about their illness via 
accessing the internet which publicises and promotes the use of TM/CAM. As TM/CAM is 
distinguished by the lack of well conducted clinical trials in the determination of its efficacy and 
risks, as a result, decisions about its use cannot be based on benefit/risk analysis and genuine 
informed consent cannot be achieved which does not warrant its corporation in the intensive care 
practice (Young et al., June 2001). 
 
1.4 Legislative and regulatory control of TM/CAM  
  
In most countries, traditional medicine is regulated in an administrative framework to safeguard 
public health. In general, the regulatory control is less stringent than the legislative control on 
western medicines. The debate on whether traditional medicine should be subjected fully to 
conventional legal framework of legislative, regulatory and licensing procedures as imposed on 
the allopathic medicines in the assurance of quality, safety and above all, efficacy is still an on 
going agenda for discussions and research. 
 
1.4.1 TM/CAM in developed countries 
 
For most developed countries, the regulation and legislation on TM/CAM are changing rapidly 
for administering the appropriate course of direction. In the U.S., the Food and Drug 
Administration (FDA) classified the natural products as dietary supplements. Manufacturers 
must label these products on mandatory basis with a statement “this product has not been 
evaluated by the U.S. FDA and it is not intended to diagnose, treat, cure or prevent any disease,” 
whether products are foods or drugs is undecided (Rousseaux & Schachter, 2003). In Australia, 
the Therapeutic Goods Administration (TGA) regulates the quality, safety and efficacy of 
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traditional medicine (Briggs, 2005). The Australian Regulatory Guidelines for Complimentary 
Medicines (ARGCM) on the Evaluation of Complementary Medicine Substances constitutes a 
model scheme of listing and registration in the assessment of complementary medicines which 
are as rigorous as for pharmaceutical drugs (Therapeutic Goods Administration, 2005). The 
manufacturers (local or overseas) are required to comply with Good Manufacturing Practice 
(GMP) licences approved by the TGA to authenticate their starting materials, testing of the 
products and auditing the product performance for herbal products that are intended for sale in 
the market. This mechanism of control does not scrutinise the raw herbs dispensed by Chinese 
medicine practitioners in Australia (McEwen & Cumming, 2003).  
 
1.4.1.1 Official guidelines, codes of practices and pharmacopoeial standards  
for herbal medicinal products available online or publications 
  
There are various official guidelines, codes of practices, pharmacopoeial and monographic 
standards which have been established and aim to safeguard the quality, safety and efficacy of 
medicinal herbs based on the searchable databases in the website. These sites provide 
information which ranges from comprehensive scientific references, botanical sources, names & 
composition, commercial, sources of drugs, chemistry, reported traditional & modern uses, 
dosage range (both traditional & clinical trials), safety profiles, product information (availability, 
combinations, packaging, storage), pharmacology, pharmacokinetics and regulatory status. These 
are subject to revision with features as listed in Table 1.3. These standards are available and are 
useful reference sources for countries with limited resources.  
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Table 1.3 Guidelines/Codes/Pharmacopoeial/Monographic Standards  
No. Countries/Institutions  Guidelines/Codes/Pharmacopoeial Standards  Modified and/or adopted  
1 Australia Australian Code of Good Manufacturing Practice (GMP) for 
medicinal plants 
Guidelines on manufacturing of herbal medicinal products. 
2 India Ayurveda, Unani and Siddha Pharmacopoeia of India in two 
volumes 
Provide information on standards for 158 single plant drugs. The 3rd 
volume on 100 more single plant drugs is in preparation. 
3 United Kingdom British Herbal Pharmacopoeial standards Provides monographs of quality standards for 169 herbs as botanical drugs 
in U.K.  
4 Central Institute of 
Medicinal & Aromatic 
plants (CIMAP) 
Central Institute of Medicinal & Aromatic plants (CIMAP) 
Patents 
Provides information on patents filed, production processes, 
phytochemicals, development of herbal preparations & screening processes 
for biological activities of medicinal and aromatic plants. 
5 Australia Complementary Medicines-Therapeutic Goods Administratiorn 
(TGA), Australia 
Regulatory requirements of registration, evaluation, use of complementary 
medicines, GMP requirements, guidelines for labels, kinds of evidence to 
support indications, claims, alerts. 
6 Europe European Pharmacopoeia [Pharmacopoeial standards] in both 
English and French. 
4th Edition provides 1,606 monographs with 268 new monographs of active 
substances of pharmaceuticals for human, veterinary use, herbal drugs & 
homeopathic preparations. 
7 European Scientific Co-
operative on 
Phytotherapy (ESCOP) 
European Scientific Co-operative on Phytotherapy (ESCOP) 
Monographs on the Medicinal Uses of Plant Drugs 
[Monographic Standard] 
Provide information on scientific status, pharmacodynamics, 
pharmacokinetics and pre-clinical safety of phyto-medicines, their 
harmonization & regulation in Europe.  
8 Federal Trade 
Commission (FTC) 
Federal Trade Commission (FTC) Dietary Supplements: An 
Advertising Guide for Industry [Guidelines] 
Information on labelling & advertising claims by marketers under the 
DSHEA & FTC Act. 
9 WHO Final Draft: Good Manufacturing Practices: Supplementary Addressing the procedures & techniques in manufacturing & quality 
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Guidelines for the manufacturing of herbal medicinal products control of herbal medicines exclusively. 
10 Canada Health Canada Guidelines & Policies on Medicinal Herbs in 
Traditional Herbal Medicines [Good Manufacturing Practices 
guidelines] 
Provide expanded guidance & policies respecting traditional herbal 
medicines in Canada. 
11 India Homoeopathy Pharmacopoeia of India [Pharmacopoeial 
standards] 
Provides information on standards for the preparation & test of identity, 
quality & purity of Homoeopathic drugs based on American, German & 
British Homoeopathic pharmacopoeial principles & standards. 
12 International Conference 
on Harmonization (ICH)  
ICH-Good Manufacturing Practices for Active Pharmaceutical 
Ingredients [Good Manufacturing Practices guidelines] 
Provide guidelines on manufacturing of active pharmaceutical ingredients 
(APIs) from plant sources i.e. herbal extracts & comminuted or dried herbs 
in addition to other pharmaceutical ingredients.  
13 India Indian Herbal Pharmacopoeia revised edition 2002 
[Pharmacopoeial standards] 
-Two volumes of 40 monographs on 20 medicinal plants by 
IDMA in collaboration with Regional Research Laboratory 
(RRL), Jammu. 
New edition covers 52 monographs on Indian medicinal plants. Information 
on authentic data based scientific studies & investigations conducted by 
institutions & research laboratories. 
14 India Indian Patents on Neem [Patent] 
-Working on the issue at the core of a worldwide debate on who 
controls genetic resources-traditional cultures or transnational 
corporations  
Information on the patents filed on properties, active principles, their 
extraction & stabilizing processes in US and Japan. Granted over 30 
patents. 
15 International 
Pharmacopoeia  
International Pharmacopoeia [Pharmacopoeial standards] 
 
Provides information on physicochemical techniques, analytical & 
alternative methods, specifications & identification, purity and WHO 
Model List of Essential Drugs & Updates. 
16 United Kingdom Licensing of Medicines: Policy on Herbal Medicines [Good Provides information on regulatory requirements for licensing herbal 
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Manufacturing Practices guidelines] medicines & development of use in European Union (EU).  
17 India  Patent Facilitating Center (PFC) [Patent] Provides information about patents on processing & manufacturing of 
herbal medicinal products & their therapeutic uses. 
18 WHO Quality Assurance of Pharmaceuticals [Good Manufacturing 
Practices guidelines] 
Provides concise information about WHO good manufacturing practices of 
herbal medicinal products. 
19 United States of America The American Herbal Pharmacopoeia & Therapeutic 
Compendium-Analytical, Quality Control, & Therapeutic 
Monographs [Monographic standard] 
Provides information on safety & efficacy of botanicals used as dietary 
supplements & Chinese herbal medicines. 
 20 Germany The Complete German Commission E Monographs-Therapeutic 
Guide to Herbal Medicines 
Provides standards on quality, safety & efficacy of 190 herbs & phyto-
medicines in 380 monographs. Complete profile of the herbal monographs.  
21 Japan The Japanese Pharmacopoeia [Pharmacopoeial standards] 
 
Provides the official Japanese standard for the descriptions & the quality of 
drug substances & products. Also contain 173 monographs on herbal drugs. 
22 China The People’s of China Pharmacopoeia [Pharmacopoeial 
standards]-Two volumes 
The official & authoritative compendium of drugs of 992 monographs of 
Traditional Chinese Medicines & Western Drugs.  
23 United States of America United States Patents & Trademark Office (USPTO) Database 
[Patent] 
Searchable database for patent information on herbal medicinal products & 
plant derived drugs in addition to drugs from other sources. 
24 United States of America United States Pharmacopoeia [Pharmacopoeial standards] Provides standard of more than 54 plant extracts & botanical dosageforms. 
Information on Status of USP-NF Botanical Monograph Development & 
Dietary Supplements Information Monographs. 
25 WHO WHO Guidelines on Good Agricultural & Collection Practices 
(GACP) for Medicinal Plants 
Provides general technical guidance on obtaining medicinal plant materials 
of good quality for sustainable production of herbal products. 
26 WHO WHO Monographs on Selected Medicinal Plants [Monographic 
standards] 
Comprehensive scientific reference for developing countries to develop 
national monographs on medicinal plants. 
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1.4.2 TM/CAM in developing countries 
 
Therefore, with the existing framework of regulatory and legislative control on TM/CAM, 
developed and developing countries experience issues which may be similar or different in 
nature but of different magnitudes. Table 1.4 listed the countries with fully integrative approach 
to TM/CAM as compiled by World Health Organization (WHO, 2002b). These countries have 
long history of oriental practices and traditional use of natural remedies which has become fully 
integrated from generation to generation. On the other hand, for those countries which are listed 
in Table 1.5, there exists a broad set of health care practices which are already available to the 
public that are not readily integrated into the dominant health care model because they challenge 
dominant societal beliefs and practices such as cultural, economic, scientific, medical, and 
educational (Clark, 2000).  
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Table 1.4 Countries with a fully integrative approach to TM/CAM  
              (Ref. Sources: Compiled by WHO Traditional medicine Strategy 2002-2005)  
Names of 
Countries 
 
National 
policy on 
TM/CAM 
TM/CAM 
Department in 
Ministry of 
Health 
Regulation TM/CAM 
products/industries 
TM/CAM National 
Research Institutes 
Formal Institutional 
Education of TM/CAM  
China 1949 
constitution 
contains 
policy on 
TM 
State 
Administration 
of Traditional 
and 
Complementary 
Medicine (TCM) 
-Regulation (Yes) 
-Chinese herbal Pharmacopoeia 
-Essential Drug List including herbals 
-Regulatory control on manufacturers, 
herbal farmers 
170 National and state 
research institutes 
Universities; 
Colleges; 
Medical technology 
schools of TCM 
Republic of 
Korea 
National 
policy on 
TM 1969 
Oriental 
Medicine Bureau 
-Regulation (Yes) 
-Herbal Pharmacopoeia  
1 National  research 
institute 
 
11 oriental medicine 
universities 
Vietnam National 
policy on 
TM 1955 
Department of 
TM 
-Regulation (Yes) 
-Essential Drug List including herbals 
-State manufacturers 
3 National  research 
institutes 
 
Colleges; 
Medical technology 
schools of TM 
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Table 1.5 Countries with an inclusive (recognized) approach to TM/CAM  
                 (Ref. Sources: Compiled by WHO Traditional medicine Strategy 2002-2005)  
Names of 
Countries 
 
National policy 
on TM/CAM 
TM/CAM 
Department in 
Ministry of 
Health 
Regulation of TM/CAM or herbal 
products or both 
TM/CAM National Research Institutes Formal Institutional 
Education of TM/CAM  
  
Australia No Yes  
(in some states) 
Herbal products No Yes 
Canada Yes Yes Both Yes  No 
Germany No  No Both Yes  No 
Ghana Yes Yes Both Yes  No 
India Yes Yes Both Yes Yes 
Indonesia Yes Yes Both Yes  No 
Japan No No Both Yes  No 
Nigeria Yes Yes Both Yes  No 
Norway Yes Staff in charge Both Yes No 
Sri Lanka Yes Yes Both No No 
United Kingdom Yes  No Both No No 
USA No  No Both Yes  No 
Brunei 
Darussalam 
No No Guidelines on the import of 
Traditional medicine 
National Herbarium Drug 
Museum, Department of Agriculture, Ministry 
of Industry & Primary Resources,  
Brunei Darussalam 
No 
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1.4.3 Recent development of plant natural products 
 
The application of modern scientific technologies on selective analyses, biological assay and 
quality control assessments and evaluations of plant natural products are not usually straight 
forward due to the complexities of crude plant extracts which are not standardised. 
 
Numerous studies have shown that natural plant products are a rich source of novel compounds. 
Although isolation, identification, characterization, quantification of phytochemicals and 
evaluation of their potential benefits were undertaken on selected and prospective plant species, 
only some plant species actually were developed as pharmacotherapeutic drugs.  
 
For instance, the anti-cancer dugs such as the vinblastine, vincristine alkaloids isolated from 
Catharanthus roseus, topotecan which is a camptothecin analogue from Camptotheca 
acuminate, etoposide and teniposide (semisynthetic analogs of epipodophyllotoxin) isolated from 
Podophyllum peltatum. Taxol, a more recent significant drug isolated from the bark of Taxus 
brevifolia and currently newer plant derived pharmacophores are still undergoing different 
phases of clinical development. Flavopiridol, a flavone isolated from Dysoxylum binectiferum 
(Shapiro et al., 2001), genestein from soyabeans (Wang, 2000), indole 3-carbinol from 
cruciferous vegetables i.e. Brussels sprout and broccoli, curcumin from curcuma root (Bradlow 
et al., 1999), resvertrol from red wine (Bhat & Pezzuto, 2002) and epigallocatechin from green 
tea (Fujiki et al., 2002), homoharringtonine from the Chinese tree Cephalotaxus harringtonia 
(Kantarjian et al., 2001) and many others that are continually undergoing anti-cancer research 
such as Andrographolide, isolated from Andrographis paniculata (Burm. f.) Nees (Rajagopal et 
al., 2003).  
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Currently, a traditional Chinese Medicine labelled PHY906 was firstly described about 1,800 
years ago is still under phase II clinical trial study in order to provide evidence based clinical 
claims for the treatment of hepatocellular carcinoma as conducted by PhytoCeutica Inc. in USA 
(Cheng, 2005). 
 
The novel study on Qinghaosu (Artemisia annua L.) containing Arteannuin known as ‘sweet 
wormwood’ in english has been developed commercially into anti-malarial drug which is 
effective for anti-chloroquinines malaria (WHO, 1997). This further advances into the largest 
clinical trial on 1500 patients which was conducted in Bangladesh, Burma, India and Indonesia 
funded by the Wellcome Trust which compared the effectiveness of two plant-derived drugs; 
Quinine as currently the drug of choice for severe malaria in most malaria-affected regions, 
against artesunate, a drug derived from artemisinin. The results were compelling in which 
artesunate reduced mortality by 35% and was found to be safer and easier to administer 
(Dondorp et al., 2005). It is evidental that research and development on the plant natural 
products will provide avenues for the development of future therapeutically active compounds 
which are beneficial in the treatment of many disease conditions.  
 
1.5 Classifications of TM/CAM 
 
Hawks and Moyad (2003) have catogorised CAM into five types or classifications of therapies. 
These are alternative medical systems, mind body intervention, biologiocally based therapies, 
manipulative, body-based methods and energy therapies (Hawks & Moyad, June 2003). The 
major forms of traditional medicine on the therapeutic basis are the procedure-based therapies 
which include acupuncture, chiropractic, osteopathic, energy enhancement known as qigong, 
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taiji, yoga, dietary advice, massage & exercise techniques, physical, mental, spiritual, mind-body 
therapies and all the other therapies that are pertaining to improve the well-beings of the person.  
 
In the application of these therapeutic procedures, the use of traditional medicine products 
derived from plant, animal and mineral based-materials as adjuncts are also prescribed for 
patients on complementary therapies. Table 1.6 listed the categories of TM/CAM disciplines in 
the United Kingdom (Mills, 2001) as compared to the major forms of TM/CAM illustrated in 
Table 1.7 (Zhang, 2001).  
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Table 1.6 Categories of Complementary (CAM) and alternative therapies of United Kingdom 
(Ref. Source:  (Mills, 2001). 
Categories of CAM in United Kingdom 
Group 1 Group 2 
1.1     Professionally organised alternative therapies 2.1      Complementary therapies 
Acupuncture Alexander technique 
Chiropractic Aromatherapy 
Herbal medicine Bach and other flower extracts 
Homeopathy Body work therapies, incl. massage 
Osteopathy Counselling stree therapy 
 Hypnotherapy 
 Meditation 
 Reflexology 
 Shiatsu 
 Healing 
 Maharishi Ayurvedic medicine 
 Nutritional medicine 
 Yoga 
Group 3  Alternative disciplines 
3.1     Traditional systems of healthcare 3.2     Other Alternative disciplines 
Anthroposophical medicine Crystal therapy 
Ayurvedic medicine Dowsing 
Chinese herbal medicine Iridology 
Eastern medicine Kinesiology 
Naturopathy Radionics 
Traditional Chinese Medicine (TCM)  
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Table 1.7  Categories of TM/Complementary (CAM) and alternative therapies of WHO                      
Categories of TM/CAM of WHO (Zhang, 2001) 
Group 1 
Major forms of TM/CAM – Therapeutic Basis  
Group 2 
Major forms of TM/CAM – Systems 
Basis  
 
1.1 Medication 1.2 Procedure-based  
       Therapies 
2.1 Systems of  
       TM/CAM 
2.2 No systems of  
      TM/CAM 
Medicinal plants  Acupuncture Chinese traditional 
medicine 
Indigenous 
medicine 
Mineral materials Chiropractic Ayurvedic medicine Traditional 
medicine used in 
individual countries 
Animal materials Osteopathy Unani medicine  
 Manual therapies Homeopathy  
 Qigong, Taiji, Yoga Chiropractic  
 Physical, mental, 
spiritual and mind-body 
therapies 
  
 
 
 
 
 
 20
1.6 Important key issues in TM/CAM 
 
Traditional medicine in particularly herbal medicines which formed the basis of health care 
throughout the world since the beginning of mankind are stll used by many communities and 
have considerable importance in the world trade. Medicinal plants are important for the 
pharmaceutical research and development, in the form of starting materials for the drug synthesis 
or as models for designing pharmacologically active compounds and in most instances as plant 
constituents taken directly as therapeutic agents for many disease conditions. Research and 
development on traditional medicine is usually taxing on time, financial and manpower 
resources. 
 
The United Nations Convention on Biological Diversity stipulated that the conservation and 
sustainable use of biological diversity is of critical importance for ensuring that the needs of the 
growing world population are met on the basis of sharing both genetic resources and 
technologies worldwide (Jayasuriya, 1990). 
 
The regulatory and legislative controls on TM/CAM vary widely from country to country. Most 
countries have prioritised and adopted various appropriate approaches to address the important 
key issues such as licensing, dispensing, manufacturing, trading systems to ensure the quality, 
safety and efficacy of TM/CAM in order to safeguard public health. With the paradigm shift in 
the evidence-based Western medicines, interest into research and development on TM/CAM 
encompasses education, practices, training and access to the world population to ensure the 
appropriate delivery of TM/CAM alongside mainstream healthcare is expanding. Development 
and research on the key strategies to improve research rationales, promote collaborative 
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relationships between researchers and generate key resources to fund priority research are among 
some of the important challenges of TM/CAM (Bensoussan, 2005).  
 
The quality assurance and control measures such as the guidelines on the specifications and 
standards on good manufacturing practices (GMP), good clinical practices (GCP), good 
laboratory practices (GLP), good agricultural and collection practices (GACP) of the starting 
materials of herbal origin to the complex finished end products and various other guidelines 
which are needed to ensure a steady, affordable and sustainable supply of medicinal plant 
materials of quality, safety and efficacy (WHO, 2003). The progress on the quality assurance and 
quality control on herbal medicines from its starting raw materials right through to its complex 
finished end products is a mammoth task. As it is also known that the efficacy of herbal 
medicines has a characteristic of a complex mixture of constituents present in a single herb and a 
combination of herbs or medicinal plants are used together for the treatment of many ailments.  
 
Such practices pose many difficulties in the quality assurance and control evaluations and 
assessments of herbal medicines in order to ensure quality, safety and efficacy of the herb or 
herbal preparations (Liang et al., 2004). Such a scenario calls for the collaborative efforts from a 
multidisciplinary approach such as biochemistry, molecular biology, and cell biology in 
establishing quantifiable and reproducible bioassays to provide assurance of quality, safety, 
efficacy and consistency. Research and development across the board of interdisciplinary 
approach among many researchers, hoping to discover the novel therapeutics which is comprised 
of multiple chemical constituents is still a long journey. 
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1.7 Pharmacovigilance of TM/CAM 
 
Worldwide efforts have been made recently to monitor possible adverse reactions and drug-herb 
interactions to various TM/CAM products. As a result of the increasing pressure to regulate these 
products to pharmaceutical industry standards of quality and safety, the challenge for the 
regulatory authorities and TM/CAM industry is to provide a level of postmarketing surveillance 
to the equivalent level of pharmacovigilance of pharmaceuticals. A total of 16,154 suspected 
herbal case reports were compiled in the WHO database and the most common conditions 
reported are illustrated in Table 1.8 (Mohamed, 2006). In line with the WHO guidelines on safe 
monitoring of herbal medicines, the Ministry of Health Brunei Darussalam, alike many countries 
have embarked on the monitoring of the adverse effects associated with TM/CAM based on the 
similar mechanism of pharmacovigilance activities of the WHO Collaborating Centre at Uppsala, 
Sweden.  
 
The regulators worldwide face the biggest challenge in the necessary assessment and reviewing 
of traditional medicine to safeguard public health but as more stringent criteria and greater 
obstacles are imposed on pharmaceuticals and the greater is the temptation and tendency for the 
industries to exploit TM/CAM in the light of commercial interest of gain. As it is mandatory for 
western medicines to declare their side effects and toxicities, coupled with the 
pharmacovigilance activities which seems to place the risks over the benefits, this tends to push 
the consumers turning towards traditional medicine which in most cases usually claim to be safer 
and effective with lesser emphasis on risks.  
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For many years, researches have been trying to provide evidence-based medicines from the 
traditional medicine but most are unattainable or unsuccessful as it is not an easy and simple task 
at all. Therefore, just because traditional medicine contains natural ingredients in a product does 
not necessarily mean it is an automatic proof of that product’s safety and efficacy. At the same 
time, one should also remember that many important modern drugs are derived from plant, 
animal, or mineral origins. As a result, a better understanding of the traditional medicine can help 
to perform benefit/risk analysis for the patients. 
 
The biggest challenging question among all key players is still “quality, safety and efficacy”. 
Such scenario calls for a concerted effort among key players in the field of traditional medicine 
with the objective to ensure the continuity of good complementary health care to the patients, 
consumers and public at large with confidence and minimal risks involved.  
 
Table 1.8 Suspected herbal adverse reactions case reports in WHO database.  
Commonly reported reactions Most commonly reported critical terms for ADRs on 
herbal adverse reactions 
Pruritus 829 Hypertension 396 
Rash 751 Hepatitis 261 
Urticaria 751 Face oedema 243 
Rash erythematous  733 Death 226 
Nausea 682 Angioderma 209 
Vomiting 561 Convulsions 195 
Diarrhoea 546 Chest pain 191 
Headache 501 Thrombocytopenia 178 
Abdominal pain 497 Purpura 150 
Fever 460 Dermatitis 129 
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1.7.1 Adverse reactions 
 
An adverse reaction is defined by the Uppsala WHO Monitoring Centre as ‘a response to a 
medicine which is noxious and unintended, and which occurs at doses normally used in man’. 
Such description is of importance that it concerns the response of a patient, in which individual 
factors may play an important role, and that the phenomenon is noxious (an unexpected 
therapeutic response, for example, may be a side effect but not an adverse reaction). 
 
An adverse event or experience is defined as ‘any untoward medical occurrence that may present 
during treatment with a medicine but which does not necessarily have a causal relationship with 
this treatment’. In this case, it is the coincidence in time without any suspicion of a causal 
relationship. With the rapid increase in the worldwide use of TM/CAM, unfortunately the 
number of reports on adverse drug reactions or events with negative health consequences on 
consumers which affect the quality of life and in certain cases resulting in death, is also on the 
increase (WHO, 2000).  
 
It is a difficult task however, in ascertaining the causality of the adverse reactions in association 
with the TM/CAM products in many cases as experienced by most national collaborating centres 
worldwide. Assessment of adverse reaction case reports in accordance with the procedures of 
pharmaceutical assessments requires combined expertise in specialised fields such as clinical 
medicine, pharmacology, toxicology and epidemiology. And specialists in such fields are limited 
although great interest in the research of establishing the benefit of TM/CAM versus risks ratio is 
increasing. Polypharmacy is a common practice in many countries with self medicated 
community, the increased incidence of adverse reactions is further complicated by the 
widespread use of polyherbal combinations. Rational use of drugs and traditional medicine 
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require, among others, adequate assessment of the benefit versus risk. Well informed consumers 
demand continuous monitoring of drugs or traditional medicine for any adverse events 
throughout the drug’s or traditional medicine’s commercial life span as the educated public of 
today is very much involved in making their health care decisions. 
 
Several reports have been published on the adverse effects of herbal and traditional remedies and 
the causality assessments of these reports are difficult to establish. With the establishment of the 
WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre in 
1968 focusing on the safety monitoring of medicinal products which also encourage the 
reporting of adverse events experienced by practitioners and consumers who are using traditional 
remedies. Currently, there are more than 3.7 million suspected adverse reactions in the WHO 
database.  
 
In July, 2006, a total of 81 countries had joined the WHO Drug Monitoring Programme with 
another 17 countries as associate members (WHO, 2006). This figure is on the increase which 
serves as an indicator that many countries are concern about safety issues and the way forward 
would be to conduct pharmacovigilance activities. Such reporting mechanism on safety issues is 
very important for the prevention of drug or traditional remedies induced human suffering which 
affect the quality of life and also to avoid financial risks associated with unexpected adverse 
effects.  
 
Therefore, traditional remedies are of no exception as these remedies are consumed with the 
notion that it is for improving quality of life, but not necessarily risks free. We should make 
efforts to prevent tragedy of Thalidomide in 1960’s (deformities of limbs) or Mu Tong in 1990’s 
(kidney failure) or Slim 10 (herbal slimming product adulterated with thyroid gland extracts and 
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Fenfluramine) that resulted in liver failure and eventual death tragedy. According to the survey 
conducted by the government and restructured hospitals of the Ministry of Health Singapore in 
1994, there were 154 cases of complications arising from traditional medicine treatment between 
August 1994 and January 1995 (Tan, 2005). Table 1.9 illustrated some of the adverse effects 
compiled by the authorities as a result of drug interactions or due to the scheduled poisons such 
as steroids which can result in some serious complications (Koh & Woo, 2000).  
 
It was also highlighted that more recent concerns in the use of traditional medicine which poses 
potential interactions when use in conjunction with prescription or over-the-counter medicines 
(Smith, 2005). The need for scientific information on the toxicity and interaction potential of the 
herbal medicines and the dissemination of their safety profile to the practitioners/prescribers and 
patients for ensuring safety is of paramount importance (Majewski & Ahokas, 2005). Long term 
toxicity associated with the chronic use of traditional medicine remains a major issue in the 
absence of safety data of traditional medicine. 
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Table 1.9 Names of TM/CAM products with brands or manufacturer’s names where 
available, and the Scheduled Poisons detected (compiled by the Pharmacy 
Enforcement Unit, Ministry of Health Brunei Darussalam, 2002).  
No. TM/CAM products (brand and/or manufacturer’s 
names) 
Scheduled Poisons detected 
1 Air Akar-Akar Kayu Asli Dexamethasone 
2 Air Ikan Haruan Dexamethasone 
3 Akarsom Dexamethasone 
4 Akarsom Jawa Asli Dexamethasone 
5 Ba Bao Feng Shi Huo Luo Dan  Diclofenac 
6 Bai Feng Wan with Ginseng & Pearls Berberine 
7 Bansetong Rheumatic Pill Phenylbutazone 
8 Bantulin Rheumatic Pill Phenylbutazone 
9 Benzi-Lin Dexamethasone 
10 Bestrim Fenfluramine 
11 Chinccough Caps Dextromethorphan 
12 Chinicough Caps Dextromethorphan 
13 Chin Toon Lin Rheumatic Caps Phenylbutazone 
14 Chu Fong Kee Sak Wan Dexamethasone 
15 Chu Fong Kee Sar Wan Dexamethasone 
16 Chufeng Toukuwan Chlorpheniramine 
17 Chui Fong Toukuwan Caps Dexamethasone 
18 Dahuo Luodan Berberine 
19 Dr Yap Condensed Honey Chlorpheniramine 
20 Dura Tonic 20ml Sildenafil 
21 FB Slymer Fenfluramine 
22 Fuchingsong Shaiodu Chie Yang Caps (Moon Bells Brand)  Chlorpheniramine 
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23 Fukuwan Dexamethasone 
24 Gan Man Wan Chlorpheniramine 
25 Gen Tong Ping Tetrahydropalmatine 
26 Ginkutan Dexamethasone 
27 Ginseng G Pontocyn Dexamethasone 
28 Ginseng Jachiowan Diazepam, Dexamethasone 
29 Ginseng Lin-Zi Calyco Pil Cyproheptadine, Dexamethasone 
30 Ginseng Lopa Kupuwan Dexamethasone 
31 Ginseng Zaizaowan Berberine 
32 Glaxi Rheumatic Caps Dexamethasone 
33 Gu Ben Wan Indomethacin, Hydrochlorothiazide, 
Diazepam, Dexamethasone, 
Prednisolone, Caffeine 
34 Guci Dih Mai Ji Wan Promethazine 
35 Herba Sari Resdung Chlorpheniramine 
36 Hoong Heng Tse Koo Choy Santonin 
37 Hukutan Rheumatic Caps Indomethacin 
38 Hu Ku Wan  Dexamethasone 
39 Huo Lu Wan Caps Phenylbutazone 
40 Jamu Ajaib Dexamethasone 
41 Jamu Jarum Emas Cap Jarum Emas Dexamethasone 
42 Jamu Kapsul Tupai Jantan Betamethasone 
43 Jamu Madura Betamethasone 
44 Jamu Sumber Sehat Sesak Nafas Chlorpheniramine 
45 Jawa Tonik Akarsom Dexamethasone 
46 Jung Fei Pill Cyproheptadine 
47 Kapsul Farlin Jamu Cap Farlin Phenylbutazone 
48 Kapsul Pahlawan Chap 100 plus Bagus Prednisolone 
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49 Life Blood Medicine Dexamethasone 
50 Linzetan Chlorpheniramine 
51 Loong Tan Rheumatism Caps Cyproheptadine, Dexamethasone 
52 Maajun 500 Phenylbutazone 
53 Maajun Ajaib Prednisolone 
54 Maajun Ajaib Ikan Linang dan Korean Ginseng Cap Korean 
Ginseng 
Phenylbutazone 
55 Maajun Kuat Dexamethasone 
56 Maajun Lebah Dexamethasone 
57 Maajun Traditional Cap Bulan Phenylbutazone 
58 Makjun Kuat Tupai Jantan Betamethasone 
59 Makjun Lebah Betamethasone 
60 Makjun Tupai Jantan Betamethasone 
61 Man Che Too Chong Chooi Fong Wan Phenylbutazone 
62 Nasalin High Strength Chlorpheniramine 
63 Nasalin Tab Chlorpheniramine 
64 Oleiviticus Negundo Caps Theophylline 
65 Pearl & Antelope Throat Powder (spray) Berberine 
66 Pegalin Ekstrak Betamethasone 
67 Pien Tze Huang Sore Throat Powder Berberine 
68 Pemin Kan Wan (nasal clear) Dex Chlorpheniramine 
69 Pil Majun Betamethasone 
70 Primadona Pegal Linu Mefenamic Acid,  Phenylbutazone 
71 Pytazone Dexamethasone 
72 Qiangli Kuben Su Caps Methyltesterone 
73 Rheumatism Pill Dexamethasone 
74 S-Magon Morning and Night Tab Theophylline, Promethazine 
75 S-Magon Tab Betamethasone 
 30
76 Sedolin-C Caps Phenylbutazone, Prednisolone 
77 Sepilin Rheumatism Caps Phenylbutazone 
78 Sewtonlin Codeine, Promethazine 
79 Sha Hsien Chin Ointment Clotrimazole 
80 Shenchin Herb caps Diazepam, Ibuprofen 
81 Shen Po Caps Phenylbutazone 
82 She Xiang Zhui Feng Tou Gu Wan Diclofenac 
83 Shebanlin Caps Dexamethasone 
84 Shetonlin Caps Phenylbutazone, Prednisolone 
85 Shewtonlin Codeine, Promethazine 
86 Siow Lim Rheumaryin Caps Cyproheptadine, Dexamethasone, 
Prednisolone 
87 Sitonpoh Dexamethasone 
88 Skimtan Berberine 
89 Slim 10 Fenfluramine 
90 Speman Forte Reserpine 
91 Sukenlo Dexamethasone 
92 Sumber Rimba Majon Tongkat Ali Dexamethasone 
93 Super Rheumatic Caps Prednisolone 
94 Super Tunglin Dexamethasone 
95 Suxiao Gan Mao Pian Chlorpheniramine 
96 Tablet Cap Wau Dexamethasone 
97 Tackolin Caps Dexamethasone 
98 Te Xiao Zhi (Zhu Cheng Brand)  Berberine 
99 Tean Mao Tou Chong Pill Dexamethasone 
100 Thien Ma Toh Chung Chen Kuo Won Dexamethasone 
101 Thien Ma To Jung Rheumatic Dexamethasone 
102 Tian Ma Tou Gu Wan Dexamethasone 
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103 Tiean Ma Shoo Chin Wan  Dexamethasone 
104 Toh Teong Par Kit Chap Dexamethasone 
105 Tongkat Ali Super Power Dexamethasone 
106 Tongkat Ali Tonik Mujarab Cap Bulan Kris Dexamethasone 
107 Tonpilin Tab Dexamethasone 
108 Tonik Acheh Dexamethasone 
109 Tonik Jamu Dexamethasone 
110 Tonik Jawa Akarsom Dexamethasone 
111 Tonik Semangat Dexamethasone 
112 Tonik Semangat Asli Dexamethasone 
113 Tsaitsaowan (Ginseng Hui Sheng) Phenylbutazone 
114 Tu Chon Fu Kuo Wan Phenylbutazone 
115 Tuchong Tianmar Huko Wan Dexamethasone 
116 Tung Shueh Wan Caps Diazepam, Indomethacin, 
Prednisolone 
117 Tunglin Caps Dexamethasone, Phenylbutazone 
118 Ubat Demam Kanak-kanak Phenylbutazone 
119 Ubat Sakit Pinggang jamu (Toko Air Pancur, Indonesia) Phenylbutazone 
120 Ungentum Fluccinonidi Fluocinonide 
121 101 Wei Yao Ling (Mei Hua Brand) Diclofenac 
122 Wei Loong Oral Solution 20ml Sildenafil 
123 Wuchaseng Wan Caps Dexamethasone 
124 XC Rheumatic Pill Phenylbutazone 
125 Zhen Gu Wan Phenylbutazone 
126 Zhen Zhu Tou Tong Ling (Fai Yien Pai Brand) Diclefenac 
127 Zhong Gan Ling (Yang Cheng Brand) Dipyrone 
128 Zhung Gu Wan Dexamethasone 
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There have been many adverse reactions reported since 1997 on the safety issues concerning the 
adverse reactions associated with the use of herbal medicines in Australia (Drew & Myers, 1997) 
caused by a number of reasons as illustrated by examples in Table 1.10. 
 
 
Table 1.10 Reasons why adverse reactions are associated with TM/CAM  
 
No. Reasons  Examples References 
1 Misidentification: 
-Herbal ingredients or products with 
confusion between species. 
Angelica polymorpha or Angelica 
archangelica species due to 
Chinese herbal name is “dong quai 
or danggui or tang kuei”. 
(But, 1993) 
..2 Lack of standardisation:- 
Therapeutic/toxic components of plants may 
vary depending on: 
-plant used,  
-stage of ripeness, 
-geographical location of growth and storage 
conditions, etc 
Content of ginsenoside varied from 
(1.9% to 9% w/w) in 44 products: 
-Six products with absence of active 
component ginsenoside; 
-One product contains a large 
amount of ephedrine. 
 
(Cui et al., 1994) 
3 Contaminations of products:  
-by pesticide residues,  
-microorganisms,  
-aflatoxins,  
-radioactive substances and heavy metals 
such as lead, cadmium, mercury, arsenic and 
thalium  
Toxic heavy metals detected in the 
products: 
-Lead, 
-Mercury, 
-Arsenic, 
-Copper. 
(Bisset, 1994; 
Koh & Woo, 
2000) 
 33
4 Substitution of herbs either intentional or 
mistakenly due to the herbs being look alike 
Aristolochia fangchi containing the 
nephrotoxic component aristolochic 
acid in the place of Stephania 
tetrandra resulted in terminal renal 
failure. 
(Vanhaelen et al., 
1994; 
Vanherweghem J-
L et al., 1993) 
5 Adulteration with pharmaceuticals and 
chemicals intentionally by the unethical 
herbalists or the manufacturers/distributors 
for commercial gains in their compounded 
preparations for individual patients which 
resulted in severe adverse reactions.  
Adulteration of pharmaceuticals 
Scheduled Poisons containing 
diazepam and mefenamic acid in 
“Tung Shueh” pills for arthritic 
complaints 
(Diamond & 
Pallone, 1994; 
Pharmacy 
Enforcement 
Unit, 2002). 
6 Incorrect preparation/dosage due to failure of 
non-compliance of the patients/consumers 
 
Failure to comply with herbalist’s 
specific instruction to boil aconite 
accordingly. Increased the dose &  
shortened the boiling time, unable 
to reduce the toxicity of alkaloids 
timely 
(De Smet PAGM 
& Tognoni, 1992) 
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2.1      Brunei Darussalam – The Abode of Peace 
 
2.1.1 Geographical description 
 
Brunei Darussalam is situated on the north-west coast of the island of Borneo and lies in the 
heart of South East Asia. It is a peaceful and beautiful country close to the equator between east 
longitudes 114º 04’ and 11º 23’ and north latitudes 04º 00’ and 05º 05’. It has a total land area of 
5,765 square kilometres and a coastline of about 161 kilometres and bounded on the north by the 
South China Sea, on the other sides by the Malaysian state of Sarawak. It comprises of four 
districts namely the Brunei/Muara, Tutong, Kuala Belait and Temburong (Figure 2.1).  
 
 
 
 
Figure 2.1. Map of Brunei Darussalam 
(Map by ©K. Becek, Geography Department, University of Brunei Darussalam, 2005 published 
in the Brunei yearbook 2006, Borneo Bulletin). This map is intended for use to illustrate the 
geographical location only). 
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2.1.2 The National Heritage of Brunei Darussalam 
 
Brunei Darussalam has a tropical climate with uniform temperature, high humidity and annual 
rainfall ranges from around 2,790 millimetres in many parts of the interior with daily 
temperature ranging between 22ºC and 28ºC. Tropical rainforest covers 80% of the country’s 
total land area. Of this figure, 70% are virgin, primary forest, one of the most diverse and unique 
vegetative assemblages in the world, comprising of 5,000 species of plants, including 2,000 
species of forest (Department of Information, 2003). The conservatorium of plants biodiversity 
under the Forestry Department, Ministry of Industry and Primary Resources, Brunei Darussalam 
was developed to protect the plants species from their extinction for the benefit of the Bruneians 
for the future generations ahead. 
 
2.1.2.1 Tropical Medicinal Native Plants of Brunei Darussalam 
 
Ethnobotanical surveys have revealed that Brunei Darussalam has a rich source of tropical 
medicinal plants (Department of Agriculture, 2000). As 80% of the country’s land is covered by 
tropical rainforest, Brunei Darussalam may have some medicinal plants with unique 
characteristics of secondary metabolites. Some plants such as Catharanthus roseus (L.) G. Don 
and Eurycoma longifolia Jack have long been used by the local communities to treat various 
disease conditions. However, no research has been done in terms of the constituents or 
pharmacological or biological activities of the Brunei Darussalam medicinal native plants.  
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2.1.3 Challenges of TM/CAM in Brunei Darussalam  
- A Bruneian Viewpoint 
 
The vast range of indigenous, tribal folklore and traditional systems of medicines, part of the 
heritage of Brunei Darussalam still needs to be adequately explored. Although herbal medicines 
are already extensively used in this country, the potential for their wider use in primary health 
care and in modern systems of medicines have been largely unrealised. The use of current 
scientific knowledge and analytical assay methods in the extraction, isolation, purification and 
analysis of such extracts in a systematic approach has always been the priority of the research 
and development in herbal remedies. This still remains as the biggest challenge in obtaining the 
scientific information on their quality, safety and efficacy of the medicinal native plants of 
Brunei Darussalam. 
 
2.1.3.1 The practice of TM/CAM in the Primary Health Care of Brunei Darussalam 
 
The Ministry of Health Report of Brunei Darussalam (MOH, 2000) stated that the population 
growth is at an approximate annual rate of 3%. The population census of 2002 was 340,800 and 
projected to be over 436,000 by the year 2011. There are many ethnic communities comprising 
of the majority Malays, followed by Chinese, Indians and other indigenous groups living in 
harmony. 
 
Traditional medicine has always been practised in Brunei Darussalam from generation to 
generation due to its rich cultural and traditional background. The herbalists and traditional 
medicine practitioners include the Malay ‘bomoh’, the Chinese ‘sin seh’ and the Indian 
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‘ayurvedic healers/guru/yoga therapists’ and Indonesian religious and spiritual healers, all 
delivering comtemporary primary health care in one form or another to members of the public.  
These natural or traditional healers are allowed to practice their long term trades of 
traditional/complementary/alternative medicines provided they do not contravene the existing 
legal and regulatory framework on the control and practices of allopathic medicine and the 
traditional medicine practices guidelines endorsed by the Ministry of Health Brunei Darussalam. 
 
Currently, TM/CAM practices are not integrated in the public sector as it is still considered to be 
a separate discipline of alternative care therapy as compared to the conventional allopathic 
system of medicine. However, patients on treatment and consumers at large normally refer to 
TM/CAM therapies as supplementary alternative treatment. This is a very common practice 
especially in terminally ill patients who will try almost any therapies that will help to support the 
patients emotionally and spiritually. This is in agreement with the Risk Adaptation Model 
(RAM) by Ritvo, P et al. (1999) demonstrated that the motivations of cancer patients in seeking 
TM/CAM complementary therapies are, fundamentally, self-healing motivations which when 
engaged appropriately, can contribute to the patient’s psychological and physical well being 
(Ritvo et al., 1999).  
 
From the consumer’s standpoint, the increased in the self-care approach continues to expand 
locally, national, regionally and internationally. The escalating medical cost and managed care 
restricts the access to conventional medical care, the choice towards using natural products and 
other non-prescription medications will also increased in the worldwide scenario. The simple 
reason which accounts for the popularity of traditional medicine is affordability and accessibility.  
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This is coupled by the offers to heal from many directions such as advertisements, infomercials, 
magazines, promotional meetings/seminars with the objective to provide comtemporary health 
care to the public. Therefore, it has become an important issue in our health care delivery system 
and the need to ensure its rational use and practices remains a big challenge for many policy 
debates, regulatory questions, clinical and scientific arguments about natural products in the 
market and their evidence-based therapies will always be debated. Like any other developing and 
developed countries, the health care system in Brunei Darussalam is dominated by modern 
western medicine. Table 2.1 shows the socioeconomic and health indicators for year 2004 and 
the trend of the TM/CAM practices in the present health care domain is on the increase with 16 
traditional Chinese Medicines (TCM) clinics in operation and others operating TM/CAM 
practices.  
 
With the adoption of Primary Health Care delivery system to all, the alternative is TM/CAM 
which is widely practised in all communities. Currently, this practice plays an important role in 
the health systems but it is required to be defined clearly by conducting more research and 
development to evaluate the patterns of TM/CAM usage and the outcomes of these alternative 
therapies in the country. The Ministry of Health in the National Health Care Plan (2000-2010) 
continues to ensure that health for all by the year 2000 (Anon, 1993; MOH, 2000) and beyond is 
focused on the Primary Health Care approach accessible to all.  
 
2.1.3.2 TM/CAM care system in Brunei Darussalam 
 
As a global trend, in principle, the training and practices of TM/CAM traditionally involved an 
on-the-job apprenticeship with knowledge conveyed from patriarch to offspring, but this system 
is on the decline due to more practitioners are receiving formal institutional training, coupled 
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with the fact that more facilities are available for upgrading of standards, education, training and 
practices of TM/CAM. It has also been reported that fragmentation, disagreements between 
various groups of experts, and their concentration/focus on the differences rather than common 
aims and objectives were identified as one of the main problems with the existing professional 
bodies in the TM/CAM practices (Gauld, 1998). In general, TM/CAM often suffers from a poor 
research infrastructure and a lack of high quality research and the understanding of research 
ethics and methodology, the unwillingness to evaluate evidence, and an acute and chronic 
shortages of resources focusing on training on research into TM/CAM (Roach, 2000). In the 
project study on the practice and regulatory requirements of naturopathy and western herbal 
medicine conducted (Lin et al., 2005) and the study points to gaps in the key areas of 
professional conduct, educational standards and access. 
 
Such a scenario calls for a formal regulatory and legislative framework in countries with 
increasing popularity in TM/CAM in order to protect and safeguard public health from any 
potential risk of TM/CAM therapies but at the same time maximising the beneficial potential of 
the TM/CAM. It is imperative to provide equal opportunities for both modern drugs and 
TM/CAM therapies to be used side by side for better health care needs of the communities.  
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Table 2.1 Data on Socioeconomic and Health Indicators for 2004 
Indicator (s) for Brunei Darussalam Data 
1. Area (in 1000 sq.km.) 5,765 
2. Estimated population (‘000) 359.7 
3. Annual population growth rate 2.9 
4. Percentage of population:   0-4 years 
                                                5-19 years 
                                                20-54 years 
                                                55-64 years 
                                                65+ years & Over 
                                                Median Age     
13.2 
27.2 
54.0 
3.3 
2.3 
23.5 
5. Number of population (total no. by sex) (‘000) 189.4 Male 
170.3 Female 
6. Rate of natural increase of population (% per annum) 2.9 
7. Crude birth rate (per 1000 population) 19.9 
8. Crude death rate (per 1000 population) 2.8 
9. Life expectancy at birth                                                            
 
74.6 Male  
77.5  Female 
10. Infant mortality rate (per 1000 live births) 8.8 
11. Estimated population for the year 2011 ('000) 436 
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12. Main causes of morbidity 
ICD-9 code     (Single leading causes of Inpatient Morbidity) 
460-465     acute upper respiratory infection 
630-639                  abortion 
493                          asthma 
401-405      hypertensive diseases 
009                          gastroenteritis/diarrhoea 
250      diabetes mellitus 
466,480-487      acute lower respiratory infections 
393-398, 410-429    heart diseases 
 
 
680 
1,009 
788 
695 
771 
606 
743 
680 
13. Ten leading causes of death 
ICD-I0 code 
C00-C97                  malignant neoplasms 
100-109                    heart diseases 
E10-E14                   diabetes mellitus  
I60-I69                     cerebrovascular diseases      
J40-J46                     bronchitis, chronic & unspecified emphysema &         
                                 asthma  
V01- I10-I15            hypertensive diseases 
V01-V99                  transport accidents  
P00-P96                   conditions originating in the perinatal period  
Q00-Q99                 congenital malformations, deformations & 
                                chromosomal abnormalities 
 
 
218 
185 
78 
72 
48 
 
42 
38 
38 
17 
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14. No. of hospitals by organizations 
Government hospital 
Private hospital 
Private general practitioners 
Private dentists 
Specialist clinics 
Health clinics 
Health centers 
Maternity & Child Health clinics 
Travelling Health clinics 
Services to remote areas (flying medical team) 
 
 
4 
1 
63 
15 
6 
10 
15 
15 
13 
4 
15. No. of pharmaceutical premises  
Retail pharmacy (Guardian chain) 
Pharmaceutical wholesalers 
Agrochemical retailers 
Agrochemical wholesalers 
Chemical suppliers 
Veterinary retailers 
 
2 
26 
19 
7 
33 
3 
16. Traditional, Complementary, Alternative Medicine 
 
TM/CAM practices 
Medical halls  
Homeopathic clinics 
 
 
 
15 
2 
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Ayurvedic clinics 
Chiropractic clinics 
Acupuncture clinics  
Herbalists/Herbal clinics 
Traditional Chinese Medicine clinics 
Massage therapy clinics 
Nutriceutical companies/Health supplements    
Supermarket chains (Sale of O.T.C., nutritional 
products vitamins, minerals, etc.)                 
Nil 
1 
1 
16 
4 
5 
9 
11 
 
17. No. of health manpower  
17.1 Public Sector: Doctors/specialists 
Dentists 
Pharmacists 
Nurses 
Dispensers 
Pharmacy Enforcement Staff  
 
400 
53 
26 
1,923 
70 
6 
17.2 Private Sector: Doctors/specialists 
Dentists 
Pharmacists 
Nurses 
63 
15 
15 
42 
18. Ratio of health professionals to population 
Doctors/specialists  
Dentists 
Pharmacists  
 
1:777 
1:5,290 
1:8,773 
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Nurses 
Dispensers 
1:183 
1:5,138 
19. Total Health budget (B$Millions) – Government based 233.32 
20. Health Budget as percentage of National budget 6.63 
21. Per capita health budget (B$) 649 
 
Reference Sources:  
 
1. Ministry of Health National Health Care Plan (2000-2010)  
– A Strategic Framework for Action, June, 2000. 
2. Health Information Booklet 2004, Statistics Unit, Research & 
Development Section, Department of Policy & Planning, Ministry of 
Health, Brunei Darussalam. 
3. Pharmacy Enforcement Report 2004, Pharmaceutical Services, 
Ministry of Health Brunei Darussalam. 
4. Department of Economic Planning & Development, Prime 
Minister’s Office, Brunei Darussalam, Revised edition 2003. 
5. Budget & Tender Section, Ministry of Finance, Brunei Darussalam 
Ledger Section, Treasury Department, Ministry of Finance, Brunei Darussalam. 
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2.2 Policy on TM/CAM 
 
2.2.1 Existing guidelines of the Ministry of Health Brunei Darussalam on TM/CAM 
 
In Brunei Darussalam, currently there is no National Policy or Traditional medicine Act to 
regulate TM/CAM. Control on TM/CAM is only administered on guidelines stipulated by the 
Ministry of Health, Brunei Darussalam. According to the official guidelines, traditional medicine 
is defined as any product consisting of one or more substances derived from natural sources such 
as plants, animals and minerals-based materials or a combination of any one or more of these 
materials, but shall not include any medicinal product to be injected into the human body, any 
vaccine to be used by human beings, any product derived from human blood or any other item 
listed in the Poisons list under the Medicines and Poisons Act of Ministry of Health Brunei 
Darussalam. 
 
Herbal medicine in the raw or processed forms consumed by the communities are normally 
imported mainly from China, India, Indonesia, Thailand, United Kingdom, Australia, the United 
States on a commercial licence or by custom permit or by personnel imports. This is a matter of 
personal choice among the various ethnic communities in Brunei Darussalam and screening of 
product imports are scrutinised by the Pharmacy Enforcement Unit on the import declarations 
from the importers. 
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2.2.2 Legislative and regulatory control of drugs (pharmaceuticals) and TM/CAM of 
Ministry of Health Brunei Darussalam 
 
The following existing legislations and regulations of the Ministry of Health Brunei Darussalam 
are executed based on the following Acts: 
 
• Poisons Act 1956 Cap 114 and Rules 1957 enforced by the Ministry of Health:-  
This Act regulates the importation, possession, manufacture, compounding, storage, 
transport and sale of poisons. 
 
• Misuse of Drugs Act Cap 27 (Revised 1984) (MDA) and Misuse of Drugs Regulations 
(MDR) enforced by the Narcotic Control Bureau (NCB) of the Prime Minister’s 
Department. This Act incorporates further additional provisions for the regulation of the 
import, export, manufacture, possession and consumption of controlled drugs as well as 
dangerous or otherwise harmful substances. Special provisions relating to the jurisdiction 
of courts in respect of offences are also stipulated.  
  
• Registration of Pharmacist Order 2001 enforced by the Ministry of Health  
This Order incorporates provisions with respect to the registration of the pharmacy 
practice and pharmacy profession. The key requirements which are stipulated by most 
Pharmaceutical Societies of developed countries which cover the main aspects of drug 
practices and control are based on the official operations of the Pharmacy Board of the 
Royal Pharmaceutical Society of Great Britain (R.P.S.G.B), American Pharmaceutical 
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Association (A. Ph. A), the Registration of Pharmacists Regulations 1953 of Malaysia 
and Pharmaceutical Society of Singapore and other developed countries. 
 
2.2.3 Legislations and regulatory control on medicinal products (drugs/pharmaceuticals)  
 
The Poisons Act 1956 Cap 114 and Rules 1957 stipulated that the medicinal product is defined 
as any substance or article (not being an instrument, apparatus or appliance) which is 
manufactured, sold, supplied , imported or exported for use wholly or mainly in either or both of 
the following ways: 
 
• Use by being administered to one or more human beings or animals for a medicinal 
purposes; 
• Use as an ingredient in the preparation of a substance or article which is to be 
administered to one or more human beings or animals for a medicinal purpose. 
 
2.3 Definition of products in the official guidelines  
 
2.3.1 Drug or medicine (pharmaceutical) 
 
A drug or medicine is defined by the Uppsala WHO Monitoring Centre as ‘a pharmaceutical 
product, used in or on the human body for the prevention, diagnosis or treatment of disease, or 
for the modification of physiological function’ (WHO, 2000). 
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2.3.2 Herbal remedies 
 
Herbal remedy is defined as ‘any product consisting of substances produced by subjecting plant 
materials to drying, crushing or other process or a mixture whose ingredients are two or more 
substances so produced, or of a combination of such mixture with water or other inert substances 
as specified by the licensing authority’ (WHO, 2000). 
 
2.3.3 Homeopathic medicines 
 
Homeopathic medicine is defined ‘as any substances used in the system of therapeutics. 
Diseases are treated by the use of minute amounts of such substances which are capable of 
producing in healthy person’s symptoms similar to those of the disease being treated’ (WHO, 
2000). 
 
2.4 Official guidelines on the importation and regulatory control of TM/CAM in 
Brunei Darussalam  
 
These official guidelines on TM/CAM products are in place and executed to ensure quality and 
safety in order to safeguard public health (MOH, 2004b): 
 
i Traditional medicine in their raw unprocessed form is permitted to be imported into 
Brunei Darussalam and it does not contain any substance controlled under the Poisons 
Act. 
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ii Traditional medicine which have been processed into dosage forms must be properly 
packed, labelled with ingredients containing the proportions and indications. Any 
packaging without stating the ingredients listed is not permitted to be imported. 
iii The ingredients and the mode of use must be labelled in Malay or English. Other 
additional languages can be used in addition to either Malay or English. 
iv The ingredients of the Traditional medicine should not contain any modern medicines at 
all. 
v Traditional medicine must not contain any substance controlled and listed in the Poisons 
Act. 
vi Traditional medicine must not contain any injectables. 
vii        Traditional medicine with dubious or unreasonable claims on the labels are not allowed.  
viii       Traditional medicine for immoral or criminal use are not permitted to be imported. 
ix Traditional medicine exported from the countries of origin which are subjected to the 
registration requirements must be registered with the authority in the exporting country. 
x Any registration number from the country of origin or exporting country must be stated 
on the packaging labels if applicable. 
xi The batch number, expiry date and the name and address of manufacturer/sponsor must 
be stated on the packaging. 
xii Traditional/herbal medicines are not permitted to contain any heavy metals exceeding the 
permissible levels as follows:- 
 Arsenic   - 5 PPM (weight) 
 Mercury - 0.5 PPM (weight) 
 Lead       -10 PPM (weight)    
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The importers are hold responsible and are liable for the sale and distribution of traditional 
medicine as covered by the official guidelines stipulated by the Minstry of Health Brunei 
Darussalam. These restrictive guidelines are executed through the Pharmacy Enforcement Unit 
of the Pharmaceutical Services to ensure that the guidelines imposed are strictly complied by the 
importers in order to control traditional medicine containing scheduled poisons being imported 
into the country as listed in Table 1.9. These guidelines are limited in the aspect of safety and 
efficacy of the products as evidence based TM/CAM is quite a recent development and the 
assessments/evaluations for the safety and efficacy of TM/CAM still remains as the biggest 
challenge for many regulatory authorities and key players worldwide.  
 
2.5 Medicinal Native Plants of Brunei Darussalam   
 
2.5.1 Community use of medicinal plants in Brunei Darussalam  
 
In line with this worldwide trend, TM/CAM therapies in particularly from the plants origin is 
used widely by all communities in Brunei Darussalam, a country in the Western Pacific Region 
of the World Health Organization (WHO-WPRO). The herbal species are easily accessible in the 
open markets or in the backyard gardens for consumptions either as fresh vegetables or as herbal 
remedies for minor illnesses to meet the everyday needs. It is therefore of great interest to 
explore into these folklore traditional medicine which are being practised in the country 
especially when there is no written literature to provide the evidence to substantiate the 
authenticity of the intended medicinal benefits obtained from these natural remedies.  
 
In Brunei Darussalam, the warm and humid equatorial climate, coupled with varying soil 
conditions, has contributed to extremely diverse natural plant species. It has been estimated that 
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there are up to three hundred native species of plants used in traditional medicine. Such wealth of 
plant resources should not only be conserved and treasured, but explored to provide more natural 
plant materials that are beneficial to mankind, at the same time without jeopardizing the 
environment or disrupt the perpetuity of nature.  
 
Therefore, from the Brunei Darussalam research and development perspective, continued 
research on identifying novel compounds in the plant species with the potential to be developed 
into beneficial therapeutic agents has become the centre of interest and promoting the rationale 
use of medicinal plants alike many neighbouring countries in South East Asia. 
 
2.5.2 Development of herbal pharmacopoeia or monograph 
 
Currently, there is no formal herbal pharmacopoeia or monograph in documenting the herbal 
formulations or medicinal plants indicated for the beneficial treatment for a wide range of 
ailments. There is a need for the development of herbal pharmacopoeia or monograph 
documenting the medicinal plants of Brunei Darussalam which will be revised regularly to 
include the recent development and advancement in phytotherapy research. With the continued 
support from the government and proper scientific research and development, this will provide 
better understanding on the proper and rational use of traditional, complementary and alternative 
medicine (TM/CAM). Such a scenario calls for collaborative, concerted and integrated effort 
from all the professionals practising in the state of the art in traditional, complementary and 
alternative medicine (TM/CAM) for the actualization of the rational practice of TM/CAM.  
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2.5.3 Culture and tradition of TM/CAM 
 
Brunei Darussalam has a national heritage of communities with long history of culture and 
traditions in which traditional medicine practices have become a way of life. Diversity in the 
ethnic communities influences each other in a harmonious manner in terms of the various types 
of traditional medicine which are easily accessible within reach. Locally grown medicinal plants 
are mainly used by the Malay communities with some ingredients imported from Malaysia and 
Indonesia. As for the Chinese community, they tend to compound the traditional medicine based 
on the ingredients imported from China or Hong Kong as some of the ingredients are not 
available in Brunei Darussalam. Similarly, the Indian communities import the materials from 
India. As for the folklore medicines, it is used by all communities across the board due to the 
harmonious integration and fusion process of culture and traditions (Lim, 2005) within the 
country. 
 
An influx of TM/CAM are being imported from overseas such as China, Indonesia, India, 
Malaysia, Thailand (South East Asia), United States, United Kingdom and Australia as a result 
of the free trade exchange in the region and the industries marketing strategies due to demand 
and supply. In Brunei Darussalam, most of the traditional medicine are prepared by combining 
ten, twenty or even more different ingredients from plants, animals, minerals and compounded 
into a unit system of formulation. For the herbalists, single herbal species of any of the plant 
parts such as leaves, stem, twigs, barks, roots, flowers, seeds, etc are used as herbal remedies and 
the most commonly use medicinal native plants of Brunei Darussalam are listed in Table 2.2. 
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Table 2.2 Commonly used medicinal plants by the local communities in  
Brunei Darussalam  
(Adapted from the Medicinal Plants of Brunei Darussalam, published by Department of Agriculture, 
Ministry of Industry and Primary Resources, Brunei Darussalam Revised Edition 2000, for the 
intended purpose of the studies on the native medicinal plants of Brunei Darussalam). 
No. Plant Names Local Names Family Names Plant parts & Method of 
administration 
Medicinal uses 
1. Aloe vera L. 
 
Lidah buaya 
 
 
 
 
 
Aloeaceae -Mucilage of leaves -Poulticing wounds 
-Skin and hair  
 Conditioner 
2. Alpinia 
galangal (L.) 
Sw. 
Languas; 
Langkuas 
Zingiberaceae - Decoction of rhizomes &  
  base of pseudostem 
 
-To cure   
 stomachache, 
 vomiting,   
 diarrhoea   
 & indigestion. 
-Possibly a useful  
 aphrodisiac. 
3. Andrographis 
paniculata 
(Burm. f.) Nees. 
 
Daun pahit Acanthaceae - Decoction of leaves 
-Leaf poultice 
-To cure diabetes; 
-To reduce blood   
 pressure 
-To relieve skin   
 irritation  
 & insect bites  
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4. Areca catechu 
L. 
Pinang Palmae -Seeds are chewed with  
 betel leaf & lime paste.  
-For stomachache. 
-For headache. 
5. Catharanthus 
roseus (L.) G. 
Don.
Bunga pasir; 
Tahi ayam 
Apocynaceae -Decoction of roots -As contraceptive  
-Control  
 Hypertension 
6. Centella 
asiatica (L.) 
Urb. 
Penggaga; 
Pegaga 
Umbelliferae -Raw or cooked young  
 leaves are eaten as   
 vegetables 
-To cure urinary  
 tract infection and  
 stones 
 
 
7. Cosmos 
caudatus 
Kunth. 
Rancah-rancah Compositae -Young leaves & shoots  
  are eaten as raw 
vegetable 
 
-To treat gaseous  
 stomach & mild  
 gastric pains. 
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8 Curcuma longa 
L. 
Kunyit, Tamu 
Kunyit, Kunyit 
Biasa 
Zingiberaceae - Rhizomes are chewed  
and swallowed after each    
 rubbing on the abdomen 
-To relieve  
 uncontrollable and  
 frequent urination  
 due to the infection 
 of the urinary  
 system 
9. Curcuma 
zedoaria 
(Berg.) Rosc. 
Tamu putih 
(derived from 
the white-
coloured 
primary 
rhizome) 
Zingiberaceae -Rhizomes are pounded,    
 soaked in hot water &   
 warm infusion are taken  
 after child birth 
-To maintain good  
 health  
10. Cymbopogon 
nardus Rendle 
Serai wangi Gramineae -Infusion of leaves is used 
as herbal bath after 
childbirth; 
-Decoction of stems  
-To maintain good  
 health 
-For stomachache,  
 Indigestion 
11. Dillenia 
suffruticosa 
(Griff.) Mart. 
Simpor Dilleniaceae -Exudates of the broken  
 twigs, calyx, leaf stalks 
-Applied to wound  
 to stop  
 it from bleeding 
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12 Eleutherine 
bulbosa Urb. 
 
Bawang 
sampar 
Iridaceae -Decoction of boiled bulbs  
  is consumed 
-To treat piles,  
 improve blood  
 circulation, treating 
 internal physical  
 injuries.  
 
 
13. Eurycoma 
longifolia Jack. 
 
Tungkat Ali; 
Langir siam; 
Pasak bumi; 
Kayu raja; 
Petagar Ali; 
Serirana 
Simaroubaceae  -Decoction of roots 
-Infusion of  roots  
-To reduce blood   
 pressure 
-To stimulate male  
 Libido 
14. Hedychium 
longicornutum 
Baker. 
 
Halia hantu; 
Kunyit hantu 
Zingiberaceae - Decoction of roots &  
 rhizomes  
-Pounded roots for topical  
 application 
-Decoction of mixtures  
-To maintain good  
 health 
-To relieve skin  
 irritation 
-To minimise  
 Conception 
15. Manilkara 
zapota (L.) 
P.Royen. 
 
Ciku Sapotaceae -Pounded unripe fruits  
 mixed with warm water to  
 be taken orally    
-For treating  
 diarrhoea  
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16. Morinda 
citrifolia L. 
Mengkudu Rubiaceae -Ripe or Unripe fruits to  
 be brushed onto the teeth  
 of children 
-To prevent tooth  
 decay 
17. Rhodomyrtus 
tomentosa (Ait.) 
Hassk. 
Keramunting Myrtaceae -Leaves extracts & fruits -To alleviate  
 anaemia 
-For wound healing 
18. Stenochlaena 
palustris Bedd. 
 
Lamiding Blechnaceae -Baked fronds 
-Young fronds are  
 consumed as vegetables 
-Pregnant women at 
 late stage of  
 pregnancy for  
 facilitating easy  
 birth 
 
The indications of traditional medicine are normally based on empirical and folklore 
experiences. Unlike modern drugs such as pharmaceuticals, no data are required to substantiate 
the claims of these traditional remedies. Some natural products are of therapeutic potential, 
others are still in progress study and majority of the traditional medicine have not undergone any 
scientific study due to the fact that they are not prospective for the industries and also the lack of 
funding to carry out expensive research and development. This is particularly true for medicinal 
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plants used in traditional medicine for which no research on the clinical studies has been reported 
to date.  
 
Worldwide experience indicated that extensive clinical trials have been conducted on those 
prospective natural remedies but the results usually require further elucidation and investigation 
to achieve evidence-based medicine. In most developed countries, clinical trials on traditional 
medicine are almost impossible due to the costly preclinical safety requirements of the drug 
regulatory agencies. Therefore, allowances are given to these traditional medicine that have been 
used from generations to generations and if the authority is to curtail these products which will 
result in the risk of loss of these valuable ethnomedical knowledge among the future generations.  
 
It is to be noted that some medicinal plants that have been used for years by various ethnic 
groups are often not adequately documented in writing. The knowledge about the plants profile 
and usage is usually passed on verbally from person to person, i.e. grandfather to father to son, a 
generation game of knowledge handed over within the protected family circle. This knowledge is 
at risk of being forgotten, diminishing over the years and may be lost forever if studies on these 
medicinal plants are not to be taken off the ground. Ethnomedical knowledge in its indigenous 
context is utmost important especially in the chase for the search of novel therapeutic 
compounds. 
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2.5.4 Supply and demand of TM/CAM in Brunei Darussalam 
 
2.5.4.1 General use of TM/CAM in Brunei Darussalam 
 
The worldwide resurgence of interest in traditional medicine is evidenced by the numerous 
literature publications from the professionals such as policy makers, administrators, educators, 
clinicians, researchers, scientists, TM/CAM therapists and health personnels. The primary reason 
cited for its revival is a widespread fear of adverse effects associated with the western drugs and 
the belief that natural product is harmless. In addition to that, the high cost of treatment has 
turned many people to alternative remedies which are more affordable and widely available and 
accessible due to supply and demand.  
 
Although there is no research as yet been carried out on the ethnobotanical survey on the usage 
of TM/CAM among the various communities in Brunei Darussalam, the Ministry of Industry and 
Primary Resources revealed that many native plant species are extensively being used as natural 
remedies for various symptomatic diseases or minor ailments from generation to generation.  
There are a rapid increased number of traditional medicine retail outlets throughout Brunei 
Darussalam selling and supplying the natural products due to its demand by the consumers. 
There also exists a few small scale industries processing the raw materials into various dosage 
forms either as single entity or compounded preparations.  
 
The commercialisation of the traditional medicine and many other natural products has resulted 
in the influx of products in the capital which gives an indication of its popularity, used by many 
ethnic communities, not just solely by the oldfolks in rural areas. The growth of the natural 
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products market has turned into an industry of health care products of TM/CAM, may perhaps 
overtaking the orthodox medicine in the private sector in future. 
 
2.5.4.2 TM/CAM formulations and preparations in Brunei Darussalam 
 
There are many formulations of preparations on natural products which are available in the 
Brunei Darussalam market ranging from various origins of raw materials such as plants, animal 
parts, vitamins, minerals used as health food and nutritional/tonifying supplements. These are 
either processed or compounded locally or imported. These products are being used based on 
personal choice and handover practices. Generally, they are categorised as follows: 
 
• Available as various pharmaceutical dosage forms in the form of tablets, capsules, pills, 
suspensions, lotions, creams, ointments, sachets and mixtures, etc. Some preparations 
resemble the pharmaceutical dosage forms. 
 
• Strongly medicated wines which are highly alcoholic in contents usually soaked with 
animal organs and parts which are believed to be kept “the longer the better” for their 
medicinal effects. This is usually practised by the older generations as tonifying agents 
and believed to improve blood circulation. Similar practice can also be observed in Asia. 
 
• Herbal remedies such as herbal tea leaves and other plant parts which requires further 
processes before consumption in the form of maceration techniques, infusion or 
decoction or mixtures, etc. Prescriptions of mixtures of all plant parts such as dried 
leaves, flowers, twigs, seeds, barks, stalks, stems and roots that are raw in nature and are 
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cooked in a specified manner, sometimes with meat for many hours as tonifying agent for 
health promotion and supplements. These preparations are believed to strengthen the 
body. 
 
• Ayurvedic homeopathic remedies such as series of dilutions of the minute ingredient 
derived from the stock tinctures usually used in ayurvedic therapies and healing 
processes. 
 
• Aromatherapeutic preparations such as the range of external preparations which usually 
have soothing effect, with odour and essence that relieve stress and relax the mind and 
body. Aromatherapy oils used in body massages and steam baths are also gaining 
popularity especially among the young generations. 
 
• Miscellaneous preparations including mixtures that are derived from plants, animals, 
minerals in any other forms such as pastes, spice powders, dyes, food, emulsions, liquids, 
solutions, drinks and etc that are also available for commercial purposes. 
 
Among these many formulations and preparations available in Brunei Darussalam, therefore the 
accepted classification of traditional medicine as natural remedies is a natural product that must 
contain one or more naturally occurring substance(s) of plants, animals, minerals in their raw and 
unextracted or crude extract forms. Such classification is intended to avoid confusion.  
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Novel research study on medicinal plants extracts demonstrated that Catharanthus roseus (L.) G. 
Don from the Apocynaceae family which is also one of Brunei Darussalam important collection 
of medicinal plants, Herbarium Drug Museum (HDM 36), local name ‘bunga pasir; tahi ayam’ 
contains the vinca alkaloids, vincristine, vinblastine and vindesine are commercially available as 
pharmaceutical products for the treatment of acute leukaemia, lymphomas, and some solid 
tumours such as breast and lung cancer. And vinorelbine, a semi-synthetic vinca alkaloid was 
further developed for treating advanced breast cancer and non-small cell lung cancer where 
anthracycline-containing regimens have failed (BNF, 2005). All vinca alkaloids are intended for 
intravenous administration only. They are contraindicated for intrathecal administration due to 
severe neurotoxicity which is usually fatal.  
 
In the case of herbal remedies from the TM/CAM perspective, it is particularly important to 
illustrate their potential mechanisms of action at a molecular level by identifying the superior 
genotype with active components which are critical to understand their important role in the 
bioassays and as well as their potential risk to public health. At present, it is not surprising 
relatively little is proven about the efficacy and safety of TM/CAM due to the limited financial 
resources and laborious processes involved in the time consuming empirical study and keeping 
track of the performance of TM/CAM.  
 
 
 
 
 
 
 
 65
2.5.4.3 Nomenclature of the plants  
 
The nomenclature of plants can vary tremendously from country to country. For instance, at least 
fifty three vernacular names of Andrographis paniculata were used by the communities 
throughout Asia recorded by World Health Organization as listed in Table 2.3. Many problems 
of incorrect or misnaming of the plant species which can cause confusion when the plant species 
is not identified and authenticated appropriately which will have massive implications in the 
quality, safety and efficacy analysis of the plant. For example, confusion may arise in the 
following ways: 
 
• the same name (i.e. one particular name) may have been given to more than one plant. 
• the same plant is being called/addressed differently by different people from the same or 
different districts, regions, countries. 
• changes in the botanical name of that particular plant. 
• botanical name was given wrongly to different species. 
• same species was given different botanical names by different botanists. 
• inaccurate identification of plant species resulting in the wrong botanical name being 
given to the species. 
• wrong description of the plant species. 
• lack of standardisation in the naming of the plant species locally, nationally, regionally 
and internationally. 
• difficulties in establishing uniformity in the naming of  plant species. 
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Table 2.3 Vernacular names of Andrographis paniculata (Burm. f.) Nees  
(Adapted from the WHO monographs on selected medicinal plants  
Volume 2, World Health Organization, Geneva 2002). 
 
Index Vernacular names used for Andrographis paniculata (Burm. f.) Nees by communities in Asia  
1 Akar cerita bidara, Alui, Andrographidis Kraut. 
2 Bidara, bhoonimba, bhuinimo, bhulimb, bhuninba. 
3 Charayeta, charayetha, charita, cheranta, cherota, chiraita, chiretta, chuan-hsin-lien, chuanxinlian, cong cong. 
4 Daun pahit 
5 Faathalaaichon, fathalaai, fathalaichon, fathalaijone. 
6 Halviva, hempedu bumi, herba sambiloto, hinbinkohomba. 
7 I-chien-his. 
8 Kalafath, kalmegh, kan-jang, kariyat, khee-pang-hee, king of bitters, kiriathu, kirta, kiryata, kiryato. 
9 Lanhelian 
10 Mahatikta, mahatita, mompoit 
11 Naelavemu, naynahudandi, nelavemu 
12 Quasab-uz-zarirah 
13 Rice bitters 
14 Sambilata, sambiloto, senshinren, sinta 
15 Xuyen tam lien 
16 Yaa kannguu yijianxi 
 
 
It is a common phenomena that plants are called under more than one vernicular name which can 
cause a lot of confusion as shown in the Table 2.2, listing the commonly used medicinal plants 
by the local communities in Brunei Darussalam with their pictures depicted. Such a scenario is a 
worldwide problem. 
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2.6 Adoption of the WHO Policy and Strategy on TM/CAM 
 
In line with the WHO Policy in the promulgation of TM/CAM globally, it is suggested that the 
development strategies need to incorporate the following objectives in line with WHO policy in 
the promotion of use of TM/CAM for the delivery of health care to all. This policy will 
encompass all the important issues identified and to rectify the current situations and to improve 
further the infrastructure of TM/CAM in Brunei Darussalam, particularly in the Western Pacific 
Region Organization (WPRO): 
 
2.6.1 National Policy and Act on TM/CAM 
 
This policy is to integrate TM/CAM with the national health care systems as appropriately as 
possible through the development and implementation of national TM/CAM policies and 
programmes in the areas of importance and prioritiy for Brunei Darussalam. There is a need for 
Brunei Darussalam to formalise the legislation on TM/CAM which aims to ensure that quality, 
safe TM/CAM practices and products are available to the people in the country. Legislation 
would take the pragmatic approach of the needs of the communities and to maximise the benefits 
but minimise the risks involved in all aspects of TM/CAM therapy. 
 
2.6.2 Collaboration with regional and international centres on ensuring quality, safety 
and efficacy 
 
Brunei Darussalam needs to promote quality, safety and efficacy of TM/CAM by strengthening 
and expanding the knowledge-base on TM/CAM, and the implementation of quality assurance 
programmes on TM/CAM with the collaborating centres worldwide are to be encouraged. 
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2.6.3 Accessibility of TM/CAM  
 
The increase in the demand of TM/CAM should be in line with their increase of supply. Such a 
balance should be maintained to ensure there is a continuous availability of TM/CAM in the 
market which is affordable, effective, of good quality and safe. Therefore, in order to increase 
the availability and affordability of TM/CAM as rationally to the population, there is a need to 
promote the rational therapeutic use of TM/CAM by the health providers and consumers for the 
intended use. 
 
2.6.4 Pharmacovigilance on TM/CAM  
 
Continued efforts on the collaborations and networking with the international, regional, national 
MADR Centres on Adverse Drug Reactions (ADRs) or adverse events associated with TM/CAM 
use are very important. The needs to conduct post marketing surveillance on TM/CAM in the 
market and to step up research and development on their pattern of use, benefit versus risks ratio 
of these products are of paramount importance. 
 
2.6.5 Harmonisation process  
 
The identification of key areas which are ready for some degree of integration to take place that 
is of priority to the health care needs of the people (Kairullah, 2005; Merican, 2005). 
Development and research into areas of common core for community health needs to be explored 
further. The key to the future of TM/CAM in Brunei Darussalam would be in the integrative and 
collaborative partnerships through bilaterial and multilateral exchange and sharing of 
information on all aspects of TM/CAM processes and practices at national, regional, and 
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international levels. This would be for better use of resources and manpower in the most cost 
effectiveness manner and attainable. 
 
2.7 Recommendations on the proposed strategic framework of TM/CAM  
for Brunei Darussalam 
 
The use of native medicinal plants at the primary health care level has many advantages and 
should always be encouraged for the effective treatment of many ailments with good safety 
profile. In retrospect, during war experiences, there was a deprivation of modern medicines 
which has highlighted the importance of traditional medicine among many people in South East 
Asia. Communities would prefer to take herbal remedies which they grow in their own gardens, 
countries and will always be easily accessible and affordable when needed. For these old folks, 
they still remember this war experience and the need for essential medicine such as modern 
western drugs and for self-sufficiency medication; there is a clear need to encourage more 
widespread use of herbal medicine as natural reserves. These will, in fact, be an insurance in the 
communities’s perspective against such a situation from arising again and their endless 
endeavour to develop a reservoir of herbal armamentarium as alternative treatment for the next 
generations in need is clearly understood.  
 
Integration of the traditional and allopathic system and a unified approach to health care, not 
only at the primary health care level but at all levels, remains as the future long term goals. In 
our endeavor to achieve the ultimate goals, doctors, clinicians, pharmacists and nurses and other 
health care professionals should be trained both in the allopathic system as well as the traditional 
system in order to complement each other in the delivery of health care to the community. In a 
better position to treat patients either using allopathic medicine or with medicines from the 
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traditional system, both systems of medicines can be practised side by side in an integrated 
manner for the benefit of mankind. 
 
2.8 Development of national strategy on traditional and complementary medicines 
(TM/CAM) in Brunei Darussalam 
 
The Ministry of Health Brunei Darussalam recognises the immense potential benefits of the 
national TM/CAM heritage for the people of Brunei Darussalam and the future generations to 
come. In order to ensure that safe use of TM/CAM is in tandem with the mainstream healthcare 
infrastucture, appropriate legislation and regulation stipulated in the National TM/CAM Health 
Policy should be in place. With the promulgation of the Traditional medicine Act which aims to 
ensure that quality and safe TM/CAM practices, standards and products are available to the 
people of Brunei Darussalam, actualization of healthcare for all can be achieved. Therefore, the 
health policy and TM/CAM Act in place should address important issues such as safe practices, 
standards, education, training, products and to prioritize research and development in TM/CAM. 
 
Research and development strategies on the legislative and regulatory framework on TM/CAM 
with the objectives of improving quality health care to the communities in Brunei Darussalam. 
These strategies can be used in many settings to assess potential problems in TM/CAM use and 
to prioritize and focus subsequent efforts to ensure that TM/CAM is to be appropriately 
integrated into the Bruneian healthcare system in order to achieve a holistic approach in the 
improvement of quality of life of the Bruneians.  
 
TM/CAM is readily available at an affordable level by all communities worldwide. Due to its 
increasing demand and supply, it is used by all communities in Brunei Darussalam either 
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obtained locally in their crude forms as raw materials or as processed forms mostly imported 
from China, Malaysia, Singapore, Thailand and Indonesia. The health and nutritional 
supplements in the form of pharmaceutical preparations are normally imported from U.S.A., 
U.K., and Australia. 
 
Many factors such as easy availability of herbal remedies, accessibility to natural herbalists at all 
times and affordability coupled with the inherent faith, particularly in the ‘natural belief’, also 
complement the desire of large sectors of the population, to use medicinal herbs for therapeutic 
purposes. The influx of traditional medicine/herbals remedies into Brunei Darussalam is on the 
increase although there is no specific regulation or legislation on the importation, sale and use of  
TM/CAM. Currently, the Pharmacy Enforcement Unit of the Pharmaceutical Services of 
Ministry of Health exercise screening and control activities such as: 
 
• to screen all the import declarations for drugs (pharmaceuticals) containing scheduled 
poisons, OTC drugs, traditional medicine/herbal remedies as well as various 
classification of medicines for personal use. 
 
• to analyse on samples taken at random from sales premises and wholesalers’ warehouses 
to ensure that the importers comply to the official guidelines (as described fully in section 
2.4 of Chapter 2) on the importation on traditional medicine as imposed by the Ministry 
of Health. The traditional medicine should contain the ingredients and strengths as stated 
on the label as well as to eliminate the inclusion of certain adulterated harmful 
substances. 
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• to detect traditional medicine/herbal remedies which are adulterated with Scheduled 
Poisons/Prescription Only Medicines (P.O.M.) such as steroids and heavy metals upon 
laboratory analysis at random (Table 1.9). Therefore, it is imperative for us to consider 
regulatory and legislative control on the use of these substances. Linked to this are issues 
of quality control, both of the raw materials and of the finished products, and of 
standardization of traditional medicine/herbal remedies. 
 
As traditional medicine has become part of the cultural and traditional beliefs and practices of 
the communities, it is therefore important to bring the use of these traditional remedies into an 
existing framework of rational scientific use of medicines.  
 
The national strategies are aimed at enhancing the regulatory status and rational scientific 
framework of the TM/CAM in Brunei Darussalam. The following approach is adapted from the 
existing framework of pharmaceuticals setting but with some modifications which are 
appropriately integrated into the existing health care system of Brunei Darussalam. The 
integration process is proposed to be incremental in magnitude and efforts are to be made into 
identifying key areas for harmonisation and integration on TM/CAM in Brunei Darussalam. 
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2.9 Objectives 
 
The main objective is to propose to the Brunei Darussalam government a national strategy 
regarding the proper use, research & development and control of TM/CAM in the country. It is 
focused on the future collaborations in the key areas on the exchange and sharing of information 
on quality, safety and efficacy of TM/CAM. This framework is in line with the WHO 
promulgation of the use of TM/CAM worldwide on the basis of collaborative efforts of 
integration and harmonisation processes. 
 
2.9.1 Quality assurance of TM/CAM 
 
The following procedures are based on a pragmatic approach on TM/CAM for Brunei 
Darussalam to serve as an impetus in order to ensure that the quality assurance of TM/CAM is 
achieved: 
 
• Implementation of product listing of TM/CAM. 
• Laboratory analysis and assessment on samples submitted for application at random. 
• Monitoring control and inspection system. 
• Post Marketing Surveillance (P.M.S.). 
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2.9.2 Clinical evaluations and assessments  
 
Development of clinical evaluations, assessments and trials on the clinical use of TM/CAM are 
required: 
 
• Clinical evaluation and assessments on the TM/CAM. 
• Well planned and properly conducted clinical trial methodology and to make certain the 
results are analysed properly. 
• Conduct multicentre clinical trials on the treatment of uncomplicated disease conditions 
by using the medicinal native plants of Brunei Darussalam. 
 
2.9.3 Research and development strategies on TM/CAM 
 
This objective aims at obtaining up-to-date scientific information on quality, safety and efficacy 
of the tropical medicinal native plants of Brunei Darussalam in order to spearhead the planning 
of various research strategies on the community use of medicinal plants: 
 
• Identification and development of a model list of medicinal plants used in Primary Health 
Care settings (P.H.C.) in line with the WHO model list illustrated in Table 2.4. 
• Implementation of herbal formulary for more effective and proper use of traditional 
medicine/herbal remedies and improved herbal therapeutics. 
• Development of medicinal plant pharmacopoeia/monographs on the tropical medicinal 
native plants of Brunei Darussalam. 
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• Official guidelines developed by WHO and other collaborating centres on TM/CAM are 
useful reference guides and can be cost effective for setting up development of TM/CAM 
in developing countries with limited financial and manpower resources. 
 
2.9.4 Herbal pharmacovigilance activities 
 
Pharmacovigilance monitoring activities to encompass the adverse reactions and events 
associated with traditional medicine or use in conjunction with polypharmacy are for collecting 
important data on safety issues associated with traditional medicine. Evaluation, assessment, 
interpretation and analysis of data collected can be useful for early detection of risk associated 
with TM/CAM therapies or products. Brunei Darussalam as a member to the WHO 
Collaborating Centre will benefit from this collaborative effort and support on 
pharmacovigilance: 
 
• Reporting suspected adverse reactions associated with traditional medicine to the Uppsala 
Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Stora 
Torget, S-75320 Uppsala, Sweden. Establishment of world databank on the adverse drug 
reactions and herbal reactions for sharing of critical management of these adverse events 
in the most effective and efficient manner.  
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2.9.5 Collaborations on the exchange and sharing of information on TM/CAM 
 
Effective and efficient integration in the collaboration of sharing and exchange of information on 
many aspects TM/CAM in order to achieve quality TM/CAM care to the communities: 
 
• Strengthening the mechanisms on the activities of sharing and exchange of information 
among technical working groups on TM/CAM areas of collaborations at national, 
regional and international levels.  
 
• Create increased efficiencies through greater bilateral and multilateral collaborations, 
economies of scale and sharing resources with participating countries. 
 
• Collaborating with WHO Collaborating Centers on traditional medicine which plays a 
very important role in global collaboration as these centers are officially mandated and 
designated to ensure that the WHO policy on the strategy on TM/CAM in the propagation 
of the safe, quality assurance and efficacious TM/CAM to the communities globally is 
achieved.   
 
• Networking to the Global Information Hub regarding potential clinical benefits, safety 
and risks of TM/CAM products and practices made available to all participating member 
countries should be encouraged and well supported for the benefit of communities. 
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2.9.6 Public education 
 
• Public education and information on the proper and rational use of TM/CAM and other 
natural products.  
 
• Sharing, exchange of information and experiences on the use of traditional medicine of 
common interest among the public in public forums and group discussions to promote 
rational and quality use of traditional medicine. 
 
The national research and development plan on TM/CAM are geared to address key issues in 
public health, resources sharing through collaborative efforts and provision of funds for 
conducting scientific research and development on TM/CAM. The integration process requires 
good coordination, coherency, consistency in all areas of collaborations should be in tandem 
with the need to position TM/CAM in the best interest of all parties towards achieving the 
common goal of holistic approach in enhancing the health and quality of life of the community at 
large. 
  
2.10 Guidelines on the Product Listing  
 
On the basis of the definition of ‘traditional use’ adopted by the Complementary Medicine 
Evaluation Committee of the TGA for the purpose of the guidelines for levels and kinds of 
evidence to support indications and claims for non-registrable medicines, including 
complementary medicines, and other listable medicines (ARGCM, 2005) and reviews on the 
developments of TM/CAM from other countries, it is proposed that the Ministry of Health 
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Brunei Darussalam adopt a similar system but with some modifications. Such modifications are 
taken into considerations of the wide range of products available in the country. It is therefore 
required to categorize products which are defined under the existing official guideline of the 
Ministry of Health as a traditional medicine containing one or more naturally occurring 
substance(s) of plants, animals or minerals in their unextracted or crude extract forms. These 
guidelines need to address the levels and kinds of evidence to support claims for therapeutic 
products.  
 
2.10.1 Product listing of TM/CAM  
 
Listing of products is proposed to be categorized according to the claims made for the following 
categories of products containing plants, animals and minerals origin which are pertaining to the 
needs of the population of Brunei Darussalam: 
 
• Traditional medicine (Non scheduled poisons)  
• Raw materials 
• Crude or pure extracts 
• Pharmacopoeial items 
• Monographic herbs (format of the medicinal plant monograph as illustrated in 
Table 2.4 for documentation of each medicinal plant)  
• Standardized materials 
• Essential oils, aromatherapeutic agents 
• Homeopathic (Ayurvedic) preparations 
• Miscellaneous and other vague origin that may pose health risks to the public. 
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Table 2.4 Outline of the Medicinal plant Monograph Format  
[adapted from WHO Model, (Chaudhury, 1992)] 
Outline of the Medicinal native plant Monograph Format 
1. Scientific name: 
 
2. Synonyms: 
 
3 Common names of the plant (districts, country, region): 
 
4. Definition of plant parts used: 
 
5. Active and inactive chemical constituents (complete listing): 
 
6. Qualitative and quantitative control: 
• Certificate of authenticity (including scientific name, part of plant used, site of harvest, date of 
harvest and storage conditions of plant) 
• Microscopic description of drug (pharmacognosy) 
• Assays procedure, what is measured, %w/w contents of active constituents, references 
7. Pharmacology - review of current available scientific data and information 
 
8. Toxicology - review of available data and information on safety 
 
9. Historical/traditional/folkloric claims for short and long term uses 
10. Acceptable claims/indications for non-prescription use, denoting those claims which are supported by: 
-human data; 
-animal data;  
-traditional/folkloric use. 
11. Contraindications/cautions/warnings/interactions: groups at risk, include a standard statement in most 
cases that herb is not recommended for use in children under the age 12, pregnant or lactating women. 
 
12. Dosage and directions for use: 
• Accept doses found in the British Herbal Pharmacopoeia in most cases 
• Pharmacopoeial and/or folk medicine doses 
• Doses specified for different dosage forms (e.g., extracts and tinctures), as well as “equivalent doses 
of crude dried herb” which is obtained by calculation when the specification of the extract or 
tincture is known. Specifications of extracts and tinctures (1:1, 1:10 etc) clearly stated. 
• Single dose, dosage frequency and total daily dose wherever possible. 
13. Official pharmacopoeial preparations (Ref: USP, BP, NF, Indian, Chinese, EP and others) -past and 
present 
-Updated Scientific information  
14. Acceptable combinations/compound preparations - in general terms only, e.g. laxatives and 
carminatives. Problematic combinations. 
15. Closely related herbs e.g. other varieties or other species. 
16. References: (Specific statements in the monograph should be numbered to relate to the appropriate 
reference, whenever possible. A general reference list could also be used). 
Other up-dated information on clinical benefits, safety and risks.  
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2.10.2 Implementation of quality assurance on traditional medicine 
 
The main objective of the categorized product listing for products which are intended for 
commercial marketing purposes is to ensure that all TM/CAM available in Brunei Darussalam 
are safe, of acceptable quality and effective which is geared primarily for the benefits of the 
public so that such remedies will remain useful for alleviating or curing diseases without undue 
risks to the population. This objective can be achieved by carrying out the following activities: 
 
• to receive and screen applications for product listing purposes before it is 
approved for use in the market. 
• to list the number of TM/CAM to be marketed. Product listing number is issued 
for each product approved. 
• to assess product quality prior to evaluation. 
In applying for finished product listing, the manufacturer or importer must first request 
permission to produce or import sample products to be listed. Sufficient samples must be 
submitted for screening together with certificate of free sale. All information pertaining to the 
product must be completed with the following basic product profile for evaluations and 
assessments by the relevant evaluation committees: 
 
• product formulation(s) 
• indication(s) 
• dosage form 
• dosage regimen 
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• chemical and herbal data if applicable 
• method of assay 
• pharmacological data 
• toxicological data 
• clinical trials 
• label claims  
• package insert 
• any other information which are important to assist in the overall evaluations and 
assessments of the products 
• adverse reactions or events associated with the product which may be suspected, 
probably, certain, etc which are useful in the assessments of benefits versus risks. 
• pamphlets, inserts of the product information profile including side effects, 
precautions, interactions and contraindications.  
• Information on clinical benefits, safety and risks of TM/CAM products. 
 
The following evaluation and assessment criteria are applicable for the herbal/plant species 
which are intended for commercial marketing purposes. Basic information is required as follows: 
 
• Name of plant (genus, species, authority and family)  
• Plant part used (leaves, stems, barks, roots, seeds, etc) 
• Quality requirement (percentage of active principle, if known) 
• Purity (foreign matter, adulterant, other contaminants) 
• Physicochemical analysis: 
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 - Qualitative (including micro-chemical tests) 
 - Quantitative (if major active ingredients are known, analytical procedures - e.g. thin layer 
chromatography (TLC), high pressure liquid chromatography (HPLC), other newer 
techniques which were developed to quantify the total and individual constituents. Even 
if active principles are known, one can still obtain characteristic special profiles for the 
plant material. 
• Packaging. 
• Storage conditions, shelf life and stability monitoring and re-testing. 
• Deterioration of the plant materials and re-assessments of the contents of active constituents. 
 
The schematic flowcharts of Figures 2.2, 2.3, 2.4, 2.5 illustrated the processes involved in the 
listing of products by submission of applications to the Division of TM/CAM Authority of   
Ministry of Health Brunei Darussalam. These recommended procedures are needed to safeguard 
the interest of public health and at the same time to fully support the rational or quality use of 
TM/CAM in Brunei Darussalam. 
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STAGE 1 
 
 
 
  Not Approved 
(Application for 
product listing will 
not be accepted) 
     Approved 
 
 
 
 
 
 
     Upon importation/manufacture 
     of product concerned 
 
STAGE 2 
 
         
             
         
 
        I.   Ensure all necessary 
             documents are submitted 
 
        II.  Applicant is informed of  
(Application for  Fail             Pass         analysis results from laboratory 
product listing will      
not be accepted)      III. Laboratory analysis fee is paid 
 
STAGE 3 
        I.  Only applications with 
            complete documentation  
            will be accepted. 
 
     
  
           II. Processing fee to be paid 
Applicant submits application 
for product listing
Laboratory analysis 
Application submits sample to 
TM/CAM evaluation committee 
for analysis 
Processing of application
Application requests for permit 
to import/manufacture 
product concerned 
Preliminary
screening 
Application submits Letter  
of intent to TM/CAM evaluation 
Committee 
 
 
Figure 2.2. Procedure for Processing Application for Product Listing of 
TM/CAM 
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        1.  Sample 
 
 
        2.  Manufacturer’s 
1. Invoice for payment          Analytical 
             Protocol    
            
2. Acknowledgement of receipt    3. Certificate of  
            Analysis  
 
        4. Approval letter  
            from product listing 
            division to import 
            sample 
 
 
 
 
 
 
 
1.  Laboratory analytical reports    1.  Computer entry 
 
 
 
2. Comments       2.  Distribution of sample 
             to laboratories 
 
 
 
 
 
 
 
APPLICANT 
 
LABORATORY SECTION 
 
LABORATORY ANALYSIS 
 
 
Figure 2.3. Procedure for Laboratory Analysis of Samples for Product Listing of 
TM/CAM 
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(i)  Receiving Applicant 
           Form and Payment 
Additional 
Documents 
 
 
 
     
(ii) Entry to Computer 
    (iii)Evaluation 
    (iv)Request for 
 
 
 
 
 
 
 
 
 
 
    (v)Evaluators’ Comments 
 
     (vi) Report 
 
 
          Report 
 
          Not approved 
 
viii)Applicant          Report  approved 
       informed 
       of Decision 
 
 
 
 
      (vii)Decision of TM/CAM Authority 
           entered into computer 
 
 
 APPLICANT 
 Product listing  
Division of TM/CAM 
 
TM/CAM 
Experts/Specialists’ 
Comments 
 
Comments from 
WHO Collaborating 
Centres/International 
Bodies/Associations 
 
Evaluation 
Committee 
 
TM/CAM Control Authority 
Figure 2.4. Procedure for Processing Application of Product Listing of  
TM/CAM 
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       1. New application 
 
2. Renewal of licences        
         Incomplete (returned) 
 
 
 
 
1.Unsatisfactory 
   weaknesses in  
   documentation, etc. 
  
 
2. Non-compliance 
    to Good Manufacturing 
    Practice or Good 
    Storage Practice 
 
 
 
 
                              Action / Reply 
 
 
 
         Premise Inspection 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.5. Flowchart for Application of Manufacturer’s, Wholesalers’ 
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LICENCES 
CHECK 
PRODUCT LIST FOR 
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ISSUING OF RECEIPTS 
(ADMINISTRATION 
DIVISION) 
PROCESSING OF 
APPLICATION 
REPORT 
REPORT ASSESSMENT 
 and Importer’s Licences on TM/CAM 
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2.10.3 Monitoring control/inspection system 
 
Monitoring control and implementation of inspectorate system are aimed at ensuring that 
traditional medicine comply with the criteria set by the Ministry of Health up to time that they 
are delivered to the consumers, by way of inspection, sampling test, analysis, guidance and 
punitive action which are in line with the existing framework of inspection with modifications. 
Regular inspection and suspected or petitioned inspection include: 
 
• Inspection of importers’ premises, herbal outlets and medical halls in terms of 
standard regulations, operation, documentation and stocks. 
• Confiscation of substandard quality, misleading labels or packages with false 
claims. 
• Storage facilities of the premise i.e. storage conditions with appropriate 
temperature, moisture and humidity control.  
• Regular stock turnover first in first out (FIFO). 
• Continuous availability of affordable fresh raw herbal materials. 
• Maintenance of product quality and safety in ensuring safe delivery at the 
wholesale and retail sectors throughout the country. 
  
2.10.4 Post Marketing Surveillance (P.M.S) 
 
Pre-listing evaluation and assessment of the product is to provide some form of control measures 
on its quality, safety and efficacy. Many aspects of the product’s performance can only be 
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established through cumulative experience of its use in general practice. The performance, 
therefore needs to be constantly appraised throughout the commercial and marketing lifespan of 
a product such that it will continue to meet the required standards of quality and safety. P.M.S. is 
carried out by: 
-Adverse reactions/events monitoring programmes and activities. 
-Voluntary reporting on suspected adverse reactions or events associated with products by health  
 professionals and consumers. 
-Encourage notification culture on suspected products concerning risks and safety issues. 
-Reevaluation and re-assessment of the product. 
-Product decomposition and deactivation of constituents which affect the quality, safety and  
 efficacy of products. 
 
2.10.5 Clinical evaluation and assessments 
 
To achieve the research objectives, this component is prompted to set up protocols on the 
appropriate clinical evaluation and assessment of medicinal native plants in Brunei Darussalam. 
It is important that clinical investigators to carry out clinical trial methodology, especially 
pertaining to medicinal plants is properly planned, coordinated and well conducted and make 
certain that the results are analysed properly and that correct interpretations are drawn from the 
results. The traditional medicine model approach consists of the following important primary 
steps/protocols for the research and development of medicinal plants: 
 
• Literature review on the background and understanding of the plant profile. 
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• Identification of the plant reportedly in use 
• Collection of the plant. 
• Transport of the plant to the research laboratory. 
• Storage of the plant materials. 
• Preparation of extracts for testing. 
• Administration of the extracts to animal models, protocols and designs. 
• Identification of the active principles and chemical structure. 
• Synthesis of the active substances. 
• Short and long term goals in establishing the clinical evaluation and assessment of 
the medicinal native plants of Brunei Darussalam. 
 
In ensuring the safety profile of the medicinal plants species, toxicity testings are required for the 
confidence use of the communities and the following steps need to be undertaken: 
 
• Toxicity testing of the plant species. 
• A modified and shorter duration toxicity testing to avoid long term risk.  
• Administration of the total extract or combination of plants, if used, in exactly the 
same way as it is prepared and used by the population for the actual intended 
purpose of the plant species. 
 
Community based studies on the efficacy and safety of the medicinal plants in multicentre 
clinical trials setting on the actual use of the plants to reflect real life scenario need to be 
conducted: 
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• test for efficacy in human to be approved by the ethics committee. 
• safety profile of the plants investigated and duration of the toxicity studies to be 
decreased for plants being used by human to avoid risk due to long term exposure. 
• plant is administered to human subjects in exactly the same manner as is being 
used in traditional medicine approach. 
• conduct multicentre clinical trials on large number of patients with uncomplicated 
conditions of tropical diseases using native tropical medicinal plants such as 
similar studies conducted on traditional medicine Qinghaosu for the treatment of 
malaria. 
 
2.10.6 Identification and development of a model list of medicinal plants used in Primary 
Health Care (P.H.C.)  
 
As an initial set up programme and for long term planning, it is necessary for Brunei Darussalam 
to adopt the model list for biodiversity on cultivar development which should be based on the 
following important criteria: 
  
• Availability of the planting area so that it could be readily used. 
• Allocation of lands for cultivation and also replantation of forest with the plant 
species that will be exhausted and facing treat of depletion if these species are not 
conserved. 
• Regulation on the prevention of medicinal plants from being over-harvested. 
Implementation of forest reserve scheme and policy to protect these plants from 
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extinction. Zoning of the forest areas for cultivating and farming the medicinal 
plants to be gazetted as plantations for medicinal plants. 
• Set up nursery for small and large scale holdings. 
• Conservatorium and herbarium are to be further developed for the research and 
development of important plant species and their potentials for therapeutic 
benefits. 
• Compilation of scientific information on quality, safety and efficacy of these 
native medicinal plants of Brunei Darussalam for treating various disease 
conditions.  
 
There are many disease conditions need to be identified which are normally encountered at the 
primary health care level for which herbal remedies could be used by the communities in the 
treatment of these ailments. The important criteria for the selection of plants for each of these 
conditions are: 
 
• Actual use of these medicinal plants in Brunei Darussalam. 
• Scientific literatures indicating the quality, safety and efficacy of the plants in 
certain diseases and common conditions. 
• Use of these medicinal plants for therapeutic purposes in countries outside Brunei 
Darussalam. 
• Documentation of these medicinal plants profile is essential to achieve the 
research and development objectives on medicinal plants of Brunei Darussalam. 
 
 92
2.10.7 Implementation of a national herbal formulary for more effective and proper use of 
TM/CAM 
 
The objective of herbal remedies as in line with the national drug formulary is to provide 
guidance for the traditional medicine practitioners and to health personnels of the modern system 
of medicine and allied para-professionals of this system. This will ensure that the knowledge 
about the native plants and their profiles are not lost in time for the benefit of the young 
generation and the future generation to come. Such herbal formulary is to be prepared only after 
we have identified and produced a list of plants that are used at the primary health care level. The 
herbal formulary (Chaudhury, 1992) comprises of the following basic structure about the 
medicinal plant with additional scientific data and information: 
 
• Name of plant (genus, species, authority and family). 
• Plant part(s) used for disease conditions. 
• Quality requirement (percentage of active principle, if known). 
• Purity (foreign matter, adulterant, other contaminant). 
• Physicochemical analysis: 
 - Qualitative (including micro-chemical tests). 
 - Quantitative ( if major active ingredients are known, analytical procedures 
e.g. thin layer chromatography, high pressure liquid chromatography, 
chemical fingerprinting techniques should be developed to authenticate the 
plant species or varieties, quantify individual and total constituents.  
• Bioassay testings 
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 - In vitro assay 
 - In vivo assay 
• Pharmacological/biological category for which the herbal product is indicated. 
• Posology (correct dose and directions for use). 
• Toxicity/contraindications with appropriate warning information. 
• Packaging and storage. 
• Proper packaging, storage and shelf life. 
• Scientific information on clinical benefits, safety and risks on the plant. 
 
2.10.8 Research and development strategies  
 
Fully integrated, coordinated and concerted efforts among all health care professionals should be 
encouraged and to ensure national coherency and consistency in the key areas of research and 
development on the medicinal native plants: 
• developing a coordinated scientific framework to assess the medicinal native 
plants.  
• promoting the acceptance and integration of phytomedicines in all levels of health 
care practices. 
• supporting and initiating clinical and experimental research in phytotherapy, 
• improving and extending international data banks for updated scientific and 
knowledge on quality, safety and efficacy of the medicinal native plants. 
• information on clinical benefits, safety and risks on the medicinal native plants. 
• furthering collaboration and cooperation among established 
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associations/institutions/centres on a worldwide scale. 
• taking all possible initiatives to advance these research and development 
objectives on medicinal native plants worldwide. 
• sharing and exchange findings through publications of any clinical benefits, 
safety, efficacy  and risks associated with the plant. 
 
2.10.9 Collaborative and integrative roles of relevant ministries in the research and 
development of TM/CAM 
 
The relevant ministries which play important roles as joint venture partnership with assured 
consistency and coherency in the national strategies to embark on the research and development 
of the medicinal plants of Brunei Darussalam are: 
 
• Ministry of Industry and Primary Resources 
• Ministry of Health 
• Ministry of Home Affairs 
• Ministry of Education  
• Other relevant ministries/institutions/organizations/sectors of common interest in 
the field of medicinal plants. 
 
2.10.10   Financial support & Funding mechanism 
Collaborative efforts from the various ministries and private organizations/institutions/sectors 
that are involved in the research and development projects: 
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• Public sector 
• Private sector  
-TM/CAM Industries 
-Pharmaceutical Industries 
-Research Laboratories, 
-Manufacturers and distributors in TM/CAM products. 
 
National strategies are aimed to achieve the following main objectives on a long term basis: 
 
• to encourage broader knowledge based and recognition of the importance and 
value of the medicinal plants of Brunei Darussalam. 
• to advance the science, technology and practice of medicinal plants by modern 
scientific techniques/approach. 
• to promote high standards of quality and safety in herbal remedies. 
• to foster research in phytotherapy, exploring the vast potential of medicinal plants 
and its medicinal benefits. 
• to gather and document all scientific information on the three important criteria 
such as quality, safety and efficacy i.e. clinical benefits and risks of the medicinal 
plants of Brunei Darussalam. 
• to develop important medicinal plants into potentially therapeutic agents for the 
treatment of the uncomplicated disease conditions, accessible to the communities. 
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Increased support from the public and private sectors are needed in order to achieve successful 
research on medicinal plants leading to new drug development in the following areas: 
 
• Pooling and concentrating resources from the best brains and medicinal plants 
expertise to this important field of research and development of therapeutically 
active substances fom the medicinal plants of Brunei Darussalam. 
• Use of appropriate methods and new technological advancement for cost-
effectiveness management.  
• Development of viable infrastructure and step up research and development into 
medicinal plants of Brunei Darussalam. 
• Effective and efficient use of limited resources such as funding, facilities and 
manpower. 
• Training of personnels or key professionals in medicinal plants research and 
development. 
• Renewing interest of pharmaceutical industries in medicinal plants drug 
development. 
• Establishment of the databank of genetic information on the medicinal plants 
species and varieties of Brunei Darussalam and other countries. 
• Ensuring the continuous availability of the important species and varieties of 
medicinal plants of Brunei Darussalam through biotechnological advancements in 
identifying the molecular markers of the superior genotype(s) for quality cultivar 
development. 
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• Conservation of the important cultivar of the selected medicinal plant species 
which produces high yields of active constituents for future research on their 
therapeutic effects on many disease conditions. 
 
2.10.11  Public education on the proper use of TM/CAM 
 
Strengthening the promotion of public education and information on the rational use of 
TM/CAM and other natural products in order to ensure continuing health care for the 
communities is based on the following activities: 
• to encourage public to discuss and communicate with the health professionals about the 
use of TM/CAM in daily practices. 
• to take herbal remedies/TM/CAM according to the directions and instructions prescribed 
by the practitioners. 
• to report any adverse reactions/events experience by the consumers to the National 
Monitoring Centre on TM/CAM. 
• to provide platforms for the discussion and communication on the proper use and safety 
of TM/CAM among the public.   
In conclusion, the ultimate goal of the strategic framework is to focus on the integration and  
harmonisation process of TM/CAM and to ensure safe delivery of TM/CAM in the enhancement  
of health and improving quality of life of the communities in Brunei Darussalam. There is also  
the need to explore further into the important native medicinal plant species of Brunei Darussalam  
which may contain important secondary metabolites of therapeutic significance and benefits to the  
community at large. 
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3.1 Why Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam? 
 
The search for effective phytotherapeutic agents for the treatment of various diseases or 
conditions, such as oxidative stress, inflammation, anti-allergies, tissue injuries, hepatotoxicity, 
cancer and other pathological complications remain the quest for medicines. In this context, great 
efforts have been made in studying natural plants/herbs, especially those from tropical or natural 
diversity areas or regions. Nevertheless, in certain countries or regions limited resources are 
available, thus evidence for chemistry and actions of most plants/herbs which have long been 
used in the community is still lacking.  
 
Brunei Darussalam has a wealth of natural plant resources with significant potential for 
molecular analysis to conserve the genetic diversity and consequently provides avenues for 
studies on phytochemical content and bioactivities of the plant species. Among the 340 plant 
species recorded, only 160 species were positively identified. Andrographis paniculata (AP) 
(Burm. f.) Nees of Brunei Darussalam, is a widely used medicinal herb in Asia in particularly 
China, India, South East Asia and Brunei Darussalam for many disease conditions.  
 
It was reported that there are 28 species in the world, 25 out of these are distributed in India and 
23 occurred in peninsular region (Index Kewensis, Royal Botanic Garden, Oxford University 
Press, Oxford, 1977-87). Andrographis species such as A. elongata, A. viscosula, A. echioides 
were identified but among these, Andrographis paniculata species is widely distributed in South-
East Asia and is one of most popular herbs used among the communities in Asia. However, 
literature reviews indicated that the genetic diversity and variation information of the 
Andrographis paniculata species and varieties is very limited. There is no documented genetic 
diversity analysis of Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam. Therefore,  
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the genetic profile of genus Andrographis collected from different phytogeographical 
distributions need to be assessed in order to provide important linkages for further research into 
the plants medicinal benefits. The understanding of the correlation between the genetic profile 
and the phytochemical profile may provide vital information on the intraspecific variation of the 
biochemical profile. Such a profile may lead to the understanding of the mechanisms behind the 
various important aspects of the phytochemical profile and the pharmacological effects of this 
important medicinal plant.  
 
3.2 Medicinal Uses of Andrographis paniculata (Burm. f.) Nees  
 
Andrographis paniculata (Burm. f.) Nees is a member of the plant family Acanthaceae, with 
pharmaceutical name Herba Andrographitis paniculatae. It is known as Chuan Xin Lian (CXL) 
in China, mainly cultivated and is collected or harvested in early autumn when foliage branch 
growing luxuriantly, and dried in the sun. The leaves are extremely bitter in taste. It is 
documented in the Chinese Pharmacopoeia, 2000 to be used for a number of disease conditions 
including removing heat, counteract toxicity, and induce subsidence of swelling. In addition, it is 
also applied for influenza with fever, sore throat, ulcers in the mouth, cough, colitis, dysentery, 
urinary infection and snake bite (Martz, 1992; Poolsup et al., 2004; Singha & Roy, 2003; 
Thamlikitkul et al., 1991). Some of these indications are alike those of use in many other Asian 
countries, mostly in India, South East Asia including Brunei Darussalam. Fasihuddin B. Ahmad 
(2004) conducted research study on the medicinal plants used by various ethnic groups such as 
Dusun, Kadazan and Murut in Sabah, a neighbouring Malaysian state close by to Brunei 
Darussalam reported that Andrographis paniculata known as ‘Mompoit’ (vernacular name in 
Sabah) is widely used by the local communities to treat a range of diseases such as hypertension 
and diabetes (Ahmad, 2004). The Andrographis paniculata leaves are usually consumed steeped  
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in hot water for drinking. In addition to that, the ASEAN Regional Centre for Biodiversity 
 Conservation (ARCBC) in 2004 data collection listed in the checklist of medicinal plants in 
South East Asia reported that the upper ground aerial part of Andrographis paniculata is used as 
tonic, diuretic, anti-pyretic, stomachache, typhus, diabetes, counters eczema, against itchiness, 
hypertension, tonsillitis, flu and chest pain (ARCBC, 2004). Andrographis paniculata is also 
well known as “King of Bitters” in India and is found in the Indian Pharmacopoeia in many 
ayurvedic formulae. In Scandinavian countries, it is used to prevent and treat common colds. 
 
The plant has a wide broad range of therapeutic applications. In the cardiovascular system it 
induces dilation of coronary blood vessels offering support for conditions such as hypertension 
and angina. It also stimulates cerebral and peripheral circulation enhancing conditions such as 
memory loss, chronic tireness and numbness of extremities. In the immune system Andrographis 
paniculata enhances phagocytic activity of macrophages and migration of T-lymphocytes to 
peripheral organs. 
 
3.3 Genetic diversity profile of Andrographis paniculata (Burm. f.) Nees 
 
Currently, there is no documented genetic profiling analysis of Andrographis paniculata (Burm 
f) Nees of Brunei Darussalam. Literature search reported that the genus Andrographis also 
known as ‘King of Bitters; Kalmegh of Ayurveda’  as a whole is of potential significance to India 
as 25 out of 28 species (Padmesh et al., 1999) in the world are distributed mainly in India 
However, with the development of biotechnology, new methods/techniques are available to 
study genetic profile of medicinal plants such as DNA fingerprinting, etc. Molecular techniques 
have aided in the assessment of genetic diversity in plants with profound results as compared to 
the traditional methods which relied on the use of morphological differences between individual  
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species or varieties. Further more, the number of easily scorable morphological differences are 
limited and are sensitive to environmental influences. Many diversity assessments are currently 
performed using RAPDs, RFLP and actual gene sequences. 
 
The analysis by agarose gel electrophoresis is probably the most reliable approach, especially for 
the crude DNA preparations in order to estimate the concentration of genomic DNA extracted 
from Andrographis paniculata and to evaluate the quality of the DNA. In this study, the 
Polymerase Chain Reaction (PCR) is performed on Andrographis paniculata DNA extracted 
from its air dried powdered samples in order to generate its molecular marker profiles. 
 
Andrographolide (C20H30O5; MW 350.44), the plant-specific bicyclic diterpenoid lactone is 
intensively bitter and have demonstrated a wide spectrum of pharmaco-biological activities as 
described.  Andrographolide content on dry weight basis was found to be highest at 1.47% in the 
AP36 genotype population from Tamil Nadu and showed an overall mean value of 0.95% for all 
the populations (Sabu, 2002).  For the biodiversity rich countries in the tropics, chemical and 
genetic prospecting of the plant is a high priority and important not only for identifying superior 
genotypes/DNA molecules of potential economical importance but also for developing 
therapeutically active medicines.  
 
The study conducted by Sabu (2002) and Padmesh et al., (1999) have shed some light in the 
intraspecific variations. The genetic distances were moderate among different populations which 
substantiated previous report on the RAPD analysis of Andrographis paniculata by Padmesh et 
al., 1999. Andrographis paniculata is unlike many other plant species that is facing threat from 
extinction due to its reduced genetic variability and increased susceptibility to agents of stress.  
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It is cultivated and distributed widely in many countries in Asia such as India, China and 
Thailand which at present is facing threat of genetic depletion as a result of over-exploitation due 
to its wide popularity of medicinal uses in the primary health care system. Measures are therefore 
initiated for the conservation of Andrographis species with its varied diversity, otherwise the 
potential variants with highest productivity to be developed as superior cultivars may disappear 
once for all and resulting in extinction of such an invaluable species. Sabu (2002) concluded in 
his study that by selection of an improved natural variant for the development as cultivar and the 
isolation of a high yielding cultivar from the selected superior genotype through chemical 
mutagenesis would be the most fruitful mthods of achieving the dual objectives of conservation 
of the existing genetic diversity and sustainable utilization of this important medicinal resources 
which is affordable by the needy population of the developing world. 
 
3.4 Phytochemical profile of Andrographis paniculata (Burm. f.) Nees 
 
3.4.1 Morphology profile 
 
Sabu (2002) reported that Andrographis paniculata (Burm f) Nees, an important medicinal plant 
of India, presumably having its center of origin and diversity in southern India and Sri Lanka, 
grows abundantly in southeastern Asia (Sabu, 2002). It is also cultivated extensively in China, 
Thailand (Sandberg, 1994), east and west Indies, Mauritius (Gupta et al., 1990). Andrographis 
paniculata is such a hardy plant that grows in all types of soil, in pine, evergreen and deciduous 
forests, roadsides, and villages. It can also thrives on soil types such as serpentine soil which is 
relatively high in aluminium, copper and zinc where almost no other plant can be cultivated. 
Such hardiness accounts for its world wide-distribution and easy accessibility.  
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Andrographis paniculata appears to grow best in the tropical and subtropical areas of India, 
China and South East Asia including Thailand, Malaysia, Brunei Darussalam and Indonesia. The 
highest concentration of the active components is found just before the plant blooms, and 
harvested timely before the leaves fall.  
 
It is an annual-branched, erect up to around one meter in height. Light green coloured stems are 
squarish, with green leaves of dimensions 5 cm x 1.5 cm, simple, elliptic with acuminate tips. 
The axillary and stem terminal in panicles with upright flowers; pods to 1.7 cm long, 2-celled, 
containing 12 seeds as described (Chin, 2000). 
 
3.4.2 Phytochemical profiles of Andrographis paniculata 
 
Table 3.1 illustrates the known chemical contents of Andrographis paniculata. Gorter was the 
first to isolate the bitter water soluble diterpene lactone, Andrographolide (C20H30O5) from the 
leaves of Andrographis paniculata. Two other diterpenes, viz. Deoxandrographolide and Neo-
andrographolide with medicinal properties and clinical applications were further isolated by 
(Bright et al., 2001). It is reported to contain three active components diterpene lactones 
Andrographolide as the major compound, Deoxandrographolide and Neoandrographolide. 
Recent studies by Pramanick et al. (2005) and Shen et al. (2005) has isolated new ent-labdane 
type diterpenoids from the leaves of Andrographis paniculata (Pramanick et al., 2005; Shen et 
al., 2005) which are still undergoing various bioactivities testings. 
 
There are various laboratory techniques available in studing the content of Andrographolide in 
Andrographis paniculata products including leaves powders, liquid extracts or tinctures, such as 
thin-layer chromatography, ultraviolet spectrophotometry, liquid chromatography, conventional  
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methods of volumetric and colorimetric systems. It was reported that the leaves contain the 
highest amount of Andrographolide (2.39%), being the most medicinally active phytochemical in 
the plant whereas the seeds contain the lowest (www.altcancer.com/andcan.htm). The levels of 
other medicinal phytochemicals extracted from the leaves are low but may be active in nature 
(Sharma et al., 1992).  
 
Table 3.1 Phytochemical content of Andrographis paniculata leaves 
 
 Phytochemical content of Andrographis paniculata leaves 
References:   (Chem & Liang, 1982; Sharma et al., 1992; Shen et al., 2005) 
1 Andrographolide 
2 Deoxyandrographolide 
3 -19ß-D-glucoside 
4 Neo-andrographolide 
5 14-deoxy-11,12-didehydroandrographolide (andrographolide D) 
6 Homoandrographolide 
7 Andrographan 
8 Andrographon 
9 Andrographosterin 
10 Stigmasterol 
11 3-О-ß-D-glucopyranosyl-14, 19-dideoxyandrographolide  (ent-labdane diterpenoids) 
12 14-deoxy-17-hydroxyandrographolide (ent-labdane diterpenoids) 
13 19-О-[ß-D-apiofuranosyl(1→2)-ß-D-glucopyranoyl]-3, 14-dideoxyandrographolide 
(ent-labdane diterpenoids) 
14 3-О-ß-D-glucopyranosylandrographolide (ent-labdane diterpenoids) 
15 12S-hydroxyandrographolide (ent-labdane diterpenoids) 
16 Andrographatoside (ent-labdane diterpenoids) 
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3.5 Pharmacological actions  
 
Some of the important milestone discoveries as reported in the literature review and monographs 
(WHO, 2002c) based on the previous studies conducted on Andrographis paniculata (Burm. f.) 
Nees leaves which have led to our current understanding of the plant’s pharmacological actions 
and its medicinal value to the Asian communities. There is a renewed interest into conducting 
research on the mechanism of actions, cultivar development of Andrographis paniculata (Burm. 
f.) Nees and its potential as the therapeutic anti-cancer drug (Rajagopal et al., 2003).  
 
3.5.1 Anti-bacterial and anti-microbial activities  
 
George and Pandalai (1949) showed that the ethanol extract of Andrographis paniculata leaves 
inhibited the growth of Escherichia coli and Staphylococcus aureus in vitro (George & Pandalai, 
1949). 50% methanol extract of Andrographis paniculata leaves were found to inhibit growth of 
Proteus vulgaris in vitro (Nakanishi et al., 1965). However, there was no in vitro activity 
observed by Leelarasamee et al., (1990) when the dried powder of the leaves of Andrographis 
paniculata was tested against E.coli, Staphylococcus aureus, Salmonella typhi or Shigella 
species based on three assays conducted (Leelarasamee et al., 1990). Firstly, direct assay of 
Andrographis paniculata crude powder in water at a concentration of 25g/Litre. Second assay 
was performed on testing the serum bacterial activity after oral ingestion of Andrographis 
paniculata stem and leaves by ten healthy volunteers at 1, 2, 3 & 6 g. Third study was carried out 
on culture media testing on the lung parenchyma and liver tissue from rats which were fed on 
high doses of Andrographis paniculata from 0.12-24g/kg body weight for six months before the 
rats were sacrificed. Andrographolide and arabinogalactan proteins from Andrographis  
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paniculata showed significant anti-microbial activity may be due to their combined effects in the 
aqueous extract (Prajjal et al., 2003).  
 
3.5.2   Anti-pyretic activity 
 
Vedavathy and Rao (1991) investigated the intragastric administration of the ethanol extract of 
Andrographis paniculata leaves at 500mg/kg to rats on yeast-induced pyrexia. This extract was 
as effective as 200mg/kg body weight of aspirin (at equipotency dosage) with no toxicity 
observed at doses up to 600mg/kg body weight (Vedavathy & Rao, 1991). Intragastric 
administration of the major active component Andrographolide at 100mg/kg body weight to 
mice decreased brewer’s yeast-induced pyrexia (Madav et al., 1995). Similar study was 
conducted on deoxyandrographolide, andrographolide, or 11, 12-didehydro-14-
deoxyandrographolide at 100mg/kg body weight to mice, rats or rabbits were found to reduce 
pyrexia induced by 2, 4-dinitrophenol or endotoxins (Chang & But, 1986; Deng W et al., 1982). 
The leaves have been widely used for relieving fever and lowering body temperatures by the 
Asian communities for many years. 
 
3.5.3 Anti-Familial Mediterranean Fever 
 
ImmunoGuard, a standardized fixed combination of Andrographis paniculata (Burm. f.) 
Nees, Eleutherococcus senticosus Maxim, Schizandra chinensis Bail and Glycyrrhiza glabra L. 
extracts showed significant improvement of the clinical symptoms such as abdominal, chest 
pains, temperature, arthritis, myalgia, erysipelas like erythema in patients with Familial 
Mediterranean Fever (Amaryan et al., 2003). 
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3.5.4 Urinary tract infection 
 
Study on fifty patients post Extracorporeal Shock Wave Lithotripsy (ESWL) pyuria and 
hematuria found that Andrographis paniculata tablets at an oral dose of 250mg reduced 
symptoms in ESWL urinary tract infection (Muangman et al., 1995).  
 
3.5.5 Anti-diarrhoeal activity 
 
Gupta et al. (1990) found that ethanol, chloroform or 1-butanol extracts of Andrographis 
paniculata leaves at 300mg/ml inhibited the E. coli enterotoxin-induced secretory response-
diarrhoeal syndrome in rabbit but the aqueous extract was ineffective. Andrographolide and 
Neoandrographolide exhibited potent antisecretory activity in vivo against E. coli enterotoxin-
induced diarrhoea at 1mg of equivalent potency as loperamide when tested against heat labile  
E. coli enterotoxin-induced diarrhoea by acting through the stimulation of adenylate cyclase. 
However, at the same concentration, Andrographolide was more effective than loperamide when 
compared to Neoandrographolide against heat stable enterotoxin-induced diarrhoea by acting 
through the activation of guanylate cyclase (Gupta et al., 1990).  
 
3.5.6 Anti-inflammatory activity 
 
Intragastric administration of deoxyandrographolide, andrographolide, neoandrographolide or 
11, 12-didehydrodeoxyandrographolide to mice inhibited the increase in cutaneous or peritoneal 
capillary permeability induced by xylene or acetic acid. Among the tested components, 11, 12-
didehydrodeoxyandrographolide exhibited the most potent anti-inflammatory activity in vivo 
(Chang & But, 1986).  
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3.5.7 Anti-malarial activity 
 
Ethanol extract of the Andrographis paniculata leaves was found to inhibit the growth of 
plasmodium berghei both in vitro at 100mg/ml and also by intragastric administration in mice 
(1g/kg body weight). Andrographolide (5mg/kg body weight) and Neoandrographolide 
(2.5mg/kg body weight) were found to be effective when administered by gastric lavage in the 
treatment as anti-malarial agents. 
 
In vitro and in vivo studies of Andrographis paniculata (Najib et al., 1999) demonstrated the 
anti-malarial properties which can be further researched into the development of future potent 
anti-malarial drugs. The schizonticidal activity of Andrographis paniculata was found to be as 
potent as G. scortechinii in the inhibition of the sensitive strain, D10 of plasmodium falciparum 
but less effective inhibition towards the resistant strain, Gombak A (Najila et al., 2002). 
 
3.5.8 Anti-filarial activity 
 
Dutta and Sukul found that the aqueous extract of Andrographis paniculata leaves caused 
mortality against Dipetalonema reconditum microfilariae within 40 min in vitro (Dutta & Sukul, 
1982). The anti-filarial activity of Andrographis paniculata was measured by the relative 
movability value of the adult worms (Zaridah et al., 2001). 
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3.5.9 Anti-platelet effect 
 
Study on 63 patients of cardiac and cerebral vascular diseases taking Andrographis paniculata 
extract showed that it could inhibit the releasing of dense and alpha agranules for platelet and 
dilatation of canalicular system which suggested that Andrographis paniculata exerts its anti-
platelet effect by raising the platelet cAMP level (Zhang et al., 1994). The possible effect of 
Andrographolide on the biosynthesis of eicosanoids and the platelet-activating factor (PAF) 
indicated that its mechanism of action is most likely to be associated with the cardiovascular and 
antithrombotic activity of Andrographis paniculata (Amroyan et al., 1999). 
 
3.5.10  Choleretic effect 
 
Andrographolide demonstrated a dependent choleretic effect at a dose range of 1.5-12 mg/kg as 
indicated by the increase in bile flow, bile salt, and bile acids in conscious rats and anaesthetized 
guinea pigs (Shukla & Visen, 1992).  
 
3.5.11 Enhancement of intestinal digestion 
 
Both Andrographis paniculata leaves extract and Andrographolide increased intestinal digestion 
and absorption of carbohydrate in a dose related and time dependent characteristic activation of 
brush border membrane-bound hydrolases (Choudhury & Poddar, 1985). 
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3.5.12 Anti-fertility 
 
Male albino rats fed at a dose of 20mg/day of dried leaf powder of Andrographis 
paniculata for 60 days resulted in the cessation of spermatogenesis, degenerative changes 
in the seminiferous tubules, regression of Leydig cells in the epididymis seminal vesicle, ventral 
prostate and coagulating gland demonstrated the antispermatogenic and antiandrogenic effect of 
the plant (Akbarsha et al., 1990). Female mice on Andrographis paniculata at 2gm/kg daily for a 
period of 6 weeks were not pregnant compared to the majority of the control female mice 
(95.2%) without Andrographis paniculata were pregnant indicated its potent antifertility effect 
(Zoha et al., 1989), indicating a precaution against use during pregnancy. Extra contraception is 
necessary as Andrographis paniculata has not been proven as an absolute contraceptive. 
 
3.5.13 Anti-venom activity 
 
Andrographis paniculata is indicated for snake bites as traditional medicine therapy. 
Intraperitoneal injection of an ethanol extract of the leaves (25g/kg body weight) to mice 
poisoned with cobra venom markedly delayed the occurence of respiratory failure and death. 
This extract also induced contractions in guinea-pig ileum at concentrations of 2mg/ml, and these 
contractions were enhanced by physostigmine and blocked by atropine, but were unchanged by 
antihistamines. Studies indicated that the extracts do not modify the activity of the nicotinic 
receptors but possibly mediated by producing significant muscarinic activity, accounting for its 
anti-venom effects (Chang & But, 1986; Nazimudeen et al., 1978). 
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3.5.14 Anti-hyperglycaemic effect 
 
Diabetes is a condition strongly related to oxidative stress. Complications of the diabetes such as 
neuropathy, retinopathy, nephropathy and multi-organ atherosclerosis are believed to be 
implicated by oxygen free radicals namely superoxide (O2
•
), hydrogen peroxides (H2O2) and 
hydroxyl radicals (OH
•
) (Sabu & Kuttan, 2002). Experimental study on the anti-hyperglycaemic 
and anti-oxidant properties of ethanolic extract of Andrographis paniculata in streptozotocin-
diabetic rats at doses of 0.1-0.4g/body weight significantly reduced the fasting serum glucose 
level in a dose dependent effect similar to the metformin treatment group compared to the 
vehicle (Zhang & Tan, 2000a). The liver & kidney thiobarbituric acid-reactive substances 
(TBARS) were significantly decreased, whereas liver GSH concentrations were significantly 
higher (P<0.05) in extract and metformin treated diabetic rats. Hepatic superoxide dismutase 
(SOD), catalase (CAT) & glutathione peroxidase (GSH-PX) activities were significantly lowered 
in vehicle treated diabetic rats. However, Andrographis paniculata and metformin significantly 
increased the SOD and CAT activities but had no significant effect on GSH-PX activity in the 
diabetic rats. The results indicated that Andrographis paniculata possess anti-hyperglycaemic 
property and may also reduce oxidative stress in diabetic rats (Zhang & Tan, 2000b). 
In contrast, Andrographis paniculata (Burm. f.) Nees does not lower fasting blood sugar level in 
non-diabetic rabbits after chronic administration of aqueous extract at 10 mg/kg body weight 
over a duration of 6 weeks, probably due to its prevention on the glucose absorption from the gut 
(Borhanuddin et al., 1994).  
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3.5.15  Cardiovascular activity 
 
Zhang & Tan (1997) studied the mechanism of hypotensive activity of Andrographis paniculata 
in the anaesthetized Sprague-Dawley (SD) rats and found that it was mediated through blockade 
of α-adrenoceptors, autonomic ganglion and histaminergic receptors but not by the β-
adrenoceptor, muscarinic cholinergic receptor and angiotensin-converting enzyme (Zhang & 
Tan, 1997). Study on the cardiovascular activity of 14-Deoxy-11,12-Didehydroandrographolide 
in the anaesthetised rat and isolated right atria (Zhang et al., 1998) demonstrated its bradycardia-
inducing and β-adrenoceptor antagonistic properties. A study has shown that Andrographis 
paniculata (Burm. f.) Nees and fish oil can alleviate atherosclerosis artery stenosis induced by 
both de-endothelialization and high cholesterol diet (HCD) as well as lower restenosis rate after 
experimental angioplasty in rabbits which demonstrated that Andrographis paniculata (Burm. f.) 
Nees is superior (Wang & Zhao, 1994). 
 
The cardiovascular actions of Andrographis paniculata may also be related to its activity on 
calcium ion channels as demonstrated by Burgos et al. (2000) that Andrographis paniculata 
(Burm. f.) Nees selectively blockades the voltage-operated calcium channels (VOCs) by 
inhibiting the Ca
2+ 
influx (Burgos et al., 2000). Andrographis paniculata (Burm. f.) Nees may 
improve the activity of sarcolema ATPase in alleviating the Ca
2+
 and Na
+
 overloading by 
decreasing the harmful effect of oxygen free radical in dog model (Guo et al., 1995). 
 
Eight dogs pretreated with the root extracts of Andrographis paniculata (Burm. f.) Nees showed 
that there was no elevation of the ST segment, plasma 6-k-PGF 1 alpha and platelet cAMP were 
increased, the production of TXB2 and aggregation of platelets were inhibited, and no thrombus 
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or myocardial infarction was induced. The data obtained (Zhao & Fang, 1991) suggested that 
Andrographis paniculata (Burm. f.) Nees might promote the synthesis of PGI2, inhibit the 
production of TXA2, stimulate the synthesis of cAMP in platelets, impede aggregation of 
platelets, and prevention of thrombus formation and development of myocardial infarction. 
Chiou et al. (1998) demonstrated that Andrographolide inhibited the expression of an inducible 
isoform of nitric oxide synthase linked to endotoxin-induced circulatory shock (Chiou et al., 
1998). The protective effects of Andrographis paniculata (Burm. f.) Nees on post infarction 
myocardium in experimental dogs (Zhao & Fang, 1990) suggested that it may limit the 
expansion of ischemic area focus, exert marked protective effect on reversibly ischemic 
myocardium and demonstrated a weak fibrinolytic action. 
 
3.5.16  Immunostimulatory activity 
 
Intragastric administration of an ethanol extract of the Andrographis paniculata leaves at 
25mg/kg body weight or the purified andrographolides at 1mg/kg body weight to mice 
stimulated antibody production. The crude extract was found to be more effective than either 
Andrographolide or Neoandrographolide alone indicating that the effect may be due to the other 
active constituents involved in the immuno-stimulant response (Puri et al., 1993). 
 
3.5.17 Anti-human immunodeficiency virus (HIV) activity 
  
Study on the aqueous and methanol extracts of Andrographis paniculata leaves inhibited HIV-1 
infection and replication in the lymphoid cell line MOLT-4. Dehydroandrographolide inhibited 
HIV-1 and HIV-1 (UCD123) infection of H9 cells at 1.6µg/ml and 50µg/ml respectively (Otake 
et al., 1995). 
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3.5.18  Anti-tumour activity  
 
Recent studies have found that Andrographis paniculata (Burm. f.) Nees is a potential anti-
cancer agent. Andrographis paniculata plant extract contains diterpenes, flavonoids and 
stigmasterols with Andrographolide as the major active diterpenoid which have shown to possess 
potent cytotoxic activity against KB (human epidermoid carcinoma) and P388 (Mouse leukaemic 
lymphoblastic parental tumour cell line) (Siripong et al., 1992). Among the three diterpene 
compounds isolated, the major active component Andrographolide showed anti-cancer activity 
on diverse cancer cells representing different types of human cancers and all enhanced 
proliferation and interleukin-2 (IL-2) induction in HPBLs (Rajagopal et al., 2003). Study using 
different cancer cell lines on the modulatory influence of Andrographis paniculata (Burm. f.) 
Nees on mouse hepatic and extrahepatic carcinogen metabolizing and anti-oxidant status (Singh 
et al., 2001) also indicated that it has chemoprotective potential against chemotoxicity including 
carcinogenicity. 
 
The research conducted by Rajagopalan et al. (2003) demonstrated that Andrographolide at a 
concentration range of 5-15µM inhibits growth of human cancer cell lines such as Leukemia 
(CCRF-CEM, K562), Renal (ACHN, A498), Prostate (DU145, PC3), Ovarian (ES2, SKOV3, 
OVCAR8, PA-1), Melanoma (UACC62, A431, M14), Lung (A549, NCI-H23, HOP62, MES-
SA, MES-SA-DX5, H522), Colon (SW620, HT29, HCT116, KM12, COL0205), CNS (U251, 
SF268, SNB 19), Breast (MDA-MB-453, MCF7, T47D, MCF7/ADR) with similar potency, 
except the COLO205 cell line which showed more sensitivity to Andrographolide treatment.  
 
The findings suggested that Andrographolide exerts direct anti-cancer activity on cancer cells by 
cell-cycle arrest at G0/G1 phase through the induction of cell-cycle inhibitory protein p27 and 
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decreased expression of cyclindependent kinase 4 (CDK4). The indirect anti-cancer activity is by 
enhancing the tumor necrosis factor-a production and CD marker expression, causing an 
increased cytotoxic activity of lymphocytes against cancer cells. Its immunostimulatory activity 
is shown by the increased proliferation of lymphocytes and production of interleukin-2. This 
indicated that Andrographis paniculata (Burm. f.) Nees is a beneficial pharmacophore with anti-
cancer and immunomodulatory activities which warrant for its continued research & 
development in anti-cancer therapy. 
 
Results from the study on the increased tumor necrosis factor alpha (TNF-alpha) and natural 
killer cell (NK) function in late stage cancers using an integrative approach of a combination of 
natural products such as Transfer Factor Plus; IMUPlus; Ascorbic acid; Agaricus Blazeii Murill 
teas; Immune Modulator Mix (a combination of vitamin, mineral, antioxidants and immune-
enhancing natural products) indicated high levels of genistein and dadzein and Andrographis 
paniculata at 500 mg twice daily was quite promising as an anti-cancer agent (See & Mason, 
2002). 
 
3.5.19    Anti-hepatotoxicity activity 
 
The Andrographis paniculata leaves extract protected carbontetrachloride-induced hepatic 
toxicity better than Andrographolide (Choudhury & Poddar, 1984). Studies have demonstrated 
the in vivo hepatoprotective effect of Andrographolide against carbontetrachloride (Handa & 
Sharma, 1990b; Rana & Avadhoot, 1991), galactosamine or paracetamol-induced hepatotoxicity 
in rats (Handa & Sharma, 1990b). The significant hepatoprotective activity of aqueous extract of 
Andrographis paniculata was reported on hexachlorocyclohexane (BHC) induced severe liver 
damage in Swiss male mice by estimating serum ALT & AST and parameters such as alkaline 
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phosphatase, γ-Glutamyl transpeptidase, glutathione and lipid peroxidase (Trivedi & Rawal, 
2000). 
 
A comparative study by Kapil et al. (1993) with the known hepatoprotective agent silymarin 
demonstrated that Andrographolide exhibited a lower protective potential than Andrographiside 
and Neoandrographolide, which were as effective as silymarin in the formation of the 
degradation products of lipid peroxidation and release of glutamic-pyruvate transaminase (GPT) 
and alkaline phosphatase. The greater hepatoprotective activity of the latter two diterpenes could 
be due to their glucoside groups which may act as strong antioxidants, possibly due to the anti-
oxidant activities of superoxide dismutase (SOD), catalase, glutathione peroxidase and reductase 
as well as the level of glutathione (Trivedi & Rawal, 2001). 
 
Intraperitoneal administration of methanol extract of Andrographis paniculata leaves and also 
Andrographolide to mice inhibited the hepatotoxicity induced by carbon tetrachloride (CCl4), 
and reversing the CCl4-induced hispathological changes in the liver by suppressing the increased 
activity of serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase, 
alkaline phosphatase and bilirubin–induced by CCl4. Andrographolide being the major 
antihepatotoxic component of the plant, exhibited hepatoprotective effect in rats against 
hepatotoxicity induced by CCl4., D-galactosamine, paracetamol and ethanol, more effective than 
silymarin, the standard hepatoprotective agent (Kapil et al., 1993; Visen et al., 1993). 
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3.5.20 Toxicological studies 
 
Andrographis paniculata did not produce reproductive toxicity in male rats after 60 days of 
intragastric administration of 20-1000mg/kg body weight daily and is not mutagenic in vitro 
study. It possesses anti-mutagenic activity (Burgos et al., 1997). It is contraindicated in 
pregnancy due to the suggestion that it has abortifacient activity, however, no interruption of 
pregnancy, fetal resorption or decrease in the number of live offspring was observed in pregnant 
rats fed with 2g/kg body weight during the first 9 days of gestation (Zoha et al., 1989). As a 
general rule of thumb, any medicinal or herbal product is contraindicated unless proven safe for 
use in pregnancy.  
Due to the potential antagonism between Andrographis and endogenous progesterone, as a 
caution, it is contraindicated in pregnancy (Panossian et al., 1999) or lactation or in cases with 
known allergies to the Acanthaceae family. It is not recommended to be injected in various 
routes of administration to avoid adverse effects such as potential anaphylactic reactions. It has 
been reported to interact with Isoniazid in a synergistic manner (Chang & But, 1986). Ingestion 
of large doses of Andrographis paniculata orally have been reported to cause gastric discomfort, 
vomiting and loss of appetite as associated adverse reactions or side effects of the extremely 
bitter taste of Andrographolide. Cases of urticaria have also been reported (Melchior et al., 
1997). The evaluation of the safety of subchronic and testicular toxicity of Andrographis 
paniculata was conducted and concluded that the dried extract did not produce such toxicity 
effects in male rats (Burgos et al., 1997).  
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3.5.21 Clinical studies on Andrographis paniculata 
 
3.5.21.1 Common cold and related symptoms 
 
In a placebo-controlled, double-blind clinical trial on 61 adult patients were conducted to assess 
the efficacy of a standardized Andrographis paniculata leaves extract of 1200mg extract daily 
containing 4% Andrographolides for the treatment of common cold. Result showed a significant 
reduction of  p<0.0001 in the clinical symptoms of the patients such as sore throat, tiredness, 
muscular ache and malaise observed on day four, compared to the placebo controlled group. 
Both groups did not exhibit any adverse drug reactions (Hancke et al., 1995b). 
 
In a randomized, placebo-controlled, double-blind study was conducted to evaluate the efficacy 
of a standardized Andrographis paniculata leaves extract of 200mg extract daily for 3 months 
containing 4% Andrographolides for the prophylaxis of common cold on 107 school children 
during the winter season. On evaluation weekly by the physician, no difference was observed on 
the occurrence of common cold between the two groups at the first two months of treatment. 
There was a significant difference p<0.05 in the third month between the treated group (30%) as 
compared to the placebo group (62%) (Caceres et al., 1997). 
 
A group of 150 adult patients in a randomized double blind placebo trial received Andrographis 
paniculata dried extract (1,200 mg/day), using visual analogue scale measurements (VAS) have 
shown its effectiveness in the relief of common cold symptoms (Caceres et al., 1999). Two 
randomized double-blind, placebo-controlled parallel group clinical trial studies (Melchior et al., 
2000) showed that throat symptoms and signs were found to be significantly improved. In a 
randomized, placebo-controlled, double-blind pilot trial on 50 adult patients were conducted to 
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evaluate the efficacy of a standardized Andrographis paniculata leaves extract of 1020mg extract 
daily for five days containing 4% Andrographolides for the treatment of initial symptoms of 
common cold and uncomplicated sinusitis.  
 
Results demonstrated that the patients on the treatment group (0.21 days) were off sick less than 
the placebo group (0.96 days). In addition to that, 68% of the treated patients were totally 
recovered compared to the 36% of the placebo group. And 55% of the treated patients felt that 
the course of illness was much easier than normal compared to only 19% of the placebo group 
(Melchior et al., 1997). In a randomized, placebo-controlled, double-blind comparison study of 
152 adult patients with pharyngotonsilitis evaluate the efficacy of powdered Andrographis 
paniculata leaves 6g daily and paracetamol of 1 capsule of 325mg for improving 
symptomatology. No significant difference between the two groups at baseline comparison. 
However, the crude drug was as effective as paracetamol in the reduction of sore throat and fever 
after three days of treatment (Thamlikitkul et al., 1991). 
 
In a study, treatment of patients on Andrographis paniculata leaves extract containing 4% 
Andrographolides reduced the incidence of fever associated with common cold. The body 
temperature of patients was lowered in less than 48 hours post treatment (SICMM, 1975). This 
finding was confirmed in another study (Hancke et al., 1995a). 
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3.5.21.2 Urinary infections 
 
A clinical trial comparative study on the efficacy between Andrographis paniculata, co-
trimoxazole (sulfamethoxazole + trimethoprim) and norfloxacin in the prevention of urinary tract 
infections after extracorporeal shock wave lithotripsy. The dosage of Andrographis paniculata 
was four tablets of 250mg, three times daily, co-trimoxazole two tablets of 25mg, twice daily, 
norfloxacin was one tablet of 200mg, twice daily. The urinalysis results of 100 patients post 1 
month treatment demonstrated that pyuria, haematuria and proteinuria were reduced in all 
treatment groups with no significant difference between the three treatments (Muangman et al., 
1995). 
 
3.5.21.3  Dysentery  
 
It has been reported in some clinical studies that the combination of Andrographolide and 
Neoandrographolide were found to be more effective than either furazolidine or chloramphenicol 
in the treatment of bacillary dysentery (Chang & But, 1986). In a randomized, placebo-
controlled, double-blind comparison study of 200 adult patients on treatment with Andrographis 
paniculata and tetracycline at a dosage of 500mg, four times daily for 3 days for treating acute 
diarrhoea and bacillary dysentery (Chaichantipyuth & Thanagkul, 1986; Thanagkul & 
Chaichantipayut, 1985). Andrographis paniculata was found to decrease the diarrhoea in terms 
of frequency and amount of discharge. It was also more effective in treating diarrhoea of 
shigellosis rather than from cholera. 
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3.6    Objectives of the thesis and research aims 
 
Little is known about the genetic diversity, phytochemical profile, pharmacological actions of the 
content of the active components of Andrographolide and Dehydroandrographolide present in 
Andrographis paniculata (Burm. f.) Nees species grown in Brunei Darussalam. Despite the long 
traditional use of Andrographis paniculata by the communities in Brunei Darussalam. Therefore, 
such study will serve as the pioneering project to assess this medicinal native plant of Brunei 
Darussalam and future research on other medicinal native plants of Brunei Darussalam based on 
the fact that plants from different sources may have different phytochemical profiles and 
pharmacological actions. This study used various interdisciplinary approach to assess the genetic 
diversity, phytochemical contents, and pharmacological actions to establish the profile of 
Andrographis paniculata (Burm. f.) Nees species grown in Brunei Darussalam.  
The tropical forest of Brunei Darussalam in the Asia region remains a national heritage of 
bioprospecting avenues for the future developments of medicinal native plants. Medicinal plants 
of Brunei Darussalam available in abundance still need to be explored and subjected to rigorous 
research in order to ascertain the associated claims of medicinal uses and clinical applications. 
Traditonal medicines (‘ubat kampong’) need to be researched further for scientific proof of their 
efficacy and safety to ensure the rational and proper use. It is one of the nineteen species of 
Andrographis belonging to the family Acanthaceae (Saxena S. et al., 1997). One of the most 
widely used plants in Ayurvedic preparations in which twenty-six out of forty Indian polyplant 
formulations contain Paniculata species (Handa & Sharma, 1990a). 
 
The objective of this research, therefore, is to evaluate the bioactivities and investigate the  
correlation of the genetic fingerprinting of Andrographis paniculata species/varieties and its  
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bioactivities. The findings of this study may provide critical information on the potential 
therapeutic use of Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam as promising 
therapeutic drugs.  
 
3.6.1 Aims of the thesis 
 
There are several research aims in the present project based on extensive literature reviews and 
an interdisciplinary systematic approach of scientific analyses, which are:    
 
  to develop the strategic framework on TM/CAM for Brunei Darussalam   
 
 to study the genetic diversity profile of Andrographis paniculata (Burm. f.) Nees of  
      Brunei Darussalam using DNA fingerprinting techniques of RAPD and RFLP analyses. 
 
 to study the phytochemical profile of Andrographis paniculata of Brunei Darussalam by 
HPTLC and HPLC analyses. 
 
 to determine the %w/w content of the active components Andrographolide  
(A) and Dehydroandrographolide (D) in Andrographis paniculata of  
Brunei Darussalam. 
 
 to evaluate the pharmacological actions of Andrographis paniculata (Burm. f.) Nees 
extracts on oxidative radicals, iNOS-mediated response, mast cell derived histamine 
release, tumour cell growth as well as its anti-tumour and general hepatocyte toxicity. 
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4.1 Introduction 
 
Brunei Darussalam has a wealth of natural plant resources with great potential for discovering 
new molecules with bioactive activities. An estimated 5,000 native species have been found in 
the tropical rain forests which constitutes 80% of the total land area. Ethno botanical surveys 
recorded 340 species with 160 species were positively identified (Department of Agriculture, 
2000). Out of these species, Andrographis paniculata is a widely used medicinal plant in Asia in 
particularly India, China and South East Asia including Brunei Darussalam for many disease 
conditions. It is a popular plant from the ‘Acanthaceae’ family used by the communities to lower 
high blood pressure, managing diabetes and to relieve abdominal pains. However, at present 
there is a lack of study on the genetic diversity of of Andrographis paniculata of Brunei 
Darussalam. The aim of this study was to use RAPD and PCR-RFLP at 5S-rRNA region to 
determine the intraspecific genetic variability of nine genotypes of Andrographis paniculata 
collected from three districts of Brunei Darussalam.  
 
Studies on the genetic diversity information of this species or varieties are important not only for 
the authentication of the plant species but also for future studies of correlations between genetic 
markers and their metabolic compounds or chemotypes. Literature search reported that the genus 
Andrographis also known as ‘King of Bitters; Kalmegh of Ayurveda’ is of potential significance 
to India as 25 out of 28 species in the world are distributed mainly in India with 23 of them 
occurring in the peninsular region. These different species and varieties of Andrographis 
paniculata are used interchangeably as traditional medicine worldwide as described in Table 2.3 
of Chapter 2. Andrographis paniculata has also been listed as herbal medicines in the Chinese 
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Pharmacopoeia Volume II 2000, the British Pharmaceutical Codex 1911 and Therapeutic Goods 
Administration (TGA), Australia 2004 for its medicinal benefits.  
With the advent of the development of molecular cloning and polymerase chain reaction (PCR) 
techniques, DNA based markers are advocated as one of the important  techniques to identify 
and authenticate plant species or varieties of plant medicinal materials (Joshi et al., 2004). The 
application of conventional chemical analysis is limited as identification and authentication tools 
since the amount and profiles of the plant species ginsenosides are affected significantly due to 
variable factors such as the growth, storage conditions, samples freshness and post-harvest 
processing (Ngan et al., 1999). The DNA-based markers are less affected by age, physiological 
conditions of samples and environmental factors and is popularly used for the identification and 
authentication of natural products such as plant and animal species due to its robustness (Shaw et 
al., 2002). 
 
DNA profiling can specifically identify herbal species/varieties or cultivar, to ensure the quality 
if there is any linkage of its genetic identity with either their chemical constituents or 
bioactivities and to ascertain the genetic uniformity of herbal materials. Therefore, continued 
research on the establishment of the correlations between the genetic diversity profile and the 
chemical constituents and compositions of medicinal plants used by the community at large need 
to be supported. 
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4.1.1  RAPD-PCR and PCR-RFLP 
 
Random Amplified Polymorphic DNA (RAPD) is a useful tool in genetic analysis, in 
classification of species and in taxonomic studies. The key to RAPD is that oligonucleotides of 
arbitrary sequence are used as PCR primers and if these primers are short, then complementary 
sequences will occur frequently in the target genome (Malyshev & Kartel, 1997). There is a 
finite chance that not only the pairs of sequences are complementary to the primer and at the 
same time they will be arranged with 3’ ends pointing towards each other. Under appropriately 
optimised thermal cycling conditions, annealing of the primer to the target genome will result in 
the production of an amplified fragment (Malyshev & Kartel, 1997). RAPD analysis enables 
good differentiation between closely related organisms in the form of the different banding 
patterns in PCR products generated due to the difference in DNA of different strains of species 
(Foster et al., 1993; Tommerup et al., 1995). RAPD is a commonly used molecular technology 
which has been extensively applied to study the genetic diversities and authenticate different 
species or varieties of plant materials (Shaw et al., 2002). PCR-RFLP has also been used to study 
plant profiling. It reveals variation in DNA sequences between organisms that can be recognised 
through the use of restriction endonucleases which identify particular sequences and consistently 
make double stranded cuts in DNA. 
 
RAPD and PCR-RFLP analyses have become a popular means for the identification and 
authentication of natural products such as plant and animal species. For instance, they have been 
used to characterise species such as Epimedium species (Nakai et al., 1996) and to examine the 
genetic relationships within genera of herbal species (Kim et al., 2004a; Roser et al., 2001). 
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Interspecies variation studies on various genera of Glycyrrhiza (Yamazaki et al., 1994), 
Echinaceae (Kapteyn et al., 2002), Curcuma (Chen et al., 1999) were also conducted. Wang et 
al., (2004) revised the phenotypic relationship between 20 species from the subgenus Yulania 
based on RAPD technique (Wang et al., 2004). The significant genetic distance between the 
species derived from different geographical locations of Asia and America were investigated 
among 17 species of subgenus Yulania using RAPD analysis which generated high levels of 
polymorphisms. In general, RFLP markers are much less polymorphic, more expensive and 
labour intensive compared to RAPD.  
 
4.2 Materials and methods  
 
4.2.1 Plant materials 
 
The Andrographis paniculata plant materials were collected from the various districts (Figure 
4.1). Andrographis paniculata leaves samples were authenticated by the Department of 
Agriculture, Ministry of Industry and Primary Resources, Brunei Darussalam. The reference 
control Chuan Xin Lian (CXL) leaves were authenticated by the Chinese Medicine Clinic of 
RMIT University, Bundoora West Campus, Melbourne, Victoria. 
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Collection of 
the Herbal
accessions:-
CXL;
T;
KB;
AP.
 
 
Figure 4.1. Collection of herbal accessions 
The fresh leaves from nine accessions of Andrographis paniculata were obtained from the 
following districts of Brunei Darussalam. Bandar Seri Begawan from the Brunei/Muara district 
(designated as AP2, AP4, AP6, AP8, AP11, AP14, AP15); Kuala Belait (district designated as 
K.B.); Temburong district (designated as T). The materials were air dried and transported to 
RMIT University, Australia. Dried herbal materials Chuan Xin Lian (CXL) were also obtained 
from China by the Chinese Medicine Clinic, Chinese Medicine Division of Royal Melbourne 
Institute of Technology, Bundoora West Campus, Australia. 
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4.2.2 DNA extraction and PCR primers 
 
Total DNA from air-dried fresh leaves were extracted using the DNeasy Plant Mini Kit 
(Qiagen). Thirty four random oligonucleotide primers-10mer (Operon Technologies Inc.) and 
5S-rRNA sequences using primers-20mer 5SP1 (forward) (5’-GTG CTT GGG CGA GAG TAG 
TA-3’) and 5SP2 (reverse) (5’-TTA GTG CTG GTA TGA TCG CA-3’) purchased from 
Geneworks were designed for Random Amplified Polymorphic DNA (RAPD) and Restriction 
Fragment Length Polymorphism (PCR-RFLP) analyses respectively.  
 
4.2.3 RAPD analysis 
 
The RAPD analysis was modified from that described in published literature (Cui et al., 2003; 
Shaw & But, 1995). The 25µl PCR mixture comprised of 40ng of template DNA, 2.5μl of 
10xPCR buffer (100mM Tris-HCl, 500mM KCl, 0.01% gelatin, Invitrogen, Australia), 0.75μl of 
50mM MgCl2, 6μl of 1mM dNTP, 1μl of 10µM primer and 1 unit Taq Polymerase (Invitrogen, 
Australia). PCR reaction consisted of 3 min at 94°C, followed by 15 seconds at 94°C 
(denaturing), 1 min at 40°C (annealing), 1 min at 72°C (extension) for 35 cycles, and terminating 
with 5 minutes at 72°C for RAPD analysis by Px2 Thermal Cycler (Thermal Electron 
Corporation, UK). Each PCR product was electrophoresed in 1.5% agarose gel and visualized by 
ethidium bromide staining. The Discovery Series Quantity One 1-D Analysis Software (BioRad, 
Australia) was used for imaging the electrophoresis gels. 
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4.2.4 PCR-RFLP analysis 
 
As for the PCR-RFLP analysis, a pair of PCR-primers, 5SP1 (forward) 5’-GTG CTT GGG CGA 
GAG TAG TA-3’ and 5SP2 (reverse) 5’-TTA GTG CTG GTA TGA TCG CA-3’ were used. 
They are designed to amplify the 5S ribosomal RNA (5S-rRNA) spacer (Wolters & Erdmann, 
1988). The 25μl PCR mixture containing 40ng leaf DNA, 2.5μl of 10×PCR buffer, 0.75μl of 
50mM MgCl2, 6μl of 1mM dNTP, 1μl of 10μM forward primer, 1μl of 10μM reverse primer 
and 1 unit Taq polymerase (Invitrogen, Australia). PCR reaction was performed using 38 cyc1es 
consisting of 5 min at 94°C, 1 min at 94°C, 1min at 60°C, 1 min at 72°C, terminating with 10 
min at 72°C and hold at 4°C in a Px2 Thermal Cycler (Thermal Electron Corporation, UK). 
Restriction enzyme 10×Buffer was recommended for use by the manufacturer’s product 
information.  
 
Briefly, 4μl of the PCR products from the 5S-rRNA gene were then digested with the 13 
restriction enzymes in purified BSA 100x (New England Biolabs, USA) were incubated at 37°C 
for 2hr (Lin et al., 2001b) and out of these, HinfI, MnlI, MspI, HaeIII, NlaIV, Tsp 509I were 
found to be suitable (Table 4.3). Each PCR products was fractionated in 2.0% agarose gel and 
visualized by Ethidium Bromide staining. The Discovery Series Quantity One 1-D Analysis 
Software (BioRad, Australia) was used for imaging the electrophoresis gels. Only clear, coherent 
and consistent banding patterns revealed by RAPD analysis were scored. RAPD bands were 
scored as present (1) or absent (0) for each genotype.  
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4.2.5 Data collection and analysis 
 
On the basis of Nei’s coefficient, a matrix of genetic distances estimation between the accessions 
of Andrographis paniculata from different districts of Brunei Darussalam based on dissimilarity 
(D=1-SXY) indices was obtained by POPGENE version 1.31, a Microsoft Window-based free 
software for population genetic analysis (Yeh et al., 1999). The Molecular Evolutionary Genetics 
Analysis 2 (MEGA 2) was used for reconstruction and comparing the genetic distances between 
all individuals by an Unweighted Pair Group Method with Arithmetic Mean (UPGMA) method 
(Kumar & Tamura, 2000; Kumar et al., 2001). The linearised tree was expressed as percentage 
of the dissimilarity indices.   
 
4.3    Results  
 
For RAPD analysis, 34 random primers were screened and of these, 13 primers (Table 4.1) were 
found to be suitable for the identification of DNA from the leaf samples investigated but 21 
primers were not suitable (Table 4.2). Andrographis paniculata populations are genetically and 
moderately different in Brunei Darussalam on the basis of RAPD analysis. The genomic DNA 
fingerprinting by RAPD among fresh accessions from Andrographis species showed distinctive 
DNA fragments. 
 
There was a considerable level of polymorphism among the genotypes investigated. Of the total 
67 loci scored, 61% were polymorphic with an average of 3 bands per primer (Table 4.1). The 
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number of bands produced per primer ranged from 1 (OPA-11) to 9 (OPW-04) with an average 
of 5 bands per primer and the products ranged in size from 280bp to 3000bp.  
 
Table 4.1 Polymorphic bands generated by 13 RAPD primers which were suitable 
RAPD Primers 
(Operon Technologies) 
Sequence  
5’  -  3’ 
Total No. 
of bands 
No. of  
Polymorphic 
bands 
OPA-11  
OPB-08 
OPC-19 
OPG-13 
OPG-14 
OPM-04 
OPN-04 
OPP-10 
OPT-13 
OPW-04 
OPW-09 
OPX-17 
OPZ-10 
 
 
Total No. of bands 
Mean per primer 
CAATCGCCGT 
GTCCACACGG 
GTTGCCAGCC 
CTCTCCGCCA 
GGATGAGACC 
GGCGGTTGTC 
GGACTGGAGT 
TCCCGCCTAC 
AGGACTGCCA 
CAGAAGCGGA 
GTGACCGAGT 
GACACGGACC 
CCGACAAACC 
1 
3 
6 
4 
2 
7 
8 
3 
6 
9 
4 
8 
6 
 
 
67 
5.15 ≈ (5) 
0 
1 
3 
2 
1 
7 
8 
1 
3 
7 
3 
3 
2 
 
 
41 
3.15 ≈ (3) 
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Table 4.2 RAPD primers screened but not suitable 
RAPD primers Sequence 5’ – 3’ 
OPZ-02 
OPZ-04 
OPZ-12 
OPZ-16 
OPAW-03 
OPAW-05 
OPV-06 
OPU-03 
OPT-17 
OPT-03 
OPA-07 
OPB-18 
OPB-17 
OPB-12 
OPB-07 
OPB-06 
OPB-04 
OPB-03 
OPA-14 
OPZ-06 
OPZ-08 
 
CCTACGGGGA 
AGGCTGTGCT 
TCAAGGGGAC 
TCCCCATCAC 
CCATGCGGAG 
CTGCTTCGAG 
ACGCCCAGGT 
CTATGCCGAC 
CCAACGTCGT 
TCCACTCCTG 
GAAACGGGTG 
CCACAGCAGT 
AGGGAACGAG 
CCTTGACGCA 
GGTGACGCAG 
TGCTCTGCCC 
GGACTGGAGT 
CATCCCCCTG 
TCTGTGCTGG 
GTGCCGTTCA 
GGGTGGGTAA 
 
 
Nine genotypes were grouped into two main clusters based on the maximum dissimilarity of 
10% between genotypes (Figure 4.2). The maximum genetic distance was 0.3545 between 
accessions AP6 and CXL. The minimum genetic distance was 0.0303 between accessions AP15 
and AP6 as shown in Figure 4.3. Chuan Xin Lian (CXL) from China (Family: Acanthaceae, 
Species: Andrographis paniculata, Genus: Andrographis) as reference control, was found to be 
the most genetically distant from all other accessions where the greatest dissimilarity was 
between CXL and AP6 (15%). Cluster I consisted of AP8, KB, AP4 and Cluster II consists of 
AP11, T, AP2, AP14, AP15 and AP6 (Figure 4.4). Chuan Xin Lian (CXL) is about 4% dissimilar 
from all the Brunei Darussalam accessions by combining Clusters I and II together as one major 
group. On an individual basis, CXL is 6% dissimilar to Cluster I and 9% to Cluster II. 
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PCR amplification using the 5S-rRNA primers produced a 400bp amplicon. Restriction enzyme 
digestion using six endonucleases revealed that all the restriction fragments were identical 
among all genotypes (Table 4.3). 
Table 4.3 The restriction endonuclease digestions of the 5SP1 and 5SP2 PCR products.  
  
Restriction 
Enzymes Number/Colour of Buffer 
Sequence (Promega 
Technologies) 
Length of 
Amplifications of the 
5S-rRNA region 
HinfI No. 2/Blue Buffer G-ANT C C TNA-G 
150bp 
250bp 
 
MnlI 
 
 
No. 2/Blue Buffer 
CCTC(N)7- 
GGAG(N)6- 
70bp 
100bp 
220bp 
MspI No.2/Blue Buffer 
C-CG G 
G GC-C 
100bp 
125bp 
150bp 
NlaIV No.4/Green Buffer GGN-NCC CCN-NGG 
200bp 
200bp 
HaeIII No.2/Blue Buffer 
GG-CC 
CC-GG 
70bp 
70bp 
100bp 
150bp 
Tsp 509I No.1/Yellow Buffer -AATT TTAA- 
180bp 
220bp 
                  
HhaI 
 
No.4/Green Buffer 
G CG-C 
C-GC G 
Restricted amplicon 
into two equal 
fragment 
               
AluI No.2/Blue Buffer 
AG-CT 
TC-GA 
No restriction 
BsaJI No.2/Blue Buffer C-CNNG G G GNNC-C 
No restriction 
BstXI No.3/Red Buffer CCAN NNN-NTGG GGTN-NNN NACC 
No restriction 
DdeI No.3/Red Buffer C-TNA G G ANT-C 
No restriction 
ApoI No.3/Red Buffer A-AATT T T TTAA-A 
No restriction 
MseI No.2/Blue Buffer T-TAA AAT-T 
No restriction 
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 10% 
Cluster II 
Cluster I 
 
Dissimilarity matrix 
Figure 4.2. A dendrogram showing genetic relationship of the nine accessions of  
Andrographis  paniculata from Brunei Darussalam compared to the reference control  
Chuan Xin Lian (CXL) (matrix scale is expressed as percentage x100). 
 
 
Chuan Xin Lian (CXL) 
Temburong (T) 
Kuala Belait (KB) 
Brunei (AP) 
________________________________________________________________________ 
 CXL     T   KB  AP2 AP4 AP6 AP8 AP11 AP14 AP15 
CXL    1.0000      
 
T          0.2729     1.0000 
 
KB       0.2729     0.1616 1.0000 
 
AP2     0.3129     0.0938 0.1974 1.0000 
 
AP4     0.1793     0.2157 0.1793 0.2534 1.0000 
  
AP6     0.3545*   0.0938 0.2344 0.0616 0.2927 1.0000 
 
AP8     0.3129     0.0938 0.1272 0.1616 0.1442 0.1974 1.0000 
 
AP11   0.2157     0.0776 0.2157 0.1103 0.1616 0.1103 0.1793 1.0000 
 
AP14   0.3335     0.1103 0.1793 0.0458 0.2729 0.0458 0.1793 0.1272 1.0000 
 
AP15   0.3129     0.0938 0.2344 0.0616 0.2927 0.0303# 0.1974 0.1103 0.0458 1.0000 
________________________________________________________________________ 
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Figure 4.3. Dissimilarity matrix of nine accessions of Andrographis paniculata 
* greatest dissimilarity                                        # least dissimilarity 
 
 
 
                Cluster I*    Cluster II 
 
______________________________________________________________________________________ 
 
             *                *        *  
        CXL    AP8          KB AP4  AP11    T      AP2    AP14    AP15     AP6      
     
CXL      100%     8%          8%         6% 10%     10%   11%    12%    13%      13% 
 
 
 
 
Figure 4.4. Clusters I * and Cluster II 
(%dissimilarity of nine accessions of Andrographis paniculata) 
 
In a related HPLC study, Chua et al., (2006, unpublished) attempted to obtain the correlation 
between the polymorphisms of three genotypes CXL, T & K.B. and the levels of %w/w 
Andrographolides (A) and %w/w Dehydroandrographolides (D). Their genetic differences and 
the medicinally active principles were analysed quantitatively using HPLC to study their 
phytochemical diversity from different geographical locations. In addition to the cluster analysis, 
principal component analysis of the similarity coefficient was performed and the diagram of the 
components extracted was constructed as illustrated in Figure 4.5. The HPLC analysis of three 
accessions CXL, T and K.B. as mentioned in section 5.3.3.2 of Chapter 5 accumulating 
significant concentrations of %w/w Andrographolide were 1.14%, 3.43% and 0.67% and %w/w 
Dehydroandrographolide were 0.66%, 0.12% and 0.24% respectively, may be potentially useful 
for breeding and cultivar development. The results of the dendrogram and principal component 
analysis were in agreement with the overall representation of relationships among the genotypes 
studied. 
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Figure 4.5. Principal component diagram based on RAPD analysis.  
 
The two main principal components extracted from the PCA were plotted and analysed. The first 
component accounted for 59.55% and the second component was 26.60% of the total variance. 
The combined cumulative was 86.14% among the genotypes studied. Three clusters of genotype-
specific RAPD markers were identified from the PCA plot as shown in Figure 4.5. These 
markers may be employed in future studies to identify these genotypes, but additionally may be 
useful as predictors of Andrographolide and Dehydroandrographolide levels in accessions of 
Andrographis paniculata. However, further studies are required to confirm the linkages of these 
RAPD polymorphisms with the gene loci responsible for Andrographolide production. 
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4.4 Discussion 
 
The data obtained in this study reflected the utility of RAPD and PCR-RFLP in the analysis of 
genetic variability distribution within Andrographis paniculata. The finding of the close genetic 
distances between all the nine accessions from Brunei Darussalam and Chuan Xin Lian (CXL) 
are in agreement with the other studies on lotus (Campose et al., 1994), sweet potato (Cannoly et 
al., 1994), and Andrographis paniculata of India (Padmesh et al., 1999) which suggests that 
RAPD is more appropriate for the analysis of genetic diversity in closely related genotypes. This 
study provides a better understanding of genetic variation at the intraspecific level would help in 
identifying superior genotype(s) for cultivar development. To the best of our knowledge, this is 
the first study conducted on Andrographis paniculata from Brunei Darussalam. The 
polymorphism obtained can be used as a marker for screening the genotypes. The genomic DNA 
fingerprinting by RAPD among fresh accessions from Andrographis species showed distinctive 
DNA fragments which may be used for the authentication, identification and quality assessment 
of the plant species or varieties. 
 
This finding is in agreement with the RAPD analysis in the study by Padmesh et al., (1999) and 
Sabu (2002) on the intraspecific genetic diversity of Andrographis paniculata where the genetic 
dissimilarity is at 0.51 between AP-29 from Assam and AP48 from Thailand (Padmesh et al., 
1999; Sabu, 2002). The nine accessions of Andrographis paniculata in the current study were 
collected from Brunei Darussalam, whereas the accessions in previous studies were obtained 
from different parts of India, Thailand, Malaysia and Indonesia. It is possible that the genotypes 
from different distantly geographical regions can be genetically similar to genotypes with 
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immediate spatial relationships association which may be attributed to the unique, broad genetic 
base combinations, seed movement and gene flow since Andrographis paniculata (Burm. f.) 
Nees is an introduced species into Thailand and Brunei Darussalam. This species is also reported 
from Hongkong, Borneo, Sulawesi, Jamaica, Barbados, Bahamas and Christmas Island in Indian 
Ocean but there is no precise data with regards to the introduction and naturalisation of 
Andrographis paniculata in these countries. As this study focused on the intraspecific genetic 
diversity of the species, the future study of interspecific variability of the different species of 
Andrographis paniculata from different near and distant geographical locations may be useful 
and lead to better understanding of these existing findings. 
    
In contrast, the RAPD analysis potentially explores genetic polymorphism across the entire 
genome therefore may potentially reveal greater genetic diversity with higher degree of 
polymorphism (Lynch & Milligan, 1994). Such characteristic features of the RAPD are useful 
for the identification of medicinal plants despite the weakness of RAPD method with low 
reproducibility and high sensitivity of contaminants during the hash processing of DNA (Penner 
et al., 1993). The PCR-RFLP of multi copy genes, such as 5S-rRNA, may perhaps be more 
appropriate for the differentiation and authentication of medicinal plants as in it’s  application in 
differentiating four medicinal Codonopsis species from their related adulterants, Campanumoea 
javania and Platycodon grandiflorus (Joshi et al., 2004). 
 
The findings from 5S-rRNA digestions indicated that the nine accessions of Andrographis 
paniculata from Brunei Darussalam were closely related. There are different varieties of 
Andrographis in India, the native homeland of the plant which has always been the interest of 
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researchers to analyse them genetically. At present, no information is available whether the 
different varieties have arisen due to more than one introduction to Brunei Darussalam or as a 
result of genetic mutation. PCR-RFLP digestion can be a useful tool for resolving subspecies 
taxonomic status, but in this analysis the 5S-rRNA region is not variable enough for taxonomic 
comparison. However, future study using a larger number of restriction enzymes may possibly 
uncover differences in the taxonomic pattern. Although in this section PCR-RFLP was not a 
useful diagnostic tool, PCR-RFLP’s were reported to be useful for deciphering phylogenetic 
relationships between two varieties of Imperata cylindrica L. Beauv. (Congograss) (Chou & 
Tsai, 1999). 
 
The study on DNA fingerprinting profiles of Andrographis paniculata from Brunei Darussalam 
was established using RAPD technique. The RAPD profile revealed the genetic relationship of 
the medicinal materials and demonstrated the genetic dissimilarities through RAPD markers. 
PCR-RFLP analysis was also performed in which the 5S-rRNA region was used for the 
establishment of DNA fingerprints. The findings shows similar patterns indicating that they are 
closely related which is in agreement with the fact reflecting that they are within the same 
species. RAPD is the preferred method for identification in this study. It would be most 
encouraging to expand into future study on the application of RAPD and PCR-RFLP analyses in 
the different species of Andrographis. The RAPD analysis in the genetic diversity revealed 
moderate variation within the species which provide sensitive and rapid technique to identify and 
evaluate Andrographis paniculata which may contribute to the quality assessment of this 
important medicinal plant. 
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The findings of this study using RAPD and PCR-RFLP of 5S-rRNA region of the phylogenetic 
diversity of nine accessions samples collected from the three districts namely Bandar Seri 
Begawan from the Brunei/Muara district (AP2, AP4, AP6, AP8, AP11, AP14, AP15), Kuala 
Belait district (K.B.), Temburong district (T) and Chuan Xin Lian (CXL) from China constituted 
as the first report on the genetic diversity study on Andrographis paniculata from Brunei 
Darussalam. Andrographis paniculata populations are genetically and moderately different in 
Brunei Darussalam on the basis of RAPD analysis. 
 
This study also provides a better understanding of the correlation of the level of contents of A 
and D to the genetic variation at the intraspecific level as discussed earlier in this chapter. 
Geographical location and season may also explain the differences in the contents of the active 
components in the herb (Hu & Wu, 1995). Such finding would help us in identifying superior 
genotype(s) for cultivar development of Andrographis paniculata (Burm. f.) Nees. Further 
studies are needed to elucidate this correlation in particularly the genotype of the Andrographis 
paniculata from the Temburong sample.  
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5.1 Introduction 
 
Herbal medicines are complex mixtures of active and inert ingredients/constituents which 
contain usually hundreds of chemically different constituents to which only a few, if not one, 
compounds are responsible for the beneficial therapeutic as well as the hazardous effects (Pavel 
& Jitka, 2004). Therefore, efficient and effective methods of identification, extraction, 
standardisations, qualitative, quantitative, bioassays and pharmacological testings are essential 
and must be highly selective in order to achieve the optimal outcomes. 
 
Advances in analytical techniques in particular chromatographic, spectroscopic, plant cell, tissue 
culture and genetic manipulation techniques have paved the way for the better understanding of 
not only the profile of medicinal plants but also providing means for economic production of 
important plants with markers of high cultivar. The important secondary metabolites are often 
used as important markers for quality control in the chemotaxonomy, chemical ecology, 
agriculture and food industry. 
 
Based on a simplistic approach, the analysis of the two components A and D by conventional 
thin layer chromatography (TLC) method was not well described. For instance, a conventional 
TLC identification method based on compositions of CHCl3-Ethyl acetate-MeOH mobile phase 
used by the Pharmacopoeia of People Republic of China (PPRC, 2000) was further modified in 
our study on the basis of an automated system (CAMAG) by adjusting and optimizing the 
separation conditions in order to separate these two constituents effectively. In this study, we 
described an improved HPTLC method for determining the contents of these two components in 
dried raw leaves samples of Andrographis paniculata. Table 5.1 illustrated the various 
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chromatographic techniques which have been reported to be useful for the phytochemical 
analyses of Andrographis paniculata. 
 
5.1.1 Common chemical techniques used in herbal analysis 
 
Generally, the methods for quality control of herbal medicines involve sensory inspection 
(macroscopic and microscopic examinations) and analytical inspection using instrumental 
techniques such as TLC, HPLC, GC-MS, LC-MS, near infrared (NIR), and spectrophotometer, 
etc (Choi et al., 2002). HPLC is a popular method for the analysis of herbal medicines because it 
is easy to learn and use and is not limited by the volatility or stability of the sample compound. It 
can also be used to analyse almost all the compounds in the herbal medicines and has received 
the most extensive applications (Cawthray, 2003; Desai et al., 1993; Imanari et al., 1996; 
Leonard et al., 2003; Li et al., 1999; Lin & Chen, 2003; Lin et al., 2001a; Loganathan et al., 
1990; Sanyal et al., 2003; Thanawiroon & Linhardt, 2003; Tsai et al., 2002) For instance, 
reversed-phase (RP) columns may be the most popular columns used in the analytical separation 
of herbal medicines. It is important to note that the good experimental design for the optimal 
separation condition for the HPLC involves many factors, such as the different compositions of 
the mobile phases, the pH adjustment, pump pressures, etc. 
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5.1.2 The Chromatograpy and chemical fingerprinting techniques of herbal  
medicines 
 
Some of the important chromatographic analytical methods which are useful as reported in the 
literature reviews from previous studies employed for analysing herbal medicines (Liang et al., 
2004).  
 
5.1.2.1 Thin Layer Chromatography (TLC) 
 
TLC was the most common conventional method of choice for herbal analysis before the newer 
and more sophisticated instrumental chromatographic methods was developed. It is a convenient 
method of determining the quality and possible adulteration of herbal products which is 
employed in multiple samples analysis. The advantages of TLC techniques are simplicity, 
versatility, high velocity, specificity and simple sample preparation and ease of use.  
 
5.1.2.2 Gas Chromatography and volatile components in herbal medicines 
 
Many pharmacologically active components present in herbal medicines contain volatile 
chemical compounds. The advantages of Gas Chromatography (GC) analysis of compounds 
containing volatile oil provide good resolution on the fingerprinting which serve as an identity of 
the plant. Furthermore, it can detect the components both quantitatively and qualitatively. The 
useful features of GC include the ease of identification, standardisation, and monitoring of the 
relative quantities and characterisation of the components and variations of compositions of the 
volatile oil. With the help of FID detection and GC-MS are highly sensitive in the detection of all 
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volatile oil composition and also its highly selective capillary column technique which has good 
resolution in the separation of volatile compounds within short duration. 
 
5.1.2.3 High Performance Liquid Chromatography (HPLC) 
 
By far, HPLC has been the most popular method used to analyse almost all compounds in herbal 
medicines and still remain as the most extensive application which has optimal separation of the 
compounds with reversed-phase (RP) columns, suitable mobile phases, pH adjustment, pump 
pressures and optimised analytical conditions. Other newer techniques which will provide new 
opportunities for good separation of specific extracts of herbal medicines such as micellar 
electrokinetic capillary chromatography (MECC) (Sanyal et al., 2003), high speed counter-
current chromatography (HSCCC), low-pressure size-exclusion chromatography (SEC) (Pervin 
et al., 1995), reversed-phase ion-pairing HPLC (RP-IPC-HPLC) (Karamanos et al., 1997) and 
strong anion-exchange HPLC (SAX-HPLC) (Rice & Lindardt, 1989). Over the recent years, 
there has been an increased use of HPLC coupled with evaporative light scattering detection 
(ELSD) which is ideal in the detection of non-chromophoric compound (Christie, 1992; 
Nebinger et al., 1983). 
 
5.1.2.4 Electrophoretic methods 
 
Capillary electrophoresis is a versatile and powerful separation tool with high separation 
efficiency and selectivity in the analysis of mixtures of low molecular mass charged components 
ranging from simple inorganic ions to DNA.  
Table 5.1. Chromatographic techniques used for the phytochemical analyses of Andrographis paniculata 
No. Project areas to determine active 
constituents inclusive of (A), (D) and 
other diterpenoids in Andrographis 
paniculata leaves 
Methods of determination/ 
Techniques/Optimal 
conditions 
 
Results  References 
1 Microemulsion Electrokinetic 
Chromatographic (MEEKC) for 
simultaneous determination of A and D 
in TCM and Chinese medicinal 
preparations  
Heptane 0.81%w/w, 
SDS 3.31%w/w, 
Butan-1-ol 6.61%w/w, 
10mM sodium tetraborate 
buffer pH 9.2 
Achieved good reproducible 
Separation 
(Yanfang et 
al., 2006) 
2 HPLC for simultaneous 
determination of Andrographolide 
(AP1), 14-deoxy-11,12-
didehydroandrographolide (AP3) and 
Neoandrographolide (AP4) in the AP 
samples from Thai markets 
Methanol  & Water mobile 
phase, wavelength at 220nm 
Demonstrated that AP1 
was more stable than the others, 
Content of AP3 increased and AP4 
fluctuated during storage time. 
Different levels obtained during 
storage resulting in significant 
effect on clinical efficacy of the 
(Pholphana 
et al., 2004) 
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AP 
3 HPLC for simultaneous 
determination of Andrographolide & 
Dehydroandrographolide 
in common powdered or ultra-fine 
powdered AP 
Dissolution rates of the size of 
powders 
Ultra fine powder technique 
promotes the dissolution rates of A 
& D 
(Qui et al., 
2004) 
4 4.1    HPLC for simultaneous 
determination of the chemical 
fingerprinting of Andrographolide & 
Dehydroandrographolide in AP. 
 
4.2     HPTLC plates densitograms  
HPLC reagents: Hexane, 
Chloroform, Methanol and  
water extracts 
The analyses showed that 
Andrographolide & 
Neoandrographolide were absent 
in the hexane extracts but in 
substancial concentration in the 
methanol extract. Chromatograms 
are beneficial in the chemical 
fingerprinting for quality control 
and formulation preparations of 
AP 
 
(Srivastava 
et al., 2004) 
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5 2D NMR spectroscopy method in the 
determination of structures of flavonoids 
Andrographolide diterpenoids and 
others in the whole plant of AP 
Phytochemical analysis using 
2D NMR spectroscopy 
The structures of flavonoids and 
Andrographolides from AP were 
established based on 2D NMR 
spectroscopic  
(Koteswara 
et al., 2004) 
6 Extraction technology of active 
ingredients using orthogonal experiment 
with supercritical carbon dioxide 
Ethanol solvent, 
extractor pressure 25 MPa, 
extractor temperature 46ºC, 
separator I pressure 6 MPa, 
separator I temperature 65ºC, 
separator II pressure 6 MPa, 
separator II temperature 45ºC, 
CO2 rate of flow 40kg/h. 
Higher purity and more stable 
quality than the conventional 
extract technology 
 
 
 
 
 
 
 
 
 
 
(Ge et al., 
2002) 
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7 Separation of bioactive diterpenes using 
high-speed counter-current 
chromatography 
Water-methanol-ethyl acetate-
n-hexane (2.5:2.5:4:1) solvent 
system AT 280 min separation, 
electrospray MS, one 
dimensional NMR, circular 
dichroism, optical rotation 
dispersion & specific optical 
rotation [alpha] D 
Bioactive diterpenes 
Andrographolide & 
Neoandrographolide were 
successfully separated by high 
speed counter current 
chromatography 
(Qizhen et 
al., 2003) 
8 Determination of active diterpenes 
Andrographolide, deoxyandrographolide 
& Neoandrographolide by micellar 
electrokinetic capillary chromatographic 
(MEKC) method  
Water:ethanol extract, 15mM 
sodium dodecyl sulphate in 
30mM borate buffer (pH 9.5) 
with UV detection wavelength 
at 214nm and constant voltage 
of 16 kV. 
 
The MEKC separation method 
demonstrated efficiency, 
sensitivity, linearity and 
repeatability, easier and less 
expensive to use and does not 
suffer from column contamination. 
 
 
  
(Zhao et al., 
2002) 
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9 Determination of active diterpenes 
Andrographolide, deoxyandrographolide 
& Neoandrographolide by micellar 
electrokinetic capillary chromatographic 
(MEKC) method  
Water:ethanol extract, 20mM 
sodium dodecyl sulphate in 
20mM borate buffer, 10mM 
sodium cholate (pH 8.3), with 
fused-silica capillary tube UV 
detection wavelength at 214nm 
and constant voltage of 25 kV. 
The MEKC separation method 
demonstrated efficiency, 
sensitivity, linearity and 
repeatability, easier and less 
expensive to use and does not 
suffer from column contamination  
(Cheung et 
al., 2001) 
10 Validated analytical methods (HPLC, 
CE and GC-MS) were used for the 
determination of active diterpenes in 
Pharmacokinetic study  
Detector UV diode-array 
detection method were used  
Maximum plasma levels of 
Andrographolide at 393 ng/ml 
(approximate 1.12µM) at 1.5-2 
hours. Half life & mean residence 
times were 6.6 & 10.0 hours (one 
compartmental model). In two 
compartmental model, the max. 
plasma level was 660 ng/ml  
(Panossian 
et al., 2000) 
 
It has been reported in literatures that Andrographolide is the major bitter active components 
responsible for the pharmacological properties of Andrographis paniculata, and its related 
component Dehydroandrographolide is lesser in activity. Our main objective in this Chapter 5 is 
to investigate the %w/w of Andrographolide (A) and Dehydroandrographolide (D) of the 
Andrographis paniculata leaves samples collected from Brunei Darussalam compared with the 
samples of CRS (China Reference Standard Herbs) and Chuan Xin Lian (CXL) from Chinese 
Medicines Clinic, RMIT University by HPTLC and HPLC analyses.  
 
As this is the first study conducted on Andrographis paniculata (Burm. f.) Nees from Brunei 
Darussalam based on the HPTLC and HPLC analyses of the contents of active components 
Andrographolide and Dehydroandrographolide which are often used as marker compounds for 
the quality control of Andrographis paniculata related herbal products. The structures of these 
two compounds are quite similar as shown in Figures 5.1 and 5.2, and the separation of these two 
compounds in some analysis process may be relatively difficult. HPTLC and HPLC analytical 
methods have been reported to be useful for quantitative determination of the contents of 
Andrographis paniculata (Handa & Sharma, 1990a; Saxena et al., 1999). 
 
 
Figure 5.1. Structural formula of Andrographolide (A) 
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Figure 5.2. Structural formula of Dehydroandrographolide (D) 
 
 
5.2 Determination of Andrographolide and Dehydroandrographolide in Andrographis 
paniculata (Burm. f.) Nees of Brunei Darussalam by High Performance Thin Layer 
Chromatography (HPTLC). 
 
5.2.1 High Performance Thin Layer Chromatography (HPTLC) 
 
The analysis of these two components A and D by conventional thin layer chromatography 
(TLC) method was not well described. For instance, a conventional TLC identification method 
based on compositions of CHCl3-Ethyl acetate-MeOH mobile phase used by the Pharmacopoeia 
of People Republic of China (PPRC, 2000) was further modified in our study on the basis of an 
automated system (CAMAG) by adjusting and optimizing the separation conditions several 
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times in order to separate these two constituents effectively and efficiently. In this study, we 
described an improved HPTLC method for determining the contents of these two components A 
and D in the dried leaves samples of Andrographis paniculata.  
 
5.2.2 Materials and Methods 
 
5.2.2.1 Plant materials 
 
As previously described in Chapter 4, the identity of the plant was confirmed by the Herbarium 
Museum of the Department of Agriculture and the reference herbarium voucher specimen (HDM 
15) of the Ministry of Industry and Primary Resources, Brunei Darussalam. In this HPTLC 
experiment, the herbal extract fractions investigated were CRS and CXL from China and Brunei 
AP, Kuala Belait, Temburong from Brunei Darussalam. 
 
5.2.2.2 Ethanol extraction  
 
Cold extraction of the pulverised Andrographis paniculata leaves in absolute ethanol solvent at 
room temperature was sonicated and left overnight. The Andrographis paniculata leaves samples 
CRS, CXL, Brunei AP, Kuala Belait, Temburong were prepared in 1.67%w/v compared to the 
reference standards of Andrographolide (A) and Dehydroandrographolide (D) purchased from 
National Institute for the Control of Pharmaceutical and Biomedical Products (NICPBP) at 
0.1%w/v. The stock solutions were stored at -80ºC and diluted (with the same solvents) to the 
desired concentrations on the day of experiment.  
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5.2.2.3 HPTLC Methods 
 
5.2.2.3.1 Composition of the mobile phase 
 
After testing the solvents in various composition ratio of the mobile phase, the HPTLC 
conditions were then optimised to result in effective separation of the A and D in the herbal 
samples investigated. Proper selection of the sample concentrations and the mobile phase CHCl3-
Ethyl acetate-MeOH compositions were optimised at 4:3:0 (PPRC, 2000) to reduce the tailing 
effect of the spots. Exact volume of the samples was injected precisely by automation into each 
track using Linomat 5 CAMAG automated system. 
 
5.2.2.3.2 HPTLC development plates (CAMAG)  
 
The HPTLC development was conducted in a horizontal developing chamber (CAMAG), with 
HPTLC silica gel 60 F254 precoated plate (20 x 10 cm) from Merck spotted with extracts and 
reference standard using the CAMAG Nanomat and Capillary Dispenser autojet syringe for 
spotting precision. After plate development in mobile phase, dried on a hot plates and visualised 
under ultra violet light of wavelength at 254nm and the migration of the reference standards and 
the extract fractions were quantified by calculation of the retention factor (Rf) values and the 
distance migrated by each band divided by the distance travelled by the solvent front. 
 
5.2.2.3.3 VideoScan and VideoStore 2 software (CAMAG) 
 
The CAMAG winCATS-Planar Chromatography Manager serves as the automated Multiple 
Development, VideoScan evaluates the images captured by the CAMAG VideoStore 2 software 
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which is used for both qualitative and quantitative HPTLC evaluation to calculate the amount of 
unknowns in addition to the co-chromatographed standards on the same plate. Both evaluation 
modes will transfer the image pixel data into densitogram curves and the Rf, peak height, height 
%, peak area and area% and the calibration curve for the quantification of the unknown samples 
are generated for each detected and integrated substance.  
 
5.2.2.4 Data collection and statistical analysis 
 
The results were expressed as a percentage w/w of Andrographis paniculata leaves powder 
samples. Values were expressed as mean ± Standards Error of Mean (S.E.M.), n denotes the 
number of experiments.  
 
5.2.3 Results 
 
By Video scanning the HPTLC plate, chromatography peaks (densitogram) for Andrographolide 
and Dehydroandrographolide standards and herb samples were obtained as shown in Figure 5.3. 
The content of Andrographolide and Dehydroandrographolide in the leaves sample was 
calculated from a formula derived from the standard calibration curves using CAMAG 
VidieoStore 2 and VideoScan equipment. The CAMAG video scan facilities demonstrated good 
chromatography peaks of Andrographolide and Dehydroandrographolide standards illustrated in 
Figure 5.4 and Figure 5.5.   
 
The densitograms of the Andrographis paniculata leaves extract samples investigated were 
shown in the Figures 5.6 to 5.10. HPTLC analysis of the relative components of the extract 
fractions of Andrographis paniculata leaves by comparison to the reference standards 
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Andrographolide (A) and Dehydroandrographolide (D) were conducted. Among the tested 
sample fraction, %w/w Andrographolide content in CRS were (0.52 ± 0.04%), CXL (1.36 ± 
0.12%), Brunei AP (1.84 ± 0.1%), Kuala Belait (0.86 ± 0.15%) and Temburong (2.50 ± 0.26%) 
as illustrated in Figure 5.11. The %w/w Dehydroandrographolide content in CRS were (0.54 ± 
0.05%), CXL (1.41 ± 0.07%), Brunei AP (0.84 ± 0.07%), Kuala Belait (0.56 ± 0.07%) and 
Temburong (0.40 ± 0.05%) as illustrated in Figure 5.12. 
 
The HPTLC results indicated that the %w/w content of the major active constituent of 
Andrographolide in the Andrographis paniculata leaves samples were higher level in the Brunei 
samples compared to the CXL and CRS from China. Conversely, the %w/w of 
Dehydroandrographolide level is higher in the CXL and CRS than in the Brunei Darussalam 
samples. The official method of the Chinese Pharmacopoeia (as benchmarking) which stipulated 
that the China Reference Standards of the Andrographis paniculata leaves should contain not 
less than 0.8%w/w of the total amount of A (C20H28O4) and D (C20H30O5). Figure 5.13 indicated 
that the %w/w A and D of the herbal samples combined were CRS (1.06 ± 0.04%), CXL (2.77 ± 
0.03%), Brunei AP (2.68 ± 0.05%), Kuala Belait (1.42 ± 0.19%) and Temburong (2.90 ± 0.22%) 
which is in agreement with the assay limits stipulated in the Chinese Pharmacopoeia of People 
Republic of China (PPRC, 2000). As a result indicating that the samples fractions investigated 
actually comply with the assay limits of the Chinese Pharmacopoeia. Results are mean ± SEM 
for n=6, expressed as a percentage of weight for weight of the dried Andrographis paniculata 
leaves samples.  
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Figure 5.3. The CAMAG video scan facilities  
Demonstrated good chromatography peaks of the Andrographolide & 
Dehydroandrographolide reference standards and the extract of dried 
Andrographis paniculata herbal leaves samples. 
 
Track 1-8:     0.1% w/v Andrographolide; Dehydroandrographolide Standards: 1μl, 3μl, 9μl, 
18μl; 0.5μl, 2.0μl, 6.0μl, 12μl respectively. 
 
Track 9-18: 1.67%w/v Samples CRS, CXL, Brunei AP, KB, T: 30μl each. 
Video scan the developed HPTLC plate above, chromatographic peaks 
(densitograms) for the reference standards and the samples were obtained.  
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5.2.3.1 Standard curves  
 
 
The % w/w content of Andrographolide and Dehydroandrographolide were determined from the 
formula derived from the calibration standard curves of A and D using CAMAG VideoStore 2 
and VideoScan Equipment samples can be obtained as shown in Figures 5.4 and 5.5. The linear 
regression calibration method generated the y-axis which represents the height/peak area of the 
substances A and D. The x-axis represents the amount detected for A (µg) and D (ng).  
 
Calibration results  
 
Area calibration for substance: Andrographolide 0.1% 
 
 
 
 
 
Figure 5.4. Calibration curves for the determination of A in the herbal samples 
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Calibration results  
 
Area calibration for substance: Dehydroandrographolide 0.1% 
Figure 5.5. Calibration curves for the determination of D in the herbal samples 
 
The y-axis of the densitograms illustrated represents the peak areas of the substances  
(peak 1 denotes A) and (peak 2 denotes D) and the x-axis represents the Rf  values. 
Figure 5.6. Densitogram of CRS Ee (Andrographis paniculata herbal sample) containing  
 A and D   
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Figure 5.7. Densitogram of CXL Ee (Andrographis paniculata herbal sample) containing 
A and D   
 
 
 
Figure 5.8. Densitogram of Brunei AP Ee (Andrographis paniculata herbal sample) 
containing A and D   
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Figure 5.9. Densitogram of Kuala Belait Ee (Andrographis paniculata herbal sample) 
containing A and D   
 
 
Figure 5.10. Densitogram of Temburong Ee (Andrographis paniculata herbal sample) 
containing A and D 
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Figure 5.11. Andrographolide (A) content (%w/w) in Andrographis paniculata  
leaves powder samples analysed by HPTLC (CAMAG). Results are mean ± 
SEM for n=6, expressed as a percentage of weight of the dried herb. 
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Figure 5.12. Dehydrographolide (D) content (%w/w) in Andrographis paniculata  
leaves powder samples analysed by HPTLC (CAMAG). Results are mean ± 
SEM for n=6, expressed as a percentage of weight of the dried herb.   
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Figure 5.13. The Andrographolide (A) + Dehydrographolide (D) content (%w/w) in 
Andrographis paniculata leaves powder samples analysed by HPTLC 
(CAMAG). Results are mean ± SEM for n=6, expressed as a percentage of 
weight of the dried herb. 
5.2.4 Discussion  
 
TLC was the common method of choice for herbal analysis before instrumental chromatography 
methods like GC and HPLC were established. TLC is still frequently being used for the analysis 
of herbal medicines as various pharmacopoeias such as American Herbal Pharmacopoeia (AHP), 
Chinese drug monographs and analysis, Pharmacopoeia of the People’s Republic of China 
(PPRC, 2000) and many others are still using TLC to provide first characteristic fingerprints of 
herbs (Liang et al., 2004). HPTLC has the advantages of many-fold possibilities of detection in 
the analysis of herbal medicines. HPTLC is rather simple to use and can be employed for 
multiple sample analysis for instance, more than a series of 30 spots of samples can be studied 
simultaneously in one time. 
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As a result of its usefulness to get qualitative and quantitative information from the developed 
HPTLC plate, it is still a popular convenient method of choice in the analysis of herbal 
medicines. The CAMAG video store system (CAMAG, Switzerland) and TLCQA-UV methods, 
and the image analysis and digitalized technique developed in computer science, the evaluation 
of similarity between different samples is also possible (Chau et al., 1998). The advantages of 
HPTLC to construct the fingerprints of herbal medicines are its simplicity, versatility, high 
velocity, specific and simple sample preparation. For improvement in the agriculture, drug 
analysis development, more sensitive and accurate analytical method is required for the 
quantitation of important of diterpenoids which are present in the plant (Hu & Zhou, 1982; Jain 
et al., 2000; Qizhen et al., 2003; Reddy et al., 2003; Zhao et al., 2002).  
 
Among the tested samples fractions, %w/w of Andrographolide and Dehydroandrographolide (A 
and D) contents were much similar in trends to those obtained using the HPLC analytical 
technique which validated the HPTLC procedures. Such procedures based on the computerised 
densitometer applied to the two dimensional spectrographic image analysis of the HPTLC plates 
employed indicating that HPTLC is a useful diagnostic tool in the analysis of Andrographis 
paniculata. 
 
The findings demonstrated that the content of Andrographolide and Dehydroandrographolide in  
Andrographis paniculata extracts varied significantly, ranging from 0.52% - 2.50%. The highest 
Andrographolide content was found in the Temburong sample (2.50 ± 0.26%), followed by 
Brunei AP (1.84 ± 0.1%), CXL (1.36 ± 0.12%), Kuala Belait (0.86 ± 0.27%) and CRS (0.52 ± 
0.04%). In contrast, the highest Dehydroandrographolide content was found in CXL (1.36 ± 
0.12%) followed by Brunei AP (0.84 ± 0.07%), Kuala Belait (0.56 ± 0.07%), CRS (0.54 ± 
0.05%) and Temburong (0.39 ± 0.07%). This ranking order of the content of A and D levels is 
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also in close agreement of the HPLC analysis on the Andrographis paniculata extracts found in 
in section 5.3.3.2 of Chapter 5.  
 
The HPTLC determination of Andrographolide and Dehydroandrographolide contents in the 
Andrographis species is relatively simple and easy to apply. The stable nature of the A and D 
molecules (Huang et al., 2002) which is not subject to decomposition during the extraction 
process produced good separated chromatographic peaks (densitograms). The content of 
Andrographolide and Dehydroandrographolide combined is not less than 0.8% in the raw herb 
which is in accordance with the recommended conventional TLC methods of the Pharmacopoeia 
of People Republic of China (PPRC, 2000). The Pharmacopoeia has only a descriptive 
identification method for the raw herb on the content of Andrographolide and 
Dehydroandrographolide using TLC analytical method but the HPTLC quantitative analytical 
method was not mentioned. 
 
In this study, a sensitive and useful HPTLC method for quantitative determination of 
Andrographolide and Dehydroandrographolide in raw herb samples of Andrographis paniculata 
has been developed. Compared to the conventional analysis method of HPLC, LC-MS or TLC, 
this method provides more direct and audio-visual results of many spots of samples on a single 
HPTLC plate, and is both cost and time effective. It may be useful for routine and quick analysis 
of Andrographis paniculata contents in samples containing Andrographis species.  
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5.3 Determination of Andrographolide and Dehydroandrographolide in Andrographis 
paniculata (Burm. f.) Nees of Brunei Darussalam by High Performance Liquid 
Chromatography (HPLC) Analysis 
 
 
5.3.1 High Performance Liquid Chromatography (HPLC) Analysis 
 
Generally, the methods for quality control of herbal medicines involve sensory inspection  
(macroscopic and microscopic examinations) as well as analytical inspection using instrumental 
techniques such as TLC, HPLC, GC-MS, LC-MS, near infrared (NIR), and spectrophotometer, 
etc. HPLC is a popular method for the analysis of herbal medicines because it is easy to learn, 
adapt and use and is not limited by the volatility or stability of the sample compound. It can also 
be used to analyse almost all the compounds in the herbal medicines and has received the most 
extensive applications in a timely and cost effective manner. For instance, reversed-phase (RP) 
columns may be the most popular columns used in the analytical separation of herbal medicines. 
It is important to note that the good experimental design for the optimal separation condition for 
the HPLC involves many factors, such as the different compositions of the mobile phases, the pH 
adjustment, pump pressures and all conditions need to be optimised prior to the analytical 
process. 
 
5.3.2 Materials and Methods 
 
5.3.2.1 Plant materials 
 
Plant materials were described previously in section 5.2.2.1 of Chapter 5.   
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5.3.2.2 Stability of diterpenes 
 
It has been reported that Andrographolide (A) is quite stable for months. Andrographolide is by 
far the most stable active constituent compared to the other diterpenes. Dehydroandrographolide 
(D) is not a metabolite of Andrographolide. On prolong heating treatment during the production 
of formulations of Andrographis paniculata into tablets and other dosage forms, it is quite 
possible that Dehydroandrographolide content may increase (Huang et al., 2002). By chemical 
treatment such as esterification of Andrographolide can produce esters which can be active 
compounds such as 14-deoxy-11,12-didehydroandrographolide and others. The HPLC fractions 
of Andrographis paniculata samples were prepared in absolute ethanol by cold extraction and 
stirred for one hour according to the Chinese Pharmacopoeia Volume I for HPLC method of 
analysis. There was actually no heat or chemical treatment at all which do not affect the stability 
of the A and D in the HPLC samples analyzed. Huang et al (2002) demonstrated that by avoiding 
or reducing heating treatment, time is the main factor to protect and preserve the effective active 
ingredients in the herb (Huang et al., 2002). The stability of the crystalline Andrographolide was 
highly stable at 70 ºC (75% relative humidity) over a period of three months whereas the 
amorphous phase degraded promptly.  
 
5.3.2.3  Extraction methods 
 
5.3.2.3.1 Cold extraction in ethanol 
 
The pulverised Andrographis paniculata leaves were stirred with magnetic stirrer in ethanol at 
room temperature overnight. The extracts were centrifuged at 5000 rpm for 10 min and the 
supernatant filtered with Millipore vacuum filtering system (XX10 090 20-Billerica, MA, USA). 
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A rotary evaporator (Buchi Rotavapor, Brinkman company, Westbury, NY, USA was used to 
remove the solvent. Extract fractions were then redissolved in absolute ethanol. The stock 
solutions were stored at -80ºC and diluted with the same solvents to the desired final 
concentration of 200µg/ml on the day for HPLC analysis. Sample fractions CRS, CXL, Brunei 
AP, Kuala Belait and Temburong were analyzed. 
 
5.3.2.3.2 Cold extraction for fractions tested in anti-tumour and general  
cytotoxicity assays 
 
Cold extraction fractions of CRS Ee STIR, CXL Ee STIR and Brunei AP Ee STIR were prepared 
in 200µg/ml final concentration for HPLC analysis prior to their investigation in the anti-tumour 
and general cytotoxicity assays as described in Chapter 9 and 10 respectively.  
 
5.3.2.3.3 Solvent Extraction with Accelerated Solvent Extraction (ASE) Dionex 
                    System 
 
The Andrographis paniculata leave powder was accurately weighed and extracted separately 
using the ASE extraction (Dionex system) in ethanol and MilliQ water as solvents into various 
herbal fractions CXL Ee ASE, Brunei AP Ee ASE, CXL We ASE and Brunei AP We ASE were 
prepared in 200µg/ml final concentration. The pure standards of Andrographolide (A) and 
Dehydroandrographolide (D) purchased from National Institute for the Control of 
Pharmaceutical and Biomedical Products, Ministry of Health Beijing, China (NICPBP) were 
prepared in 1.0µg/ml, 2.5µg/ml, 5µg/ml, 10µg/ml, 25µg/ml in ethanol solvent. After HPLC 
analysis, all these fractions were used in the anti-tumour and general cytotoxicity assays as 
described in Chapter 9 and 10 respectively.  
 173
5.3.2.3.4 HPLC analytical conditions 
 
After testing different solvents in various composition ratio of the mobile phase, the HPLC 
conditions were then optimised to result in effective separation of the A and D in the herbal 
fractions investigated. Proper selection of the sample concentrations and the mobile phase 
Methanol: Water (52:48) compositions were optimised to reduce the tailing effect of the peaks 
eluted. Exact volume 20µl of the fractions were injected precisely using Shimazu (Japan), LC-
10AT liquid chromatography instrument, equipped with  and controlled by a model SCL-10AVP 
System, a model SIL-10ADVP Auto Injector, a 20ul sample loop and a multidimensional UV-
VIS detector (SPD-M 10AVP), DGU-14A Degasser, CTO-10AVP Column Oven and FCV-
10AL VP. The data is to be collected with a Pentium Computer (Datamini) and HP-deskjet 
printer. Solvents were filtered using a millipore system and the analysis is performed on a Waters 
make µ Bondapak C18 Column (300 x 3.9mm, I.D. 10 µm). A constant flow rate of 1ml/min, 
column temperature of 27ºC, detector wavelength at 254nm, the absorption maxima is close to 
all the compounds. 
 
5.3.2.4 Data collection and statistical analysis 
 
The results were expressed as a percentage of w/w of the Andrographis paniculata herbal leave 
powder. Values were expressed as mean ± Standards Error of Mean (S.E.M.), n denotes the 
number of experiments.  
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5.3.3 Results 
 
HPLC analysis of the active components of Andrographis paniculata leaves detected the 
presence of Andrographolide (A) and Dehydroandrographolide (D) in all the extract fractions.  
 
5.3.3.1 Standard curves 
 
The HPLC system demonstrated good resolutions of the chromatography peaks of 
Andrographolide and Dehydroandrographolide reference standards and the extract fractions of 
Andrographis paniculata leaves samples as shown in Figure 5.14. In this study, an automated 
10μl injection volume of Andrographolide (A) and Dehydroandrographolide (D) reference 
standards of concentrations at 1μg/ml, 2.5μg/ml, 5μg/ml, 10μg/ml, 25μg/ml were used. And an 
automated 20μl injection volume of all the extract fractions were analyzed by HPLC and the 
chromatographic peaks were illustrated in Figures 5.15 to 5.19.  
 
The %w/w content of Andrographolide and Dehydroandrographolide were determined from the 
formula derived from the calibration standard curves of A and D. Linearity was determined by 
using five concentrations in a working range of 1-25µg/ml of both components A and D 
combined. Linear regression equations and good correlation coefficients for the A and D were 
obtained. Calibration plots of peak areas versus concentrations are linear, with r values between 
0.9999 and 1.0000. These values indicated good linearity in the examined concentration range. 
The retention time (Rt) of A is 8.57 ± 0.05 mins, % relative standard deviation (RSD) is 1.55% 
and the retention time of D is 20.67 ± 0.17 mins, %RSD is 2.05%.  
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Figure 5.14. Calibration curves for the determination of A (a) and D (b) in the herbal 
fractions.  
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D 
A
Figure 5.15. The HPLC Chromatogram Peaks for the sample fractions.  
Y axis represents the peak area and x-axis represents the retention time 
(mins) 
                                                                    
(a) Standard Mix A + D at 10µg/ml 
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(c) CXL (clinic) at 200µg/ml  
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(d) Brunei AP at 200µg/ml 
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(h) Brunei AP Ee ASE (Bru Ee ASE) at 200µg/ml 
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(l) Brunei AP We STIR (Bru We STIR) at 200µg/ml 
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5.3.3.2 Contents of A and D in the Andrographis paniculata extract samples  
 
The results of this HPLC study indicated that the %w/w of the important major active component 
Andrographolide which is responsible for the medicinal benefits of the plant is higher in the 
Temburong (3.43 ± 0.02%), Brunei AP (1.86 ± 0.02%), compared to the samples CXL (1.14 ± 
0.01%), Kuala Belait (0.67 ± 0.02%), CRS (0.51 ± 0.01%) as shown in Figure 5.16. On the 
contrary, the %w/w Dehydroandrographolide, being the lesser potent component of the plant 
seems to be lower in the descending order of CXL (0.66 ± 0.01%), Brunei AP (0.24 ± 0.01%), 
Kuala Belait (0.24 ± 0.05%), CRS (0.14 ± 0.01%) and Temburong (0.12 ± 0.01%) illustrated in 
Figure 5.17. 
 
The HPLC results indicated that the %w/w content of the major active constituent of 
Andrographolide in the Andrographis paniculata leaves samples were higher level in the Brunei 
samples compared to the CXL and CRS from China. Conversely, the %w/w of 
Dehydroandrographolide level is higher in the CXL and CRS than in the Brunei Darussalam 
samples. The official method of the Chinese Pharmacopoeia (as benchmarking) which stipulated 
that the China Reference Standards of the Andrographis paniculata herbal leaves should contain 
not less than 0.8%w/w of the total amount of A (C20H28O4) and D (C20H30O5).  
 
Figure 5.18 indicated that the %w/w A and D of the herbal samples combined were CRS (0.65 ± 
0.02%), CXL (1.80 ± 0.02%), Brunei AP (2.10 ± 0.03%), Kuala Belait (0.91 ± 0.06%) and 
Temburong (3.55 ± 0.03%) which is in agreement with the assay limits stipulated in the Chinese 
Pharmacopoeia of People Republic of China (PPRC, 2000). As a result indicating that the 
samples fractions investigated actually comply with the assay limits of the Chinese 
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Pharmacopoeia. Results are mean ± SEM for n=6, expressed as a percentage of weight for 
weight of the dried Andrographis paniculata leaves samples.  
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Figure 5.16.    Andrographolide (A) content (%w/w) in Andrographis paniculata  
leaves powder samples analysed by HPLC. Results are mean ± SEM for n=6, 
expressed as a percentage of weight of the dried herb.   
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Figure 5.17.   Dehydroandrographolide (D) content (%w/w) in Andrographis paniculata  
leaves powder samples analysed by HPLC. Results are mean ± SEM for n=6, 
expressed as a percentage of weight of the dried herb.   
 185
CRS CXL Brunei AP Kuala Belait Temburong
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
%
w
/w
 A
nd
ro
gr
ap
ho
lid
e 
+
D
eh
yd
ro
an
dr
og
ra
ph
ol
id
e
 
Figure 5.18. Andrographolide (A) + Dehydroandrographolide (D) content (%w/w) in the 
Andrographis paniculata extracts by HPLC. Results are mean ± SEM for n=6, 
expressed as a percentage of weight of the dried herb.   
 
5.3.3.3 Contents of A and D in the herbal extract fractions used for anti-tumour and 
general cytotoxicity assays 
 
On the basis of the extraction techniques of cold extraction by stirring (STIR) versus ASE 
(Dionex) system, among the tested standardised herbal fractions 200ug/ml, the %w/w 
Andrographolide (A) content in CRS Ee STIR (0.51 ± 0.01%), CXL Ee ASE (3.4 ± 0.02%),  
Bru Ee ASE (9.55 ± 0.03%), CXL Ee STIR (1.63 ± 0.02%), Bru Ee STIR (2.3 ± 0.03%), CXL 
We ASE (3.08 ± 0.04%) and Bru We ASE (3.40 ± 0.02%) as shown in Figure 5.19. 
 
As for the Dehydroandrographolide (D) content in %w/w CRS Ee STIR (0.14 ± 0.13%), CXL Ee 
ASE (4.23 ± 0.19%), Bru Ee ASE (2.63 ± 0.04%), CXL Ee STIR (10.65 ± 0.04%), Bru Ee STIR 
(11.59 ± 0.12%), CXL We ASE (1.78 ± 0.01%) and Bru We ASE (0.31 ± 0.01%) as illustrated 
in Figure 5.20. 
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When combining both Andrographolide and Dehydroandrographolide contents, Bru Ee STIR 
(13.89 ± 0.15%), CXL Ee STIR (12.28 ± 0.06%) and Bru Ee ASE (12.18 ± 0.05%) were found 
to contain the higher levels among the seven extract fractions as shown in Figure 5.21. 
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Figure 5.19.   Andrographolide (A) content (%w/w) in Andrographis paniculata  
leaves powder samples analysed by HPLC. Results are mean ± SEM for n=6, 
expressed as a percentage of weight of the dried herb.  
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Figure 5.20. Dehydrographolide (D) content (%w/w) in Andrographis paniculata  
leaves powder samples analysed by HPLC. Results are mean ± SEM for n=6, 
expressed as a percentage of weight of the dried herb.  
 187
Bru Ee STIR CXL Ee STIR Bru Ee ASE CXL Ee ASE CXL We ASE Bru We ASE CRS Ee STIR
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
%
w
/w
 A
nd
ro
gr
ap
ho
lid
e 
+
D
eh
yd
ro
an
dr
og
ra
ph
ol
id
e
 
Figure 5.21.  Andrographolide (A) + Dehydroandrographolide (D) content (%w/w) in the 
Andrographis paniculata extract fraction samples for anti-tumour and 
general cytotoxicity assays by HPLC. Results are mean ± SEM for n=6, 
expressed as a percentage of weight of the dried herb.  
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5.3.4 Discussion 
 
The findings of the HPLC analysis of the Andrographis paniculata fraction samples for the anti-
tumour and general cytotoxicity assays as described in Chapter 9 and 10, demonstrated that the 
%w/w content of Andrographolide in the Brunei ethanol extract fraction (Bru Ee ASE) and CXL 
Ee ASE based on the Accelerated System Extraction (ASE) Dionex system was 9.55 ± 0.03% 
and 3.40 ± 0.02% respectively.  
 
However, the %w/w content of Dehydroandrographolide of Bru Ee ASE (2.63 ± 0.02%) which 
was lower when compared to CXL Ee ASE at 4.23 ± 0.19%. This is again in close agreement 
with the HPTLC and HPLC analysis described earlier that the level of content of 
Andrographolide is higher and conversely, the Dehydroandrographolide is lower in the Brunei 
Darussalam fractions compared to the Chuan Xin Lian (CXL) from China.  
 
As a result of the content of Andrographolide difference is higher between these two samples, 
our interest to look into the correlation of the contents of Andrographolide and 
Dehydroandrographolide of these two sample fractions were then further investigated for their 
anti-tumour and general cytotoxicity effects in Chapter 9 and 10. 
 
This study demonstrated that Andrographolide and Dehydroandrographolide have obtained good 
linearity in the range of 1 mg/L to 25 mg/L with the correlation coefficients of 0.9999 and 
1.0000 compared to the correlation coefficients of 0.9976 and 0.9986 respectively (Xu et al., 
2002) which is in agreement with the previous study. The active constituents of Andrographis 
paniculata were investigated by Jain et al., 2000 using the mobile phase composition of varying 
the percentage of acetonitrile in water/methanol, in water giving rise to a good resolution of the 
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active components (Jain et al., 2000). The structures of three major Andrographolides namely 
Andrographolide, Neoandrographolide, 14-Deoxy-11,12-didehydroandrographolide were 
resolved in the optimised operating conditions such as acetonitrile-water (70:30, v/v), flow rate 
of 1ml/min, column temperature 26ºC, detector wavelength 230nm, with the absorption maxima 
closed to all the compounds.  
 
In the other previous study, the content of Andrographolide content in the leave sample obtained 
from the experimental farm of Central Institute of Medicinal and Aromatic Plants (CIMAP), 
Lucknow, India were found to be 1.71% by HPTLC analytical method (Saxena et al., 1999) and 
1.78% by HPLC analytical method (Jain et al., 2000). In our study, based on the similar 
chromatographic conditions, the Brunei AP samples were found to be 1.84 ± 0.1% (HPTLC) and 
1.86 ± 0.01% (HPLC) which seems to be in close agreement with the previous studies 
conducted. This may suggest that the Andrographis paniculata sources from India (King of 
Bitters) and Brunei Darussalam (Daun pahit) are both originated from the tropics whereas Chuan 
Xin Lian (CXL) and CRS from China with temperate climate. 
 
Based on the literature review, Andrographis paniculata leaves are rich and dark green in colour 
and thrives well in the tropics would provide a rich source of chlorophyll contents that may 
potentiate the level of active constituents in the leaves. This may suggest that the Andrographis 
paniculata source from the tropics may have higher level of active constituents which may be 
more potent that those derive from the temperate conditions. This requires further elucidation on 
the study of Andrographis paniculata source from countries with different climatic conditions 
and other factors that may affect the level of contents of active constituents in the leaves (Ngan 
et al., 1999). It has also been reported that geographical locations and seasons may explain the 
differences in the contents of the active components in the plants (Hu & Wu, 1995). However, 
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further studies are required to elucidate the different levels of contents of constituents in 
Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam compared to Andrographis 
paniculata from other geographical locations in order to have a better understanding on this 
possible explanation. 
 
The results obtained in this study reflected the utility of HPTLC and HPLC in the analysis of the 
contents of A and D variability distribution within Andrographis paniculata. The finding of the 
contents between extract samples investigated from Brunei Darussalam and Chuan Xin Lian 
(CXL) are in close agreement with the previous studies (Jain et al., 2000; Saxena et al., 1999). 
Both HPTLC and HPLC results demonstrated that the contents of A combined with D comply 
with the assay limits of not less than 0.8% which is in accordance with the Chinese 
Pharmacopoeia (PPRC, 2000) suggest the appropriateness of these two analytical methods for 
Andrographis paniculata (Burm. f.) Nees.  
 
This study also provides a better understanding of the correlation of the level of contents of A 
and D to the genetic variation at the intraspecific level as discussed earlier in Chapter 4. Such 
finding would help us in identifying superior genotype(s) for cultivar development of 
Andrographis paniculata (Burm. f.) Nees. Further studies are needed to elucidate this correlation 
in particularly the genotype of the Temburong Andrographis paniculata sample. In conclusion, 
both the HPTLC and HPLC chromatographic procedures employed may also serve as simple and 
useful chemical fingerprint analysis of Andrographis paniculata for the quality control purposes 
and in the preparation of formulations based on the herb (Srivastava et al., 2004). 
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6.1 Introduction 
 
It is documented that extracts of many plants and natural products have anti-oxidant and free 
radical scavenging properties. Free radical oxidative stress, usually resulting from deficient 
natural anti-oxidant defenses (Halliwell & Gutteridge, 1984), has been implicated in the 
pathogenesis of a wide variety of clinical disorders, such as degenerative diseases (Cross, 1987). 
It may contribute as a factor in aging (Beckman et al., 1998) and progressive impairment of the 
immune function (Pike & Chandra, 1995).  
 
Andrographis paniculata has been studied for its anti-oxidants activities in relation to the anti-
hepatotoxicity effect of the diterpenoid components of the herb (Kapil et al., 1993; Singh et al., 
2001; Trivedi & Rawal, 2001; Zhang & Tan, 2000b). However, only few reports on the anti-
oxidant activities of Andrographis paniculata are available. 
 
Therefore, it is beneficial to conduct this study on Andrographis paniculata (Burm. f.) Nees 
grown in Brunei Darussalam. In this study, the aqueous, ethanol and methanol extracts of 
Andrographis paniculata leaves were analyzed for their potential anti-oxidant activities. It is 
believed by many in the anti-oxidant therapy that the administration of compounds with anti-
oxidant properties perhaps acts as an effective drug therapy in the preventative and curative 
therapeutic agents of many diseases conditions. This study provides a better understanding of the 
anti-oxidant profile of Andrographis paniculata (Burm. f.) Nees grown in Brunei Darussalam on 
their scavenging activities of 1,1-diphenyl-2-picryhydrazyl (DPPH), hydroxyl radical, hydrogen 
peroxide scavenging and the inhibition of nitric oxide formation in the cell-free systems.  
 
 
 195
6.1.1    Importance of anti-oxidants of natural products 
 
It has been well established that oxidative stress caused by the imbalance between oxidants and 
anti-oxidant is involved in many pathological conditions such as mutagenesis, cancer, 
atherosclerosis, cardiovascular diseases, degenerative disorders and aging process (Darlington & 
Stone, 2001; MacNee, 2001; Wei & Lee, 2002). Thus anti-oxidants have an important role in the 
prevention or treatment of these diseases conditions. The natural food products industry in their 
continued effort to use alternative natural anti-oxidants to synthetic antioxidants in food 
manufacturing due to the beneficial safety profile of natural plant products. It has long been 
known that many plants possess potent anti-oxidant activities. Many research and development 
have been focused on the characterization of these anti-oxidants constituents which are 
responsible for the pharmacological and biological activities (Brown & Goodman, 1998). 
 
6.1.2    Reactive oxygen species (ROS)  
 
The formation of the reactive oxygen species such as the superoxide anion (O2
•-
), hydroxyl 
radical (OH
•
), peroxyl radical (ROO
•
) and hydrogen peroxide (H2O2) in most cellular processes  
during phagocytosis of invading pathogens  has been implicated in the pathogenesis of a series of 
clinical disorders resulting in the degenerative diseases. The state of oxidative stress occurs as a 
result of the imbalance of the levels of ROS thus causes reactions with cellular lipids i.e. lipid 
peroxidation, proteins and nucleic acids of cells. Such a state may also be a causative factor in 
ageing process, resulting in the deterioration and impairment of the immune function. 
Complications such as inflammatory, cardiovascular, cancer diseases become the end stage if the 
imbalance is not restored to normal state. Compounds with potent anti-oxidant properties are 
protective and help to reduce damages caused by ROS. It is known that many extracts of plants 
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have anti-oxidant and free radical scavenging which are beneficial and employed in the 
therapeutic management of most free radical oxidative stress (Chiang et al., 1994; Cos et al., 
1998; Cross, 1987; Halliwell & Gutteridge, 1984) 
 
Reactive oxygen species (ROS) are categorised into free radicals (superoxide radical anion O2
-• 
, 
Nitric oxide NO
•
, hydroxyl radical 
•
OH) and non-radical compounds (hydrogen peroxide H2O2, 
hypohalous acids and their salts HOCl, singlet oxygen 
1
O2, peroxynitrite ONOOH). These potent 
oxidants are often generated as by products of biological reactions or from exogenous factors. 
Their involvement in the pathogenesis of diseases including rheumatoid arthritis, 
artherosclerosis, diabetes mellitus, reperfusion injury, asthma, carcinogenesis and other medical 
complications have been well documented. Therefore, powerful scavengers of these ROS will 
protect and prevent tissue injuries and are of therapeutic importance. The most likely mechanism 
of the anti-oxidant is by interfering with the damages caused by 
•
OH not by direct 
•
OH 
scavenging but by scavenging or blocking formation of its precursors  
(O2
-•
,
 
H2O2, HOCl, ONOO
-
) and/or by binding with transition metal ions needed for 
•
OH 
formation from O2
-•
 and H2O2 (Halliwell et al., 1995). The use of synthetic anti-oxidants in the 
food industry as inhibitors of the reactive oxygen species such as butylated hydroxyanisole 
(BHA) and butylated hydroxytoluene (BHT), as due to its instability and has become the 
suspected carcinogenesis promoters. The use of natural plant products with potential anti-oxidant 
activities are now the centre of importance in the food industry (Candan F & Sokmen, 2004; 
Zaprorozhets et al., 2004). 
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6.1.3 Pathological roles of the ROS in the anti-inflammatory mechanism of Andrographis 
paniculata 
 
Reactive oxygen species (ROS) play an important role in the pathogenesis and many symptoms 
of inflammatory processes of the respiratory tract trigger by potentially toxic and infective 
airborne molecules and particles as environmental impacts (GraBmann & Hippeli, 2000). Studies 
have shown that anti-inflammatory mechanism of actions of Andrographis paniculata, are 
associated with its inhibition of platelet-activating factor (PAF)-mediated inflammatory response 
and inhibition of expression of nitric oxide synthase in macrophages (Chiou et al., 1998), but not 
via the inhibition of the biosynthesis of eicosanoids, different from NSAID pathways (Amroyan 
et al., 1999). 
 
ROS are generated by neutrophils or alveolar macrophages as defence mechanism against the 
invading microorganisms. Neutrophils, upon stimulation release superoxide which dismutated 
into H2O2 and O2. Neutrophils also produce nitric oxide which reacts with superoxide to form 
peroxynitrite and myeloperoxidase (MPO), thus oxidize halides to hypohalous acids. 
Subsequently, reacts with H2O2 as oxidant to form singlet oxygen. ROS also include hydroxyl 
radical produced by iron-catalyzed decomposition of H2O2 which is an extremely powerful 
oxidant. Andrographolide was studied in the suppression of rat neutrophil reactive oxygen 
species production and adhesion suggested that its potential use as an effective anti-inflammatory 
agent (Shen et al., 2002). 
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6.1.4 ROS and Neuronal pathways 
 
The potential and beneficial use of a combination of a NOS inhibitor, (N
G
 nitro-L-arginine 
(LNA) and the anti-oxidant /superoxide scavenger, di-tert-butyl-hydroxybenzoic acid (DtBHB) 
are synergistic toward the reduction of neuronal damage during ischaemia-reperfusion and 
supported that NO, superoxide anion, and peroxynitrite, both independently and cooperatively 
play important roles in neuronal injury (Spinnewyn et al., 1999). Nitric oxide reacts with 
superoxide radical (Huie & Padmaja, 1993) to form peroxynitrite, an endogenous mediator of 
many forms of tissue injury ranging from neurodegenerative diseases, chronic inflammation and 
immunological disorders, atherosclerosis and other pathological diseases (Beckman et al., 1990; 
Darley-Usmar et al., 1995; Kaur & Halliwell, 1994; Swain et al., 1994). It induces lipid 
peroxidation (Radi & Beckman, 1991), oxidize protein and non protein thiol groups (Radi et al., 
1991), damage DNA (Inoue & Kawanishi, 1995), react with tyrosine residues to 3-nitrotyrosine 
(Beckman, 1996; Ischiropoulos et al., 1992). 
 
6.1.5 Types and sources of natural antioxidants 
 
6.1.5.1 Medicinal herbs  
 
Danchunhwan (Radix Salviae miltorrhizae and Rhizoma Cnidii) protects human neuroblastoma 
SH-SY5Y cells from apoptotic death by free radicals including peroxynitrite and NO via 
generation of anti-oxidation, GSH (Kim et al., 2001). The inhibitory effects of water extracts 
from fruiting bodies of cultured Cordyceps sinensis on raised serum lipid peroxide levels and 
aortic cholesterol deposition in atherosclerotic mice which may have beneficial effects on the 
process of artherogenesis and aging with few side effects (Yamaguchi et al., 2000). 
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6.1.5.2 Animal ingredients 
 
The anti-inflammatory actions of Uncaria tomentosa known as cat’s claw or ‘una de gato’ (UG), 
a Peruvian traditional medicine, protects cells against oxidative stress by inhibiting 
lipopolysaccharide (LPS)-induced iNOS gene expression, nitrite formation, peroxynitrite-
induced apoptosis and negated the activation of NF-KB (Sandoval-Chacon et al., 1998). 
 
Quantification of total oxidant scavenging capacity of anti-oxidants for peroxynitrite, peroxyl 
radicals, and hydroxyl radicals was studied (Regoli & Winston, 1999). The quantification of the 
absorbance capacity of anti-oxidants on three potent oxidants such as hydroxyl radicals, peroxyl 
radicals, and peroxynitrite which were generated by the iron plus ascorbate-driven Fenton 
reaction, thermal homolysis of 2, 2’-azobis (2-methyylpropionamidine) dihydrochloride 
(ABAP), 3-morpholinosydnonimine N-ethylcarbamide (SIN-1). Reactions between these three 
oxidants and α-keto-γ-methiolbutyric acid (KMBA), oxidized to ethylene. Quantification of their 
total oxidant scavenging capacity is measured on the ability to inhibit ethylene formation relative 
to the control reaction. 
 
6.1.5.3 Green tea 
 
The investigation by Dyke et al., (2000) on the anti-oxidant properties of the polyphenols in the 
green tea extract which markedly inhibit luminal-dependent chemiluminescence activated by 
peroxynitrite (a potent oxidant about 1000 times more active than equidose hydrogen peroxide) 
produced by the hydrolysis of linsidomine (SIN-1) (Dyke et al., 2000). The screening for the 
efficacy of ten kinds of green tea for their tyrosinase inhibitory activity of active components i.e. 
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(-)-epicatechin 3-O-gallate (ECG), (-)-gallocatechin 3-O-gallate (GCG), and (-)-epigallocatechin 
3-O-gallate (EGCG) (No et al., 1999). The study suggested that the kinetic analysis for such 
inhibition of tyrosinase revealed a competitive nature of GCG with this enzyme for the L-
tyrosine binding at the active site of tyrosinase. 
 
The mechanism of how the increases in the levels of free radicals could be due to the increased 
production and/or decreased destruction. Anti-oxidant enzymes such as catalase (CAT), 
glutathione peroxidase (GSH-Px) and superoxide dismuthase (SOD) and non-enzymatic 
scavenger components gluthathione (GSH) and vitamin E offer good protection to cells and 
tissues against oxidative injury (Simmons, 1984). 
 
6.2 Materials and Methods 
 
6.2.1 Chemical materials  
 
1,1-Diphenyl-2-picryhydrazyl, ethanol, ascorbic acid, deoxyribose, potassium dihydrogen 
orthophosphate, potassium hydroxide, iron (III) chloride, EDTA, H2O2, TBA, TCA, NaOH, 
horseradish peroxidase, phenol red, sodium nitroprusside, griess reagent (1% sulphanilamide, 2% 
o-phosphoric acid and 0.1% naphthyl ethylenediamine dihyrochloride) were commercially 
available from BDH Chemicals Australia (Kilsyth, Victoria, Australia), Sigma Chemical Co. (St. 
Louis, MO, USA). 
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6.2.2 Plant materials 
 
The Andrographis paniculata leaves samples were described earlier in Chapter 4. The Brunei 
AP samples were used in the anti-oxidant assays.  
 
6.2.3 Extraction with ASE (Accelerated Solvent Extraction) Dionex System 
 
The herbal leave powder of Andrographis paniculata of Brunei Darussalam, air dried at room 
temperature was extracted in absolute ethanol, methanol and Milli-Q pure grade water as 
solvents respectively using the ASE 100 Dionex System (Dionex Pty Ltd, Lanecove, 1595, 
NSW). Operating procedure was based on the in built set up method 1 by Dionex with the 
following specifications and extraction conditions:  Dionex Part No. 056780 Filter grade: D28, 
Size: 30mm; Temperature: 100ºC; Pressure: 1,500psi (10MPa); Heating time: 5 min; Static 
time: 5 min; Flush time: 60%; Purge time: 100s; Static cycle: 3; Total extraction: 30 min per 
sample. The extracts were then filtered through a Whatman filter paper No. 1.  
 
The ethanol and methanol were evaporated using a rotary evaporator under vacuum (Biichi 
Rotavapor, Brinkman Company, Westbury, NY, USA). The concentrated aqueous extracts were 
transported in liquid nitrogen for freeze drying using Freeze Drier Dynavac FD 12 (Airvac 
Engineering Pty Ltd, Melbourne, Australia) to remove water. The stock extracts were stored at  
-80ºC and dissolved in the respective solvents to the appropriate concentrations on the day of 
use. The extracts were resuspended in absolute ethanol resulting in ethanol, methanol and 
aqueous extract used for the anti-oxidant assays. 
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6.2.4 Data collection and statistical analysis 
 
Statistical Analysis was performed using Graph Pad Prism Version 4.0 for Windows (San Diego, 
CA, USA). Data was analyzed by One Way Analysis of Variance (ANOVA) followed by 
Bonferroni multiple comparison test. Where applicable values are given as mean ± Standard 
Error of Mean (SEM) of n observations. *P-value <0.05 was considered to be statistically 
significant. 
 
6.3 Anti-oxidant screening assays 
 
6.3.1 DPPH Scavenging Assay 
 
The hydrogen-donating ability of each extract in the presence of a DPPH stable radical was 
examined according to the method developed by Blois and Cao et al., 1997  (Blois, 1958; Cao et 
al., 1997). All the Andrographis paniculata leaves extracts were diluted with vehicle control to 
final extract concentrations of 0.1, 0.2, and 0.3mg/ml of aqueous, ethanol and methanol extracts. 
 
10µl, 20µl and 30µl of each extract with stock concentration of 10mg/ml were added to a 100µM 
solution of DPPH (2, 2-diphenyl-1-1-picrylhydrazyl. Absorbance of the ethanolic DPPH tincture 
from DPPH
•
 (violet colour) to DPPH2 (clear) was measured with a spectrophotometer at 517 nm 
(Bondet V. et al., 1997), Beckman  Coulter, CA, PUSA. Trolox which is a water-soluble 
analogue of Vitamin E was used as positive control compound over the same concentration 
range. 
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6.3.2 Hydroxyl radical scavenging assay 
 
The hydroxyl radicals were generated by the Fenton reaction of an iron-EDTA complex (100µM 
FeCl3; 104µM EDTA) with 1mM H2O2 in the presence of 100µM ascorbic acid. The degradation 
of the deoxyribose (2.8mM) by the hydroxyl radicals into products which then react with 
Thiobarbituric acid (1%w/v in 0.05M NaOH), form a pink chromogen on heating. Extracts with 
anti-oxidant properties scavenge hydroxyl radicals to reduce the amount of deoxyribose 
degradation and chromogen formation. The aqueous, ethanol and methanol extracts (1mg/ml) 
were added to the reaction mixture and incubated at 37ºC for 15 minutes. Trichloroacetic acid 
(TCA, 2.8%w/v) was added to stop the reaction before the addition of Thiobarbituric acid (TBA) 
on 15 minutes incubation in boiling water. Absorbance reading on the production of the 
chromogen was then measured spectrophotometrically at 532nm using Trolox as reference 
positive control compound. 
 
6.3.3 Phenol red peroxidase assay 
 
Hydrogen peroxide (H2O2) scavenging assay was assessed based on the H2O2-dependent 
horseradish peroxidase (HRP)-mediated oxidation of phenol red, the reaction between H2O2 and 
phenol red which results in the appearance of a complex which absorbs at 610 nm. All aqueous, 
ethanol and methanol extracts (0.1mg/ml) were preincubated with 100µM H2O2 in potassium 
phosphate buffered saline (0.15M, pH 7.0) for 30 minutes, before the addition of 50µl of phenol 
red (2mg/ml) and 10µl of HRP (3.6mg/ml). The absorbance was measured 
spectrophotometrically after 5 minute against a sample blank at 610 nm (Tan et al., 2000) using 
Catalase 0.025mg/ml as reference positive control compound.  
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6.3.4 Nitric oxide scavenging assay  
 
The nitric oxide generated from sodium nitroprusside, was measured as described by  (Marcocci 
et al., 1994) using the griess reagent. 0.5ml of the stock concentrations of aqueous, ethanol and 
methanol extracts (2, 4 and 6mg/ml) were each incubated with 0.5ml of 25 mM sodium 
nitroprusside at 25ºC for 30min. After incubation, 1ml of the extracts was added to 1ml of griess 
reagent (1% sulphanilamide, 2% o-phosphoric acid and 0.1% naphthyl ethylenediamine 
dihyrochloride) giving a final concentration of 0.5, 1 and 1.5mg/ml were incubated at room 
temperature for 10 min. The absorbance of the chromophore formed was measured with a 
spectrophotometer (DU530, Beckman Coulter, CA, USA) at 540 nm.  
 
6.4 Results   
 
6.4.1 DPPH free radical scavenging  
 
Both the ethanol and methanol extracts were found to significantly scavenge DPPH free radical 
at concentrations of 0.1, 0.2 and 0.3mg/ml with the exception of the aqueous extract which did 
not show any significant DPPH scavenging activity. The ethanol extract at concentrations of 0.1, 
0.2 and 0.3mg/ml showed significant scavenging activity of DPPH free radicals at 25.07 ± 
2.28%, 32.39 ± 3.58% and 33.44 ± 2.75% (Figure 6.1) and methanol extract at the same 
concentrations tested displayed scavenging activity at 27.37 ± 3.72%, 37.52 ± 1.64% and 30.88 ± 
0.35% respectively. The positive control trolox over the same concentration range, showed 
%DPPH scavenging activity of 96.98 ± 3.34%, 95.32 ± 0.67 and 96.35 ± 1.89% respectively, 
significantly decrease in the absorbance compared to the control (extract blank), as a result 
validated the procedure of DPPH assay.  
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Figure 6.1.    Effect of Andrographis paniculata extracts (0.1, 0.2, 0.3mg/ml) on DPPH 
scavenging activity.  
Results are mean ± SEM n=4, *P<0.05 expressed as percentage scavenging of 
DPPH free radicals when compared to an extract blank (control). 
 
6.4.2 Hydroxyl radical scavenging assay 
 
All the aqueous, ethanol and methanol extracts were found to significantly scavenge hydroxyl 
radical at a concentration of 0.1mg/ml, exhibited significant inhibition of deoxyribose 
degradation. The aqueous, ethanol and methanol extracts displayed significant scavenging of 
hydroxyl radicals at 9.64 ± 3.63%, 19.60 ± 4.68% and 16.24 ± 4.64% respectively. Trolox, a 
relatively water soluble vitamin E analogue and known free radical scavenger, used as positive 
control was able to scavenge 87.93 ± 1.0% of the available hydroxyl radicals at 0.1mg/ml  
(Figure 6.2). 
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Figure 6.2.   Effect of of Andrographis paniculata extracts at concentration  
    (0.1mg/ml) and the known hydroxyl radical scavenger Trolox on   
    hydroxyl radical scavenging activity.  
    Results are mean ± SEM (n=4), *P<0.05 expressed as percentage of  
    hydroxyl radical scavenging activity when compared to an extract blank (control).   
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6.4.3 Phenol red-peroxidase assay 
 
All the aqueous, ethanol and methanol extracts were found to significantly scavenge hydrogen 
peroxide at a concentration of 0.1mg/ml. The aqueous, ethanol and methanol extracts displayed 
significant scavenging of hydrogen peroxide at 16.99 ± 2.07%, 17.25 ± 3.68% and 23.19 ± 6.6% 
respectively when compared to the control blank (Figure 6.3). Catalase was able to scavenge 
hydrogen peroxide at a significant inhibition of 69.96 ± 1.67% at 0.025mg/ml.  
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Figure 6.3.    Effect of Andrographis paniculata extracts concentration (0.1mg/ml)  
and catalase on hydrogen peroxide scavenging activity by phenol red-
peroxidase assay.  
Results are mean ± SEM (n=4), *P<0.05 expressed as percentage of hydrogen 
peroxide scavenging activity when compared to an extract blank (control).  
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6.4.4 Nitric oxide scavenging assay  
 
All the aqueous, ethanol and methanol extracts at the tested concentrations of 0.5, 1.0, 1.5mg/ml, 
displayed significant inhibition of the nitric oxide between a range of 63 to 90%, 49 to 69% and 
35 to 43% respectively (Figure 6.4) when compared to the absorbance control blank.  
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Figure 6.4. Effect of Andrographis paniculata extracts concentrations (0.5, 1.0, 1.5mg/ml) 
on the inhibition of Nitric oxide.  
Results are mean ± SEM (n=4), *P<0.05 expressed as percentage of Nitric oxide 
reduction activity compared to an extract blank (control).  
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6.5 Discussion 
 
Several in vitro methods have been developed to measure and assess the potential anti-oxidant 
activities of natural products from plants, animals and minerals origin. Free radicals and other 
reactive oxygen species (ROS) are oxidizing agents which can be a good anti-oxidant or good 
reducing agent (Halliwell, 2000). The anti-oxidant potential of a bioactive compound can vary 
from one assay to the other, thus a combination of several methods should be explored and used 
in the assessment and evaluation of the anti-oxidant potential of the test compound (Aruoma et 
al., 1989).  
 
In this study screening for anti-oxidant potential of Andrographis paniculata showed scavenging 
of all the assays performed with varying degree of potency indicating that the Andrographis 
paniculata (Burm. f.) Nees of Brunei Darussalam has anti-oxidant properties as previously 
reported by (Kapil et al., 1993; Singh et al., 2001; Trivedi & Rawal, 2001; Zhang & Tan, 2000b). 
Changes in the enzymatic and non-enzymatic anti-oxidant defense systems may reduce 
resistance to free radical-mediated damage (Jones et al., 1988). Therefore, naturally occurring 
compounds with anti-oxidant potential have beneficial effects on the overall disease processes 
(Stanely & Menon, 1999).  
 
The activities of Andrographis paniculata leaves extracts on scavenging 1,1-diphenyl-2-
picryhydrazyl (DPPH) free radicals, hydroxyl radical, hydrogen peroxide and nitric oxide were 
assessed in cell-free systems. 
 
The DPPH free radical compound is relatively stable with an electron when paired off with an 
anti-oxidant will change the colour from deep violet to a bright yellow colour and such changes 
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is recorded spectrophotometrically as described in section 6.3.1 of Chapter 6. It was found that 
both the ethanol and methanol extracts at the concentrations tested displayed significant DPPH 
free radicals scavenging activities in the range of 25 to 38% with the exception of the aqueous 
extracts which did not show DPPH scavenging activity. However DPPH scavenging assays is not 
capable of detecting all anti-oxidants and therefore, there is a need to use a number of assays to 
demonstrate anti-oxidant activities.  
 
Results showed that the aqueous (We), ethanol (Ee) and methanol (Me) extracts of Andrographis 
paniculata (Burm. f.) Nees of Brunei Darussalam exhibited some significant scavenging 
activities towards 1,1-diphenyl-2-picryhydrazyl (DPPH), hydroxyl radical, hydrogen peroxide 
and nitric oxide in the cell-free systems with the exception of the aqueous extract which did not 
show any significant DPPH scavenging activity. 
 
The hydroxyl radical (OH
·
), being the most reactive and damaging radical species react readily 
with and damage DNA and other important cellular components as well as initiating lipid 
peroxidation reactions. All the aqueous, ethanol and methanol extracts at 0.1mg/ml displayed 
significant hydroxyl radical scavenging activities at a range of 10- 20%. 
 
The hydrogen peroxide scavenging activities were assessed based on the H2O2 molecule which is 
not a radical but a reactive oxygen species. Superoxide radicals (O2
·-
) which are formed in vivo, 
are mostly converted to H2O2 by superoxide dismutase (SOD) and non-enzymatic dismutation 
(Halliwell & Gutteridge, 1990). Some enzymes also produce hydrogen peroxide as a by-product. 
Despite that hydrogen peroxide has low reactivity but once converted into hydroxyl radical (OH
·
) 
through catalysis by transition metal ions are damaging to DNA and other important cellular 
components. Therefore, hydrogen peroxide remains an important target for scavenging by anti-
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oxidants in the prevention of hydroxyl radical (OH
·
) formation. All the aqueous, ethanol and 
methanol extracts showed significant scavenging of hydrogen peroxide scavenging activities for 
the phenol red-peroxidase assays at a range of 17 – 23%. 
 
In addition to ROS, nitric oxide (NO) is also implicated in inflammatory diseases, cancer, and 
many other pathological conditions (Sreejayan & Rao, 1997). High levels of NO induce host cell 
death and inflammatory tissue damage (Kim et al., 2000; Lee et al., 2000). Therefore, a number 
of natural plant materials were investigated as inhibitors of NO production, and the development 
of effective inhibitors for the NO production in inflammatory cells are of great interest and 
beneficial for the therapeutic treatment of disease conditions mediated by NO (Batkhuu et al., 
2002; Chiou et al., 2000; Seo et al., 2001; Wang et al., 2000). All the aqueous, ethanol and 
methanol extracts at the tested concentrations of 0.5, 1.0, 1.5mg/ml, displayed significant 
inhibition of the nitric oxide (NO) between a range of 63 to 90%, 49 to 69% and 35 to 43% 
respectively. 
 
In a previous study by Sheeja et al., (2006) demonstrated that the methanolic extract of 
Andrographis paniculata was found to inhibit the formation of nitric oxide at 42.8% (Sheeja et 
al., 2006) compared to the finding of this study which was 43.51% in vitro. Several studies on 
the anti-oxidant activities of Andrographis paniculata in various disease conditions demonstrated 
the inhibition of nitric oxide (NO), lipid peroxide (LPO), superoxide dismutase (SOD) (Sheeja et 
al., 2006; Singh et al., 2001; Wang et al., 1997; Zhang & Tan, 2000b). 
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These series of anti-oxidant assays demonstrated that the aqueous (We), ethanol (Ee), methanol 
(Me) extracts of Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam displayed 
significant scavenging activities towards 1,1-diphenyl-2-picryhydrazyl (DPPH), hydroxyl 
radical, hydrogen peroxide and nitric oxide in cell-free systems, with the exception of the 
aqueous extract which did not show any DPPH scavenging activity. Other assays need to be 
attempted to demonstrate anti-oxidant activities of compounds as one single assay may not be 
able to detect all anti-oxidant activities. 
 
The finding that extracts exhibited the scavenging activity of the free radicals may imply that 
Andrographis paniculata possesses anti-oxidant activities which are beneficial in the treatment 
of many disease conditions such as inflammatory, immunostimulatory, cardiovascular, cancer, 
HIV diseases and other pathological diseases related with oxidative stress. It has also been well-
documented that there is an increased production of free radicals resulting in accelerated lipid 
peroxidation in disease conditions such as diabetes mellitus and hypercholesterolaemia or 
hyperlipidaemia (Stefano et al., 1997). The elevated lipid peroxidation levels may be responsible 
for some of the pathological effects of the diseases mentioned (Slatter et al., 2000). However the 
concentration of the inhibitory activity on these radicals seems relatively high, thus it is not clear 
if any of these anti-oxidant activities are involved at the therapeutic doses.  
 
Further study is clearly needed to elucidate if these anti-oxidant activities may contribute to the 
pharmacological actions and bioactivities of Andrographis paniculata which exhibited 
significant effects in anti-allergy, anti-inflammatory, anti-tumouricidal and anti-hepatotoxicity 
effects as demonstrated in Chapters 7, 8, 9 and 10. 
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7.1 Introduction 
 
Andrographis paniculata has been demonstrated for its anti-allergic and anti-inflammatory 
actions in vivo and in vitro (Anand et al., 2001; Dahanukar et al., 2000; Gupta et al., 1998). 
Gupta et al., (1998) found two active diterpenes namely Andrographolide and 
Neoandrographolide of Andrographis paniculata, administered at an oral dose of 10mg/kg to rats 
daily for four days exhibited mast cell stabilizing activities against compound 48/80 (0.5µg/ml) 
and egg albumin induced mast cell degranulation. The activities were found to be comparable to 
disodium cromoglycate with Neoandrographolide exhibited higher potency than 
Andrographolide in the inhibition of compound 48/80 induced histamine release. 
Andrographolide also attenuated inflammation by inhibition of NF-KB activation through 
covalent modification of reduced cysteine 62 of p50 (Xia et al., 2004). The inhibition on mast 
cell derived histamine release by Andrographis paniculata is considered as the main mechanism 
of its anti allergic action (Li & Zhang, 2002). However, little is known about the difference in the 
anti-histamine effects of Andrographis paniculata from different sources as well as that in 
solvent extracts such as aqueous, ethanol and methanol extracts.  
 
Therefore, the aim of this study was to investigate the effect of aqueous, ethanol and methanol 
extracts of Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam on compound 48/80-
induced histamine release measured by HPLC in rat peritoneal mast cells (RPMC). Changes in 
growth conditions may also affect the pharmacological actions of the Andrographis paniculata 
from different sources such as Brunei Darussalam and China. To our understanding, this is the 
first study in comparing the actions of different extracts of Andrographis paniculata (Burm. f.) 
Nees of Brunei Darussalam on mast cell-derived histamine release.  
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7.2 Materials and Method 
 
7.2.1 Plant Materials  
 
In this experiment, the source of Andrographis paniculata leaves extracts samples was described 
previously in Chapter 4. An accurate weight of 5.0019g of herbal powder of Andrographis 
paniculata was extracted in 60ml of absolute ethanol, methanol and Milli-Q pure grade water 
respectively using the ASE-100 Dionex System (Dionex Pty Ltd, Lanecove, 1595, NSW). 
Operating procedure was optimised by Dionex system with the following specifications and 
extraction conditions:  Dionex Part No. 056780 Filter grade: D28, Size: 30mm; Temperature: 
100ºC; Pressure: 1,500psi (10MPa); Heating time: 5 min; Static time: 5 min; Flush time: 60%; 
Purge time: 100s; Static cycle: 3; Total extraction: 30 min per sample. The herbal powder was 
extracted three times on three static cycles. The extracts were then filtered through a Whatman 
filter paper No. 1.  
 
The ethanol and methanol were then evaporated at 80°C using rotary evaporator under vacuum 
(Biichi Rotavapor, Brinkman Company, Westbury, NY, USA and the concentrated aqueous 
extract was transported in liquid nitrogen for freeze drying using Freeze Drier Dynavac FD 12 
(Airvac Engineering Pty Ltd, Melbourne, Australia) to remove all the aqueous solvent. Accurate 
weights of these completely dried extracts were then resuspended in absolute ethanol/methanol 
or Milli-Q pure grade water. The solvent extracts were then filtered with 0.45µm syringe filter 
and stored at -80°C for further analysis.  
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7.2.2 Reagents and chemicals   
 
All reagents and chemicals used were of commercial grades. The compound 48/80, spermidine 
trihydrochloride, o-phthalaldehide (OPA), histamine, toluidine blue, N-2-hydroxyethylpiperazine-
N’-ethanesulfonic acid (HEPES), sodium chloride (NaCl), potassium chloride (KCl), magnesium 
chloride (MgCl2), L-(+)-tartaric acid, sodium tartrate dihydrate, 1-octanesulfonic acid sodium salt, 
boric acid, sodium hydroxide (NaOH), and disodium ethylenediamine-tetra-acetic acid (EDTA) 
were purchased from Sigma-Aldrich (Australia). Calcium chloride (CaCl2), perchloric acid 
(HClO4), di-sodium hydrogen orthophosphate (NaH2PO4) and D-glucose anhydrous were 
purchased from Ajax Chemicals (Australia). Heparin sodium injection was obtained from BDL 
(Australia). HPLC grade methanol and ethanol were purchased from Merck (Australia).  
 
7.2.3 Preparation and Isolation of Rat Peritoneal Mast Cells (RPMC) 
 
Male Sprague Dawley rats at 8-12 weeks of age (250 – 350g) (n=22), AEC No: 0411 were 
purchased from Monash Animal Services, Victoria, Australia. All procedures employed in 
experimental animals were approved by the Animal Experimentation Ethics Committee of RMIT 
University and conformed to the Australian National Health and Medical Research Council 
guidelines. Animals were housed in the RMIT Bundoora animal facility. Animals were fed with 
standard chow with adlib water. Rats were sacrificed by asphyxiation with 95% CO2 and then 
decapitated. The RPMC were prepared as previously described (Ikarashi et al., 2001). Briefly, 
20ml of Tyrode’s buffer (NaCl, 137.0mM; KCl, 1.0mM; MgCl2, 1.0mM; CaCl2, 1.6mM; 
NaH2PO4·2H2O, 0.41mM; HEPES, 10mM and L-(-)-Glucose, 1%; pH 7.4) containing 0.3% BSA 
and 5.0 units/ml heparin sodium was injected intraperitoneally. The abdomen was gently 
massaged for 2 min, followed by the collection of peritoneal solutions containing the mast cells. 
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The solution was then centrifuged at 1200rpm for 5min at 4°C. The pellet containing RPMC was 
washed three times with 15ml of Tyrode’s solution and resuspended in 10ml Tyrode’s buffer, pH 
7.4, containing 0.1% BSA. Finally, the number of RPMC in the suspension was adjusted to 
5×105 cells/ml for further analysis. 
 
7.2.4 Effects of herbal extracts on compound 48/80-induced histamine release from 
RPMC  
 
Briefly, 10µl of various concentrations of aqueous, ethanol and methanol extracts (final extracts 
concentrations, 0.001, 0.01, 0.1, and 1.0 mg/ml), an equal volume of methanol, absolute ethanol 
or Tyrode’s buffer (aqueous) (as vehicles control), a Ca
2+
 chelating agent EDTA (100 µM) 
(positive control) was added to the cell suspension of 5×105 cells/ml, pre-incubated in the water 
bath at 37°C for 10 min to a final volume of 500µl and incubated in the water bath at 37°C for 10 
min. Histamine release from RPMC was then induced by the addition of 25µl of compound 
48/80 (at final concentration 0.5µg/ml) into the cell supernatant. The Tyrode’s buffer (10mM) or 
30% HClO4, was used to determine the basal level of histamine release from mast cells or total 
histamine level of the mast cells (Ikarashi et al., 2001). After further incubation at 37°C for 10 
min, the supernatant was chilled in ice for 10min to stop the reaction of histamine release from 
RPMC. Residual histamine in the cells was released by disrupting the cells with 30% HClO4. 
Fifty microliter of aqueous Spermidine trihydrochloride (1.0mg/ml) was added into the mixture 
as an internal standard.   
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7.2.5 HPLC determination of histamine release from RPMC  
 
The level of histamine released from RPMC was determined by HPLC using a Shimadzu HPLC 
instrument SCL-10Avp (Shimadzu, Japan) with the following conditions: a fluorescent detector 
(RF-10Axl, Shimadzu, Japan), a STR reverse-phase column (ODS-II; L 150 × 4.6 I.D. mm; 
5µM; Shimadzu, Japan.), an attached post-column for derivatization with the OPA, which is a 
reaction coil (5.0×0.5mm stainless steel tubing). Mobile phase to the main column consisted of a 
mixture of 100mM sodium tartaric acid buffer (pH 4.4), containing 25mM L-(+)-tartaric acid, 
75mM sodium tartrate dihydrate and 10mM 1-octanesulfonic acid sodium salt, and HPLC grade 
methanol (2:1), and maintained at the flow-rate of 1.0ml/min. The post column solution for 
derivatization contained a mixture of 400mM sodium borate buffer (pH 9.2), containing 400mM 
boric acid and 200mM NaOH, and 10mM OPA in HPLC grade methanol (2:1). The post column 
flow-rate was 0.5ml/min. The wavelengths for excitation and emission were 360nm and 440nm, 
respectively. The column temperature was set at 50°C and the injection volume was 10µl. Under 
these conditions, the retention time of histamine was 3.1min, and the internal standard, 
spermidine was 4.8min (Figures 7.1, 7.3 and 7.5). 
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Figure 7.1.    Representative chromatograms of histamine detection by HPLC 
Under the experimental conditions, the retention time of Histamine was at 3.1min 
and the internal standard Spermidine was detected at 4.8min.    
       
 
 
 
Base 
Vehicle 
Compound 48/80 
Total Release 
Ee 1mg/ml 
Ee 0.1mg/ml 
Ee 0.01mg/ml 
Ee 0.001mg/ml 
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Figure 7.2. The Effect of Andrographis paniculata ethanol extract (Ee) on  
inhibition of compound 48/80-induced histamine release from rat peritoneal 
mast cells.  
The column bars represent the mean ± SEM for n=6, *P<0.05, Two Way 
ANOVA, followed by Bonferroni’s test compared to compound 48/80. 
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Figure 7.3.   Representative chromatograms of histamine detection by HPLC. 
Under the experimental conditions, the retention time of Histamine was at 3.1min 
and the internal standard Spermidine was detected at 4.8min.   
       
 
 
 
 
 
 
Base 
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 222
 
 
 
 
C
om
po
un
d 
48
/8
0
1m
g/
m
l
0.
1m
g/
m
l
0.
01
m
g/
m
l
0.
00
1m
g/
m
l
0
10
20
30
40
50
60
70
80
90
100
*
Compound 48/80
1mg/ml
0.1mg/ml
0.01mg/ml
0.001mg/ml
Aqueous Extract Concentration (mg/ml)
%
 I
n
h
ib
it
io
n
 o
f 
H
is
ta
m
in
e
R
e
le
a
s
e
 
 
     
 
Figure 7.4.   The Effect of Andrographis paniculata aqueous extract (We) on  
         inhibition of compound 48/80-induced histamine release from rat    
         peritoneal mast cells.  
         The column bars represent the mean ± SEM for n=6, *P<0.05, Two Way  
         ANOVA, followed by Bonferroni’s test compared to compound 48/80. 
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Figure 7.5.    Representative chromatograms of histamine detection by HPLC 
Under the experimental conditions, the retention time of Histamine was at 3.1min 
and the internal standard Spermidine was detected at 4.8min.   
       
 
 
 
 
Base 
Vehicle 
Compound 48/80 
Total Release 
Me 1mg/ml 
Me 0.1mg/ml 
Me 0.01mg/ml 
Me 0.001mg/ml 
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Figure 7.6.    The Effect of Andrographis paniculata methanol extract (Me)  
on inhibition of compound 48/80-induced histamine release from rat 
peritoneal mast cells.  
The column bars represent the mean ± SEM for n=6, *P<0.05, Two Way 
ANOVA, followed by Bonferroni’s test compared to compound 48/80. 
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7.2.6 Data collection and statistical analysis 
 
The percentage (%) of inhibition by the different solvent extracts on compound 48/80-induced 
histamine release from RPMC was calculated using the following formula which is [the 
concentration of histamine release induced by compound 48/80 after treated by variable extract 
concentrations minus the concentration of histamine release induced by compound 48/80 after 
treated by an equal volume of absolute ethanol)/the concentration of histamine released induced 
by compound 48/80] expressed as %. 
 
Statistical data were presented as Mean ± Standard Error of Mean (S.E.M.). Statistics of 
comparisons between groups were performed by One Way or Two Way Analysis of Variance 
(ANOVA) followed by Bonferroni’s test using the Prism 4.0 (GraphicPad Software, Inc., 
U.S.A.). Values of *P<0.05 indicate significant difference. 
 
7.3 Results 
 
7.3.1 Determination of the optimum concentration of the compound 48/80 on histamine 
release from RPMC 
 
A basal level of histamine at 19.6 ± 3.5ng/ml (n=6) was produced from the unstimulated RPMCs 
in Tyrode’s buffer. Variable concentrations of compound 48/80 from 0.0001-0.5µg/ml caused a 
concentration-dependent increase of histamine release from RPMC, with the maximum 
optimised response at 0.5µg/ml of Compound 48/80 (422.9 ± 64.1 ng/ml, n=4). As a result, this 
optimal concentration of 0.5µg/ml of compound 48/80 was then used for the subsequent 
experiments. The vehicle control (compound 48/80 induced histamine release treated with an 
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equal volume of absolute ethanol) slightly inhibited the histamine release (9.5 ± 1.2%, n=6, 
P>0.05), compared with compound 48/80 alone induced histamine release. The increase in 
histamine release by compound 48/80 was significantly inhibited by 78.9 ± 5.0 % by 100 µM 
EDTA, compared with compound 48/80 alone induced histamine release (n=7, P<0.05). 
 
7.3.2 Effects of different solvent extracts on compound 48/80 induced histamine release 
from RPMC 
 
All three extracts when tested at 0.001, 0.01, 0.1mg/ml indicated a minor difference (intra) 
within the extract but moderate difference (inter) between the three solvent extracts. At lower 
concentrations of 0.001, 0.01, 0.1 mg/ml of ethanol (Figure 7.2), aqueous (Figure 7.4), and 
methanol (Figure 7.6) extracts showed a moderate inhibitory effect, but at a higher concentration 
of 1mg/ml, % inhibition of histamine release was significantly increased (Figures 7.1, 7.3 and 
7.5). Among the tested concentrations, at 1 mg/ml of methanol, aqueous and ethanol extracts  
significantly inhibited histamine release by 73.33 ± 4.55%, 57.59 ± 6.57% and 32.34 ± 3.49% 
(*P<0.05, n=6) respectively compared to 8.38 ± 0.01% in the compound 48/80 only treated cells 
as shown in Figure 7.7.  
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Figure 7.7. The Effect of Andrographis paniculata aqueous, ethanol and methanol 
extracts (1mg/ml) on the inhibition of compound 48/80-induced histamine 
release from rat peritoneal mast cells. 
The column bars represent the mean ± SEM for n=6, P<0.05,  
One Way ANOVA followed by Bonferroni Multiple Comparison test compared 
to compound 48/80. 
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7.4 Discussion  
 
This study is the first report to compare the differences in their pharmacological anti-allergic 
actions on mast cell derived histamine release from RPMC of aqueous, ethanol and methanol 
extracts of Andrographis paniculata (Burm. f.) Nees from Brunei Darussalam.  
 
By determining the histamine levels using HPLC, this study demonstrated that all the extracts 
significantly inhibited the compound 48/80 induced histamine release from RPMC at higher 
concentration of 1mg/ml but not at lower concentrations of 0.001, 0.01, 0.1 mg/ml. Further more, 
this study demonstrated a similar trend among three different solvent extracts of the 
Andrographis paniculata (Burm. f.) Nees species, histamine release at a higher concentration of 
1mg/ml but not lower.  
 
Previous studies by Gupta et al., 1998 on the two active diterpenes Andrographolide and 
Neoandrographolide isolated from Andrographis paniculata which exhibit mast cell stabilizing 
activities against compound 48/80 at 0.5µg/ml and in sensitized mast cells, against egg albumin 
induced degranulation. The activities were found to be comparable to disodium cromoglycate 
and suggested its potential anti-allergic properties with Neoandrographolide exhibited higher 
potency than Andrographolide in the significant inhibition of compound 48/80 induced histamine 
release (Anand et al., 2001; Dahanukar et al., 2000; Gupta et al., 1998). Gupta et al., 1998 
investigated the antiallergic activity of Andrographolides in Andrographis paniculata (Burm. f.) 
Wall (the former name of Nees) and found that the mast cells collected from the rats fed on 
Andrographolide 10mg/kg orally for 4 days, incubated with compound 48/80 at 0.5µg/ml 
produced a significant inhibition of 60% compared to 72% inhibition produced by Disodium 
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cromoglycate (DSCG) at the same experimental conditions. The antiallergic activity appear to be 
due to immunomodulating activity which requires further elucidation (Gupta et al., 1998). 
 
Disodium cromoglycate (cromolyn) and sodium nedocromil are used in the treatment of allergic 
rhinitis via the nasal route of administration topically (Bush, 2004). Cromolyn sodium is a class 
of therapeutic drugs in which its mode of action is not completely elucidated (Holgate et al., 
2001). The mode of action is suggested to be mast cell stabilisation activities (Mygind et al., 
1996; Naclerio, 1991) potentially through blocking Ca
2+
 channels and oxidative phosphorylation 
or inhibiting phosphodiesterase (van Cauwenberge et al., 2000). Recent studies suggested the 
mechanism of action to include inhibitory effects on eosinophil, platelets and macrophages 
(Holgate et al., 2001). 
 
However, it is not clear about the exact nature of the active component(s) involved and the actual 
mechanism of action in this anti-histamine release action given the complex nature of the active 
components in the herb as studies have indicated that Andrographis paniculata contains the 
active components diterpene lactones Andrographolide as the major compound, 
Dehydroandrographolide, Deoxyandrographolide and Neo-andrographolide. Recent studies by 
Pramanick et al (2005) and Shen et al (2005) isolated new ent-labdane type diterpenoids from the 
leaves of Andrographis paniculata. The contents of active ingredients in the various solvent 
extracts may vary due to the solubility of the active components in the extraction solvents. 
Andrographis paniculata (Burm. f.) Nees possesses Ca
2+ 
antagonist activities which selectively 
block voltage-operated calcium channels in rat vas deferens and induce relaxation of uterus by 
blocking voltage operated calcium channels and inhibits Ca
2+ 
influx (Burgos et al., 2001; Burgos 
et al., 2000).  
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As a result, the compound 48/80 may target on the peritoneal mast cells by increasing 
intracellular calcium concentrations hence inducing the release of histamine (Chakravarty & Yu, 
1986; Marshall et al., 1994). Andrographis paniculata (Burm. f.) Nees may possibly contribute to 
the regulation of degranulation of mast cells in the studies on other herbs (Brown et al., 2001; 
Ma & Han, 1995; Mitsuo, 2001). Further study is necessary to establish a correlation between the 
effect on the inhibition of histamine release and the % composition and the active components 
present in the different solvent extracts.  
 
Observation from this study indicated that the three samples, the inhibitory action for aqueous, 
ethanol and methanol extracts had only a marginal difference between lower concentrations of 
0.001mg/ml and 0.1mg/ml. However at a higher concentration of 1mg/ml, all the three extracts 
from this species actually produced a significant inhibitory effect than that obtained from 
0.001mg/ml to 0.1mg/ml. The findings indicated that the active component(s) which are of 
potential effect on the inhibition of histamine release only result in a significant effect at 1mg/ml 
of the solvent extracts. Such findings showed that Andrographis paniculata may not be 
beneficial to be used as anti-allergies or anti-histaminic therapeutic agents as the study 
demonstrated that it requires a much higher dose to exert the therapeutic effect when compared 
to other agents. The finding in this study demonstrated that the rat peritoneal mast cells is less 
responsive towards Andrographis paniculata extracts which is in close agreement with the 
previous study by (Gupta et al., 1998). 
 
A better understanding is needed on the exact composition of Andrographis paniculata which 
would contribute to the optimization of the effective dose of Andrographis paniculata (Burm. 
f.) Nees species for its clinical application as an anti-allergic agent. The observation from this 
first screening on the effect of Andrographis paniculata (Burm. f.) Nees species of Brunei 
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Darussalam showed a similar trend in the inhibition on histamine release in the various solvent 
extracts. This indication may provide a useful profile of the pharmacological actions of the 
same species grown at different geographical region or locations such as India or China as 
geographical location and seasons may also explain the differences in the contents of the active 
components in the herb (Hu & Wu, 1995). A close observation and monitoring of the profiling 
of medicinal plants in terms of the medicinal effects of its active constituents need to be 
screened in terms of qualitative and quantitative analyses, which is usually time consuming 
and expensive. So far, there is limited study specifically on the inhibition of the compound 
48/80-induced histamine release from rat peritoneal mast cells by Andrographis paniculata 
(Burm. f.) Nees extracts for assessing its anti-allergic properties.  
 
Therefore, the present study indicated that there are varying percentage composition of the active 
components and the types of components present in the aqueous, ethanol and methanol extracts 
that may account for the differences in compound 48/80 induced anti-histamine from RPMC. 
The difference in extract concentrations may be important as it is unlikely to achieve the 
therapeutic anti-allergic and anti-histaminic effects at doses less than 1mg/ml. As a result, it is 
not appropriate to be recommended as an anti-allergic or anti-histaminic therapeutic agents. 
 
In conclusion, all the three solvent extracts have similar trends of inhibition with moderate 
degree of potency in the inhibition of compound 48/80 induced histamine release in RPMC at 
1mg/ml. The ethanol extract is significantly different from the aqueous and methanol extracts 
(P<0.05, n=6) but the aqueous extract is not significantly different from the methanol extract 
(P>0.05, n=6), One Way ANOVA followed by Bonferroni’s test, compared all groups  
(Figure 7.7). Such difference may have clinical implications if they are used interchangeable. 
Further investigation is necessary to investigate the active component(s) which are responsible in 
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the inhibition of compound 48/80 induced histamine release in RPMC to ascertain the optimized 
dose of therapy for allergies. 
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8.1 Introduction 
 
It has been demonstrated that inducible NO plays an important role in systemic inflammatory 
disorders, diabetes, arteriosclerosis and other diseases complications (Connor et al., 1995; 
Stefanovic-Racic et al., 1993; Wu & Thiemermann, 1996). Therefore, natural products which 
possess the inhibitory properties on the formation of NO are potential therapeutic agents for 
treating patients with septic shock or inflammatory diseases of both local and systemic disorders 
as well as other disease conditions. Among a range of pharmacological actions of Andrographis 
paniculata, the anti-inflammatory effects of Andrographis paniculata is important in its clinical 
use. In this regard to understand the actions of Andrographis paniculata on inflammatory iNOS 
mediators will enhance our understanding of the therapeutics of Andrographis paniculata and the 
possible mechanisms involved in the iNOS pathways.  
 
The pharmacological and functional effects of Andrographis paniculata (Burm. f.) Nees grown in 
Brunei Darussalam has not yet been studied. In this study, we investigated the functional effects 
of Andrographis paniculata leaves samples from Brunei Darussalam in three different 
concentrations of ethanol (Ee) and aqueous (We) extracts at 1, 10, 100µg/ml in the inhibition of 
iNOS mediated relaxation in LPS treated rat aorta compared to the Chinese Reference Sample 
herb CRS and Chuan Xin Lian (CXL) from China. Large scale screening on Andrographolide (3-
[2-[Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naph-thalenyl] 
ethyldene] dihydro-4-hydroxy-2(3H)-fura-none), a bicyclic diterpenoid lactone present in 
Andrographis paniculata leaves (Lu et al., 1981) demonstrated inhibition of NO synthesis. Study 
by Chiou et al (1998) showed that Andrographolide (10 & 30 µM) suppressed the expression of 
inducible nitric oxide synthase and restores the vasoconstriction in rat aorta treated with 
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lipopolysaccharide LPS with *P<0.05 represents significant differences when compared to 
control rings (Chiou et al., 1998). 
 
Given that the growing condition of herbal species may affect the contents of chemical 
components and their pharmacological actions (Hu & Wu, 1995), we investigated the targeted 
pharmacological actions of Andrographis paniculata from different geographical locations of 
Brunei Darussalam. In this study we focused on the effects of Andrographis paniculata on 
inducible nitric oxide (iNOS)-mediated responses. It has been well established that nitric oxide 
(NO) is an important inflammatory mediator. NO generated through inducible nitric oxide 
synthase (iNOS) plays important roles in various pathophysiological conditions, such as vascular 
dysfunctions in septic shock (Julou-Schaeffer et al., 1990; Kilbourn et al., 1990; Rees et al., 
1990; Thiemermann & Vane, 1990; Wu & Thiemermann, 1996) and inflammatory reactions in 
arthritis and  diabetes (Connor et al., 1995; Stefanovic-Racic et al., 1993; Wu & Thiemermann, 
1996).  
 
Therefore, natural products which possess the inhibitory properties on the formation of inducible 
NO are potentially useful for treating certain inflammatory diseases or conditions. However it is 
not known if the actions of raw herbal extracts directly relates to Andrographolide content or 
other related active component(s). Thus, in this study, we compared the effects of 
Andrographolide, Dehydroandrographolide and Andrographis paniculata extracts from different 
locations in Brunei Darussalam as well as that from China on iNOS-mediated responses in the 
rat aorta in vitro 
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8.2 Materials and Methods 
 
8.2.1 Plant materials 
 
In this experiment, the Andrographis paniculata ethanol and aqueous extracts investigated were 
CRS and CXL from China and Andrographis paniculata from Brunei Darussalam. Aerial parts 
of Andrographis paniculata (Burm. f.) Nees of Brunei Darussalam samples were collected from 
Brunei/Muara district (Brunei AP Ee), Kuala Belait district (Kuala Belait Ee) and Temburong 
district (Temburong Ee) and air-dried. Commercial dried Andrographis paniculata leaves 
samples from China Chuan Xin Lian, (CXL Ee) were also collected from the Chinese Medicine 
Clinic, Chinese Medicine Division of Royal Melbourne Institute of Technology.  
 
The plant materials were authenticated by the Department of Agriculture, Ministry of Industry 
and Primary Resources, Brunei Darussalam. The Chinese samples were authenticated by the 
Chinese Medicine Clinic of RMIT University, Victoria, Australia. Samples were crushed into 
powder with a mortar and pestle. 5 g of each powder was then extracted in 60ml of absolute 
ethanol by ASE-100 Dionex System (Dionex 100, USA) under the following specifications and 
extraction conditions: Dionex Part No. 056780 Filter grade: D28, Size: 30mm; Temperature: 
100ºC; Pressure: 1,500psi (10MPa); Heating time: 5 min; Static time: 5 min; Flush time: 60%; 
Purge time: 100s; Static cycle: 3; Total extraction: 30 min per sample. Each herbal powder was 
extracted three times on three static cycles. The extracts were then filtered through a Whatman 
filter paper and the ethanol was evaporated at 80°C using rotary evaporator under vacuum 
(Biichi Rotavapor, Brinkman, USA). Accurate weights of the extracts were then resuspended in 
absolute ethanol, then filtered with 0.45µm syringe filter and stored at -80°C for further analysis.  
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8.2.2 Data collection and statistical analysis 
 
Results were expressed as Mean ± S.E.M of n observations, where n represent the number of  
animals or aortic vessels studied. Statistical analysis was performed with Student’s t-tests, or   
One Way Analysis of Variance (ANOVA) or Two Way Analysis of Variance (ANOVA),  
Bonferroni’s test. A *P-value less than 0.05 was considered to be statistically significant. 
 
8.2.3 Pharmacological Studies 
 
8.2.3.1 Animals 
 
Male Sprague-Dawley of 200-350g (n=112), age 8-12 weeks old were used for the functional 
studies (AEC No: 0327 and 0411). These rats were purchased from Monash University, Clayton, 
Victoria, Australia. Groups of up to a maximum of four rats of the same species (SD) were caged 
in standard animal boxes, housed in the RMIT Bundoora Animal Facility with proper care and 
fed with standard chow with adlib water for a few days, sometimes up to a week before 
experimentation. All experimental procedures involving animals were approved by RMIT 
Animal Ethics Committee and conformed to National Health and Medical Research Council 
Guidelines. 
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8.2.3.2 Functional studies in the inhibition of iNOS mediated relaxation in LPS treated rat 
aorta 
 
8.2.3.2.1 Physiological Salt Solution (PSS) 
 
The composition of the physiological salt solution (PSS) was (mM): NaCl, 118; KCl, 4.7; 
NaHCO3, 25; MgSO4, 0.45; KH2PO4, 1.03; and, CaCl2, 2.5. All reagents and chemicals used were 
of commercial grades. 
 
8.2.3.2.2 Rat tissue preparation 
 
The rats were killed by asphyxiation with 95% CO2 and decapitated. Aortae were isolated and 
dissected into four rings of 5mm each in accordance with set up described by (Lenon et al., 
2003). Endothelium was removed by gently rubbing the lumen with forceps. Each ring was 
mounted in a 6ml or 8ml or 10ml organ bath containing physiological salt solution (PSS) 
bubbled with 95% O2 and 5% CO2 maintained at 37ºC under a resting tension of 2g, then 
equilibrated at 60 min prior to the commencement of the experimental procedures. The tension 
was measured isometrically using Grass FT03 force-displacement transducers (Grass 
Instruments, Quincy, MA, USA), traces recorded by MacLab data acquisition system. 
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8.2.4 Endothelium dependant relaxation in rat aorta rings 
 
Cumulative concentration response curves to acetylcholine from 0.1-10µM were constructed in 
Phenylephrine PE-precontracted (1µM) aorta tissue preparations before and after 15 minutes 
incubation with ethanol extracts such as CRS Ee, CXL Ee, Brunei AP Ee or aqueous extracts 
CRS We, CXL We and Brunei AP We of final concentrations 1, 10 and 100µg/ml or vehicle 
control (absolute ethanol or Milli-Q water) or L-NAME as positive control. Tests were carried 
out in endothelium-denuded preparations using the method described previously (Ellis et al., 
2000; Griffiths et al., 1993). Briefly, the endothelium was denuded by gently rubbing the inner 
lumen with a pair of forceps and the failure of relaxation to acetylcholine 10µM indicated the 
successful endothelium denudation.  
 
8.2.5 iNOS mediated relaxation in LPS treated aortic preparation 
 
After the confirmation of the denudation of endothelium, the preparations were incubated in LPS 
(50µg/ml) and ethanol (Ee) or aqueous (We) extracts of CRS, CXL, Brunei AP at 1, 10 and 
100µg/ml simultaneously for 6 hours before the contraction to PE. Cumulative concentration-
dependant relaxations to L-arginine (1, 3, 10, 30 & 100µM) were constructed in PE 
precontraction aorta. L-NAME (100µM) as positive control was incubated 15 minutes prior to 
the experiment (Figure 8.1). 
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8.3 Results 
 
 
8.3.1 Controls 
 
 
Phenylephrine PE (1µM) induced contraction of around 1.71 ± 0.1 gw (n=22) and the cumulative 
concentration response curve to acetylcholine produced a concentration-dependent relaxation 
with maximal response with ethanol and aqueous as vehicle control at 61.49 ± 9.58% or aqueous 
vehicle control of at 67.46 ± 9.59% or L-NAME was (5.16 ± 1.02%), n=4 (Figure 8.2).    
 
8.3.2 Effect of Ethanol extracts 
 
Among the tested extract concentrations, Andrographolide Ee and Dehydroandrographolide Ee 
in ethanol at 10µM and all the ethanol extracts of CXL Ee, Brunei AP Ee, Kuala Belait Ee and 
Temburong Ee at 100µg/ml, significantly inhibited the iNOS mediated relaxation in LPS treated 
rat aorta (*P<0.05, n=4); Two Way ANOVA followed by Bonferroni’s tests, compared to the 
vehicles control. The maximal relaxations to L-arginine 100µM (Log M=-4.0) were significantly 
inhibited by Andrographolide Ee (10µM) at 15.45 ± 1.97% (Figure 8.3) and 
Dehydroandrographolide Ee (10µM) at 21.07 ± 2.57% (Figure 8.4). The maximal relaxations 
were also significantly reduced by CXL Ee at 31.52 ± 4.02% (Figure 8.6), Brunei AP Ee at 26.12 
± 4.67% (Figure 8.7), Kuala Belait Ee at 30.40 ± 3.96% (Figure 8.8) and Temburong Ee at 22.98 
± 2.91% (Figure 8.9) when compared to the vehicle control at the high concentration of 
100µg/ml. However, among all the ethanol extracts tested, CRS Ee (100µg/ml) did not show any 
significant inhibition at the maximal response of L-arginine 100µM (Log M=-4.0) in the 
inhibition of iNOS mediated relaxation in LPS treated rat aortae (Figure 8.5). All the ethanol 
extracts did not exhibit any significant difference between all groups of extracts at 100µg/ml 
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(P>0.05, n=4), One Way ANOVA followed by Bonferroni Multiple Comparison tests, compared 
with all groups of ethanol extracts (Figure 8.10). 
 
8.3.3 Effect of Aqueous Extracts 
 
All the aqueous extracts such as Dehydroandrographolide We (10µM) (Figure 8.12), CRS We 
(Figure 8.13), CXL We (Figure 8.14) and Brunei AP We extracts (Figure 8.15) at 1-100µg/ml 
did not show any significant inhibition. However, the maximal relaxations to L-arginine 100µM 
(Log M=-4.0) was significantly reduced by Andrographolide We (10µM) to 32.29 ± 4.97% 
(Figure 8.11) in the iNOS mediated relaxation in LPS treated rat aortae, compared to the vehicle 
control. All the aqueous extracts did not exhibit any significant difference between all groups of 
extracts at 100µg/ml (P>0.05, n=4), One Way ANOVA followed by Bonferroni Multiple 
Comparison tests, compared with all groups of aqueous extracts (Figure 8.16). 
 
8.3.4 Effects of Andrographolide and Dehydroandrographolide on iNOS-mediated 
relaxations 
 
Under the experimental conditions (endothelium-denuded and LPS-pre-treated preparations), 
phenylephrine (PE, 1µM) induced a contraction at 1.7 ± 0.1 gw (n=22). L-arginine (1-100 µM) 
produced a concentration-dependent relaxation which was abolished by the NOS inhibitor L-
NAME (100µM). 
 
Both Andrographolide and Dehydroandrographolide caused a concentration-dependent inhibition 
of iNOS-mediated relaxations. The maximal relaxations to L-arginine (100µM) were 
significantly inhibited by Andrographolide (10 µM) from 61.49 ± 9.58% to 15.45 ± 1.97% and 
 242
Dehydroandrographolide Ee (10 µM) from 61.49 ± 9.58% to 21.07 ± 2.57% as shown in Figures 
8.3 and 8.4 respectively.       
 
8.3.5 Effects of Andrographis paniculata extracts on iNOS-mediated relaxations 
 
The ethanol extracts of CXL Ee, Brunei AP Ee, Kuala Belait Ee and Temburong Ee 
concentration-dependently significantly inhibited the iNOS mediated relaxations, compared to 
the vehicles control (*P<0.05, n=4, Two-Way ANOVA followed by Bonferroni’s tests). At 100 
µg/ml, the maximal relaxations to L-arginine (100µM) were significantly inhibited by CXL Ee 
(to 31.52 ± 4.02%), Brunei AP Ee (to 26.12 ± 4.67%), Kuala Belait Ee (to 30.40 ± 3.96% and 
Temburong Ee (to 22.98 ± 2.91%) as illustrated in Figures 8.6, 8.7, 8.8 and 8.9 respectively, 
compared to the vehicle control.  
 
8.3.6 Correlation of Andrographolide and Dehydroandrographolide contents to 
inhibitions of iNOS relaxations by Andrographis paniculata extracts 
 
The content of Andrographolide and Dehydroandrographolide in Andrographis paniculata 
extracts varied significantly in Andrographis paniculata extracts, ranging from 0.51 – 3.43%. 
The highest Andrographolide content was found in Temburong Ee (3.43 ± 0.02%), followed by 
Brunei AP Ee (1.86 ± 0.02%), CXL Ee (1.14 ± 0.01%), Kuala Belait Ee (0.67 ± 0.02%) and CRS 
Ee (0.51 ± 0.01%). In contrast, the highest Dehydroandrographolide content was found in of 
CXL (0.66 ± 0.01%) followed by Brunei AP Ee (0.24 ± 0.01%), Kuala Belait Ee (0.24  ± 
0.05%), CRS Ee (0.14 ± 0.01%) and Temburong Ee (0.12 ± 0.01%). 
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The extent of inhibition of iNOS-mediated responses by Andrographis paniculata extracts had a 
poor correlation with the content of Andrographolide and Dehydroandrographolide levels alone. 
However, it has a significant correlation with the combined content of Andrographolide and 
Dehydroandrographolide together (with R
2
 = 0.832) as shown in Figure 8.17.   
 
 
 
 
 
 
Figure 8.1.     MacLab Trace of the positive control L-NAME
The relaxation to L-arginine (100µM) were significantly reduced by L-NAME 
(100µM) as positive control to around (5.16 ± 1.02%), n=4.
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Figure 8.2. Effect of L-NAME as positive control (100µM) on the  
    relaxations elicited by L-arginine in LPS-incubated endothelium-    
    denuded aorta. n=4; *P<0.05, One Way ANOVA followed by Bonferroni’s tests  
       compared to the vehicle control. 
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Figure 8.3. Effect of Andrographolide Ee (1, 3, 10µM) on the relaxations elicited  
by L-arginine in LPS-incubated endothelium-denuded aorta.  
                     n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests,  
            compared to the vehicles control.    
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Figure 8.4. Effect of Dehydroandrographolide Ee (1, 3, 10µM) on the                  
         relaxations elicited by L-arginine in LPS-incubated endothelium- 
                     denuded aorta.  
         n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests,  
         compared to the vehicles control.    
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Figure 8.5. Effect of CRS Ee (1, 10, 100µg/ml) on the relaxations elicited by  
         L-arginine in LPS-incubated endothelium-denuded aorta.  
         n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests,  
         compared to the vehicles control.    
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Figure 8.6. Effect of CXL Ee (1, 10, 100µg/ml) on the relaxations elicited by  
          L-arginine in LPS-incubated endothelium-denuded aorta.  
          n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests,  
          compared to the vehicles control.    
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Figure 8.7. Effect of Brunei AP Ee (1, 10, 100µg/ml) on the relaxations elicited by  
                        L-arginine in LPS-incubated endothelium-denuded aorta.  
                  n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests,  
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                  compared to the vehicles control.    
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Figure 8.8. Effect of Kuala Belait Ee (1, 10, 100µg/ml) on the  
relaxations elicited by L-arginine in LPS-incubated endothelium-denuded 
aorta. n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests,   
                  compared to the vehicles control.    
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Figure 8.9. Effect of Temburong Ee (1, 10, 100µg/ml) on the relaxations elicited  
                        by L-arginine in LPS-incubated endothelium-denuded aorta.  
        n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests,  
                    compared to the vehicles control.    
 248
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.10. Effects of Andrographis paniculata ethanol extracts (Ee) 100µg/ml on the 
maximal relaxations elicited by L-arginine in LPS-incubated endothelium-
denuded aorta.  
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                        n=4; *P<0.05; One Way ANOVA followed by Bonferroni’s tests,  
                  compared to the vehicles control.    
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Figure 8.11. Effect of Andrographolide We (1, 3, 10µM) on the relaxations elicited by L-
arginine in LPS-incubated endothelium-denuded aorta.  
                  n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s  tests,  
             compared to the vehicles control.     
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Figure 8.12. Effect of Dehydroandrographolide We (1, 3, 10µM) on the relaxations 
elicited by L-arginine in LPS-incubated endothelium-denuded aorta.  
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n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests, compared to 
the vehicles control.    
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Figure 8.13. Effect of CRS We (1, 10, 100µg/ml) on the relaxations elicited by  
L-arginine in LPS-incubated endothelium-denuded aorta.  
n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests, compared to 
the vehicles control.     
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Figure 8.14. Effect of CXL We (1, 10, 100µg/ml) on the relaxations elicited by 
L-arginine in LPS-incubated endothelium-denuded aorta.  
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n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests, compared to 
the vehicles control.      
 
-6.0 -5.5 -5.0 -4.5 -4.0
0
10
20
30
40
50
60
70
80
90
100
Vehicle control We
L-NAME
*
Brunei AP We 1µg/ml
Brunei AP We 10µg/ml
Brunei AP We 100µg/ml
L-Arginine (µM)
Re
la
xa
tio
n
(%
 P
E-
co
nt
ra
ct
io
n)
 
 
Figure 8.15.  Effect of Brunei AP We (1, 10, 100µg/ml) on the relaxations elicited by  
                        L-arginine in LPS-incubated endothelium-denuded aorta.  
n=4; *P<0.05; Two Way ANOVA followed by Bonferroni’s tests, compared to 
the vehicles control.     
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Figure 8.16.   Effects of Andrographis paniculata aqueous extract (We) 100µg/ml on  
the maximal relaxations elicited by L-arginine in LPS-incubated 
endothelium-denuded aorta.  
                  n=4; *P<0.05; One Way ANOVA followed by Bonferroni’s Multiple  
                  Comparison Tests, compared to the vehicles control.    
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Figure 8.17. Effect of % Inhibition of iNOS by %w/w of Andrographolide and 
Dehydroandrographolide (A plus D) in Andrographis paniculata 
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8.4 Discussion 
 
To the best of our knowledge, this is the first study on Andrographis paniculata from Brunei 
Darussalam. By using a well established protocol we have demonstrated that the Andrographis 
paniculata extracts significantly inhibited iNOS-mediated responses, an effect have been 
previously shown to certain Andrographis paniculata active components and Andrographis 
paniculata extracts from other regions from Asia (Chiou et al., 2000; Chiou et al., 1998). In 
addition, we found that the Andrographis paniculata from Brunei were more potent in inhibiting 
iNOS mediated responses than those from China, indicating that the growing and climatic 
conditions of Andrographis paniculata may affect the potency of its action or the contents of 
chemical components which are responsible for mediating anti-iNOS actions of Andrographis 
paniculata as geographical location and seasons may also explain the differences in the contents 
of the active components in the herb (Hu & Wu, 1995). Nevertheless, the anti-iNOS effect of 
Andrographis paniculata seems highly reserved in Andrographis paniculata from different 
geographical locations in Asia.  
 
The main active ingredients characterized in Andrographis paniculata are diterpenoid 
components, including Andrographolide, Dehydroandrographolide, Neoandrographolide, 
Deoxyandrographolide, etc (Pamanick et al., 2006; Zhao et al., 2006). Among these, 
Andrographolide has been most studied. The finding that Andrographolide inhibited iNOS 
mediated responses in the rat aorta in the present study is consistent with previous report on its 
protection of LPS-induced reduction of contractile responses to phenylephrine in vitro (Chiou et 
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al., 1998). Such effect of Andrographolide is most likely to be mediated by its inhibition of 
expression of iNOS through prevention of protein synthesis and decrease of the protein stability 
rather than affecting iNOS mRNA (Chiou et al., 2000). Similar effect was also reported for 
Neoandrographolide, which inhibited LPS-induced NO production in mouse peritoneal 
macrophages in vitro although it is weaker than Andrographolide (Batkhuu et al., 2002), possible 
through inhibition of p38 MAPKs action (Liu et al., 2006).  Importantly, the present finding that 
Dehydroandrographolide, a related diterpenoid compound, significantly inhibited iNOS-
mediated relaxations, indicates that Dehydroandrographolide also contributes to the anti-iNOS 
actions of Andrographis paniculata. Further work is necessary to find if similar biochemical 
mechanisms are involved in the action of Dehydroandrographolide.  
 
Interestingly, Andrographis paniculata extracts from different districts of Brunei Darussalam 
produced a similar but varied inhibition on iNOS-mediated response, indicating that it is likely to 
be mediated by similar active components, although such active components may vary 
significantly among different samples. It is most likely a number of diterpenoid components are 
involved. The key question is whether the anti-iNOS effect of Andrographis paniculata directly 
correlated to the contents of Andrographolide related components.  
 
Our finding suggested that the anti-iNOS effect of Andrographis paniculata extracts had a poor 
correlation with the content of Andrographolide and Dehydroandrographolide alone but it had a 
good with the total content of Andrographolide plus Dehydroandrographolide indicates the 
importance of multiple Andrographolide components working collectively in mediating anti-
iNOS response by Andrographis paniculata. In this regards, other component(s) may also 
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contribute to the inhibitory effect by Andrographis paniculata extracts as significant portion of 
the observed effect seems not related to Andrographolide and Dehydroandrographolide alone. It 
would be interesting to further study the genetic profile and correlations between genetic markers 
and their metabolic compounds of Andrographis paniculata from Brunei Darussalam. The level 
of Andrographolide and Dehydroandrographolide in Andrographis paniculata extracts from 
China in the present study is similar to those reported in the literature (Chiou et al., 2000).    
 
Given the importance of iNOS in various pathophysiological conditions, such as vascular 
dysfunctions in septic shock (Julou-Schaeffer et al., 1990; Kilbourn et al., 1990; Rees et al., 
1990; Thiemermann & Vane, 1990; Wu & Thiemermann, 1996) and inflammatory reactions in 
arthritis and  diabetes (Connor et al., 1995; Stefanovic-Racic et al., 1993; Wu & Thiemermann, 
1996), the inhibitory properties of Andrographis paniculata are potentially useful for treating 
certain inflammatory diseases or conditions. In this regards, Andrographis paniculata extracts 
from Brunei Darussalam may serve as a better herbal source for treating iNOS related 
inflammatory conditions.  
 
In conclusion, the ethanol extracts of Andrographis paniculata from different locations of Brunei 
Darussalam exhibits significant anti-iNOS mediated relaxations in the rat aorta, an effect partly 
correlated to the total content of Andrographolide and Dehydroandrographolide of the herbal 
extracts. Such anti iNOS mediated response may contribute to the beneficial effects of 
Andrographis paniculata in related disease conditions.   
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9.1 Introduction 
 
It is known over the years that the world’s population relies upon plant species as the primary 
source of medicine for the treatment of diseases. The continuous search for natural heals for the 
treatment of minor to more severe complications such as potential anti-cancer agents are focused 
on the natural products as effective and safe remedies. It was reported that more than 10 million 
people world-wide are diagnosed with cancer every year, and more than 6 million die from 
cancer, according to World Health Organization (WHO). It is projected that in the next 20 years 
these numbers will be increased by 50%. It is reported that cancer is a major cause of mortality 
and morbidity in Australia. More than 34,000 Australians died of cancer, and a further 80,000 
were diagnosed with some form of cancer. An estimated of 270,000 non-melanocytic skin 
cancers are diagnosed each year (AACR, 2001). In 2002, malignant neoplasms were the leading 
cause of all deaths (28%) in Australia (ABS, 2003).  
 
In line with the worldwide trend, cancer is a major cause of mortality and morbidity in Brunei 
Darussalam. Currently, cancer is the number one killer in Brunei Darussalam which has 
increased to about 22% in year 2004, almost double compared to 12.1% in 1996 which was only 
ranking the third leading cause of death according to the statistics of death registry of Brunei 
Darussalam. The top four cancer cases diagnosed were lungs (47), cervix (47), breast (45) and 
colo-rectal (35) (MOH, 1996, 2004a). The rate is on the rapid increase as reflected in most 
developing nations and the continued search for an effective therapeutic anti-tumour agent is 
paramount. 
 
Cytotoxic drugs are used in the chemotherapies of cancer which interfere with cell proliferation 
during the process of cell division. Unfortunately, such drug action also affects the normal 
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dividing cells, giving rise to untoward effects and complications such as immunosuppression and 
excessive hair loss (Tannock & Hill, 1998). Therefore, anti-tumour agent with specific toxicity 
targeting on tumour cells and at the same time without affecting the normal cells will become the 
ideal drug of choice in cancer therapies, with the aim to maximise the benefits and at the same 
time minimising the risks. 
 
Many compounds from natural sources are constantly being screened for cytotoxic activity 
against tumour cell lines and normal cells, with the interest to differentiate between the 
specificity and non specific tumour activites. The general cytotoxicity of the same extract 
fractions on rat hepatocytes is discussed in the Chapter 10 on the rat hepatocyte toxicity 
screening assay.   
 
Therefore, this study on Andrographis paniculata is of paramount importance for the future 
research and development of the medicinal native plants of Brunei Darussalam which are of 
therapeutic benefits to health. 
 
9.2 Materials and Methods 
 
9.2.1 Plant materials 
 
The extract fractions of the Andrographis paniculata were described previously in section 
5.3.2.3.2 and 5.3.2.3.3 of Chapter 5. 
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9.2.2 Biological materials 
 
All biological materials were provided by the Key Centre for Toxicity, RMIT. Mouse 
lymphoblastic parental PAR (P388), ADR, WEHI-164, K562 (Human Tumour cells), P815 
(Mouse mastocytoma cells), Yac-1 (T-Lymphoblastic) tumour cells (all six cell lines were 
provided by Associate Professor Paul Wright, the Key Centre for Toxicity, RMIT). RPMI-1640 
was obtained from Sigma Chemical Company (St Louis, MO., USA). Freshly isolated rat 
hepatocytes (hepatocytes cells were provided by Dr. Simone Yendle, the Key Centre for 
Toxicity, RMIT). 
 
9.2.3 Anti-tumour screening assay 
 
In-vitro anti-tumour activity of extracts fractions were determined using mouse leukaemic 
lymphoblastic Parental PAR (P388), ADR, and other cancer cell lines WEHI-164, K562 (Human 
Tumour cells), P815 (Mouse mastocytoma cells), Yac-1 (T-Lymphoblastic) tumour cells (cell 
lines were provided by Associate Professor Paul Wright, the Key Centre for Toxicity, RMIT). 
Extract fractions were dissolved in 100% absolute ethanol to ensure sterility for cell culture 
testing and then serially diluted into final concentrations of 1, 3.3, 10, 33.3, 100µg/ml in RPMI-
1640 media containing 2mM glutamine, 10% heat inactivated foetal calf serum (CSL, Parkville, 
Australia), 10mM 2-mercaptoethanol and 100µg/ml gentamicin sulfate) in a 96-well flat bottom 
cell culture sterile microtitre plate. Extract blank, ethanol solvent control and cell free wells were 
plated. The tumour cells of 1 x 10
5 
cells/ml in RPMI-1640 were added to the extract fractions 
and incubated for 48 hours at 37ºC, 5% CO2.  Cell viability was assessed by the addition of blue 
dye Resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-oxide) C12H6NNaO4 (Sigma, USA) sodium 
salt solution 0.01mg/ml in each well, which is converted to pink in metabolically active cells and 
fluoresce. 6%w/v SDS (Sodium Dodecyl Sulfate) were added in final concentrations of 40µg/ml, 
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60µg/ml, 80µg/ml, 100µg/ml in four wells of extract free as a positive control and acts as the 
inhibitor of cancer cell lines. The fluorescence of the reaction product was measured at emission 
wavelength of 560nm and excitation wavelength of 590nm after 48 hours incubation (37ºC, 5% 
CO2) using the 96 wells fluorescence flat, pico green black plates. 
 
9.2.4 Data collection and statistical analysis 
 
The results were expressed as a percentage of w/w of the herbal extract. Values were expressed 
as mean ± Standards Error of Mean (S.E.M.) and were analyzed using either student t-test, One 
Way Anova, Bonferroni Multiple Comparison Test (GB-Stat by Dynamic Microsystems Inc., 
MD, USA). Results are mean ± Standard Error of Mean (SEM), (*P<0.05, n=4). 
 
9.3 Results 
 
The anti-tumouricidal activity of Andrographis paniculata was investigated using six tumour cell 
lines as described earlier. The detection of cytotoxic compounds Andrographolide and 
Dehydroandrographolide was determined by comparison to the ethanol vehicle control. 
Andrographolide (Std A) has the most potent antitumourigenic activity which inhibited the 
growth of all the six tumour cells by 50%, the IC50 at a concentration range of 6-10µg/ml for 
P388 (Figure 9.1), ADR (Figure 9.2), WEHI-164 (Figure 9.3), K562 (Figure 9.4), Yac-1 (Figure 
9.5). However, the cell line P815 (Figure 9.6) which has a higher IC50 value of 100µg/ml, 
showed lesser sensitivity to Std A when compared to the other cell lines investigated. The other 
extract fractions tested indicated that some Andrographis paniculata fractions inhibited the 
growth of these tumour cell lines with varying degree of potency which correlated with the 
content of Andrographolide.  
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The Brunei AP Ee ASE (Bru Ee ASE) fraction has the anti-tumourigenic activity which inhibited 
the growth of all the five tumour cells by 50%, the IC50 at a concentration range of 20-50µg/ml. 
However, the IC50 of CXL Ee ASE fraction has a higher concentration range of 40-95µg/ml. 
Both have no inhibition effect on P815 tumour cell line.  
 
This anti-tumouricidal cytotoxicity finding offers support to the validity of the traditional 
medicinal uses of this plant as well as the earlier study on Andrographolide (A), the major active 
constituent of the extract of Andrographis paniculata (Burm. f.) Nees is a potential anti-cancer 
therapeutic agent.  
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Figure 9.1. Effect of Andrographis paniculata extracts at varying concentrations (1, 3.3, 
10, 33.3, 100 µg/ml) on P388 (PAR) tumour cell viability after 48 hours.  
Ethanol (1%v/v final concentration) used as a vehicle control (expressed as 100% 
viability). Data expressed as mean percent viability (relative to vehicle control) ± 
SEM (n=4) when compared to vehicle control. *Statistically significant P<0.05 
when compared to vehicle control. 
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Figure 9.2. Effect of Andrographis paniculata extracts at varying concentrations  
(1, 3.3, 10, 33.3, 100 µg/ml) on ADR tumour cell viability after 48 hours.  
Ethanol (1%v/v final concentration) used as a vehicle control (expressed as 100% 
viability). Data expressed as mean percent viability (relative to vehicle control) ± 
SEM (n=4) when compared to vehicle control. *Statistically significant P<0.05 
when compared to vehicle control. 
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Figure 9.3. Effect of Andrographis paniculata extracts at varying concentrations (1, 3.3, 
10, 33.3, 100 µg/ml) on WEHI-164 tumour cell viability after 48 hours.  
Ethanol (1%v/v final concentration) used as a vehicle control (expressed as 100% 
viability). Data expressed as mean percent viability (relative to vehicle control) ± 
SEM (n=4) when compared to vehicle control. *Statistically significant P<0.05 
when compared to vehicle control. 
Std A Std D SDS Brunei AP Ee ASE CXL Ee ASE
Brunei AP Ee STIR CXL Ee STIR Brunei AP We ASE CXL We ASE CRS Ee STIR
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Figure 9.4. Effect of Andrographis paniculata extracts at varying concentrations (1, 3.3, 
10, 33.3, 100 µg/ml) on K562 tumour cell viability after 48 hours.  
Ethanol (1%v/v final concentration) used as a vehicle control (expressed as 100% 
viability). Data expressed as mean percent viability (relative to vehicle control) ± 
SEM (n=4) when compared to vehicle control. *Statistically significant P<0.05 
when compared to vehicle control. 
Std A Std D SDS Brunei AP Ee ASE CXL Ee ASE
Brunei AP Ee STIR CXL Ee STIR Brunei AP We ASE CXL We ASE CRS Ee STIR
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Figure 9.5. Effect of Andrographis paniculata extracts at varying concentrations (1, 3.3, 
10, 33.3, 100 µg/ml) on Yac-1 tumour cell viability after 48 hours.  
Ethanol (1%v/v final concentration) used as a vehicle control (expressed as 100% 
viability). Data expressed as mean percent viability (relative to vehicle control) ± 
SEM (n=4) when compared to vehicle control. *Statistically significant P<0.05 
when compared to vehicle control. 
Std A Std D SDS Brunei AP Ee ASE CXL Ee ASE
Brunei AP Ee STIR CXL Ee STIR Brunei AP We ASE CXL We ASE CRS Ee STIR
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Figure 9.6. Effect of Andrographis paniculata extracts at varying concentrations (1, 3.3, 
10, 33.3, 100 µg/ml) on P815 tumour cell viability after 48 hours.  
Ethanol (1%v/v final concentration) used as a vehicle control (expressed as 100% 
viability). Data expressed as mean percent viability (relative to vehicle control) ± 
SEM (n=4) when compared to vehicle control. *Statistically significant P<0.05 
when compared to vehicle control. 
Std A Std D SDS Brunei AP Ee ASE CXL Ee ASE
Brunei AP Ee STIR CXL Ee STIR Brunei AP We ASE CXL We ASE CRS Ee STIR
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9.4 Discussion 
 
 
The presence of tumouricidal activity was investigated using six types of cancer cell lines. The 
detection of cytotoxic compounds was made by comparison to the ethanol vehicle control blank. 
The Andrographolide (Std A) has the most potent antitumourigenic activity inhibited the growth 
of all the six types of cancer cells by 50% (IC50) at a concentration range of 6-10µg/ml for P388 
(PAR), ADR, WEHI-164, K562, Yac-1 except for the cell line P815 which showed lesser 
sensitivity to Std A has a higher IC50 value of 100µg/ml. The other extract fractions tested 
indicated that some fractions inhibited the growth of tumour cells from the six different cancer 
types with varying degree of potency as shown from Figures 9.1 to 9.6.   
 
The cell line P815 which showed lesser sensitivity to Std A, has a higher IC50 value of 100µg/ml. 
This observation may suggest that P815 being the mastocytoma cell lines of the mouse mast cells 
is in agreement with the less responsiveness of the rat peritoneal mast cells (RPMC) in the weak 
anti-allergic effect of Andrographolide against mast cell-derived  histamine release in RPMC as 
demonstrated in Chapter 7 in which both are mouse mast cells. However, further studies are 
required to elucidate the mechanism of actions of the Andrographolide on the mast cells in order 
to have a better understanding on this possible explanation. 
 
The finding also demonstrated that the antitumourigenic effect of both the Bru Ee ASE and CXL 
Ee ASE fractions correlated with the Andrographolide content of these sample fractions as 
described in section 5.3.4 of Chapter 5. This is in close agreement that Andrographolide 
displayed significant anti-tumourigenic effect on the tumour cell lines as demonstrated in 
previous studies. 
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The cytotoxic activities of Andrographolide and its analogues were investigated and found that 
the changes in the structure of the analogues synthesized affect the cytotoxic activities of 
Andrographolide (Nanduri et al., 2004). The cytotoxic activities of Andrographolide, 
Neoandrographolide, Andrographiside, Deoxyandrographiside, and 14-deoxy-12-
methoxyandrographolide evaluated by (Tan et al., 2005) appeared to be non-cytotoxic against 
the cell lines such as Caov-3 (human ovarian carcinoma cell line), T-47D (human breast 
carcinoma cell line), Hs-578T (human breast carcinoma cell line), HepG2 (human 
hepatocarcinoma cell line), and NCl-H23 (human lung adenocarcinoma cell line). Of these cell 
lines tested using MTS assay after 72 hours of incubation, only 14-deoxyandrographolide and 
14-deoxy-11, 12-didehydroandrographolide exhibited cytotoxic activities on T-47D (human 
breast carcinoma cell line at concentration of IC50 values of 2.8µg/ml and 1.5µg/ml respectively. 
Among the active constituents examined, it was found that 14-deoxy-11,12-
didehydroandrographolide was the most potent. Our study demonstrated that the 
Andrographolide (Std A) has the most potent anti-tumourigenic activity inhibited the growth of 
all the five types of cancer cells investigated by 50% (IC50) at a concentration range of 6-
10µg/ml. 
 
There are many active components apart from Andrographolide, Andrographiside, 
Deoxyandrographolide and Neoandrographolide isolated by the researchers and newer ent-
labdane diterpenoids were isolated by Pramanick et al. and Shen et al., (2005) from the leaves of 
Andrographis paniculata (Pramanick et al., 2005; Shen et al., 2005). Rajagopalan et al., (2003) 
investigated the effect of Andrographolide in human cancer cell lines based on SRB assay where 
the amount of dye bound to the cells after staining gives a measure of cell growth. 
Andrographolide treatment resulted in a dose-dependent decrease in the viability of the human 
cancer cell lines MDA-MB-453, MCF7, T47D, SW620, COLO205, NCI-H23, MES-SA, MES-
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SA-DX5, A431, ES2, PA-1, PC3, A498, CCRF-CEM and NCI-ADR-RES, U251, SF268, 
SNB19, HT-29, HCT116, KM12, H522, H226, A549, NCI-H23, HOP62, UACC62, M14, 
SKOV3, OVCAR8, DU145 and ACHN (Rajagopal et al., 2003). With more new active labdane 
diterpenoids isolated from the Andrographis paniculata leaves, it will be most interesting to 
research further into the therapeutic potential effect of these newly isolated constituents and their 
effects on human cancer and in vitro proliferation of different tumour cell lines. 
 
Andrographolide inhibited the growth of many types of human cancer cells by 50% (IC50) at a 
concentration range of 5-15µM with the exception of COLO205 that showed more sensitivity to 
Andrographolide treatment. Results illustrated that Andrographolide inhibits the tumour cells 
growth of different cancer cell types with similar potency. 
 
However, Andrographolide’s role as an anti-cancer or anti-tumour and immuno-modulatory 
agents in human and its molecular mechanism of action has not been fully elucidated. It was 
reported that the possible mechanism of action was by exerting direct anti-cancer activity on 
cancer cells by cell-cycle arrest at G0/G1 phase through the induction of cell-cycle inhibitory 
protein p27 and decreased expression of cyclin-dependent kinase 4 (CDK4). Immunostimulatory 
activity of Andrographolide is evidenced by increased proliferation of lymphocytes and 
production of interleukin-2. Andrographolide also enhanced the tumour necrosis factor-α 
production and CD marker expression, resulting in increased cytotoxic activity of lymphocytes 
against cancer cell lines, which may possibly contribute to its indirect anti-cancer activity. Study 
by Rajagopal et al., 2003 demonstrated in vivo anti-cancer activity of the compound is further 
substantiated against B16F0 melanoma syngenic and HT-29 xenograft models. These results 
suggest that Andrographolide is an interesting pharmacophore with anti-cancer and 
immunomodulatory activities and therefore has potential for being developed as as a cancer 
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therapeutic agent. Among the three main diterpenoids, Andrographolide exhibited the highest 
degree of cytotoxicity followed by deoxyandrographolide while neoandrographolide was the 
least effective. It was suggested that Andrographis paniculata leaves and Andrographolide 
induce cell cycle arrest and affect an intrinsic mitochondria-dependent pathway of apoptosis by 
regulating the expression of some pro-apoptotic markers in HL-60 cells (Rajagopal et al., 2003). 
 
Andrographolide showed selective cytotoxicity to prostate cancer PC-3 cell death. Using 
immunocytochemistry staining and cellular caspase-3 activity assay, Andrographolide-treated 
cells exhibited considerable caspase-3 activation and caspase-8 in PC-3 cells at 4 and 2 hours 
after treatment respectively demonstrating Andrographolide-induced cell death was achieved 
through the apoptotic pathway, via the activation of an intrinsic caspase cascade (Kim et al., 
2005). 
 
The in vitro and in vivo study on the effect of the Andrographolide and its novel semi-synthetic 
analogue DRF 3188 using FACS and western blot analysis of cell cycle proteins showed that 
both compounds block the cell cycle at the G0-G1 phase through the induction of the cell cycle 
inhibitor, p27 and the concomitant decrease in the levels of Cdk4. Results indicated that both the 
compounds exhibited anti-tumour activities by a similar mechanism of action (Satvanaravana et 
al., 2004). Kumar et al., (2004) showed that the anti-tumour and immunomodulatory activity of 
the dichloromethane (DCM) fraction of the methanolic extract of Andrographis paniculata 
exhibited the highest potency, contributing for both their anti-cancer and immunostimulatory 
activities. Dichloromethane fraction significantly inhibits the proliferation of HT-29 (colon 
cancer) cells and augments the proliferation human peripheral blood lymphocytes (HPBLs) at 
low concentrations. Further fractionation of this DCM resulting in three diterpenes such as 
Andrographolide, 14-deoxyandrographolide and 14-deoxy-11, 12-didehydroandrographolide 
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were found to exhibit anti-cancer activity on diverse cancer cells of different human cancers. All 
showed enhanced proliferation and interleukin-2 (IL-2) induction in HPBLs (Kumar et al., 
2004). 
 
The effects of LianBiZhi (LBZ) injection containing Andrographolide on macrophage 
phagocytotic function and natural killer cells cytotoxicity were examined by Peng et al., (2002). 
The results demonstrated that LBZ injection could promote IFN-alpha, IFN-gamma, TNF-alpha 
inductions of PBMCs, but had no effect on IL-8. LBZ injection could not only enhanced the 
phagocytosis activity of peritoneal macrophage from guinea pig to phagocytosis cock 
erythrocyte, but also augment the cytotoxicity mediated by natural killer cells from PBMCs to 
damage the K562 cell lines suggesting that Andrographolide, being an immunostimulant agent 
can modulate both antigen specific and nonspecific immune function by means of its natural 
killer cells and macrophage and cytokines induction (Peng et al., 2002). 
 
Singh et al., (2001) investigated the effects of 80% hydroalcohol extract of Andrographis 
paniculata and butylated hydroxyanisole (BHA) at 50 and 100 mg/kg body weight/day content, 
lactate dehydrogenase (LDH) and lipid peroxidation in the liver of 6-8 weeks old Swiss albino 
mice as well as in the other organs such as lung, kidney and stomach. The finding indicated that 
Andrographis paniculata has the chemopreventive potential against chemotoxicity including 
carcinogenicity (Singh et al., 2001). 
 
In conclusion, the anti-tumour activity of the crude extracts of Andrograhis paniculata was 
determined by use of the six cancer cell types P388, ADR, K562, WEHI-164, Yac-1 and P815 
tumour cells. All compounds displayed a concentration dependent effect on the tumour cell 
viability demonstrated the tumouricidal effect of the diterpenes with the most effective and  
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cytotoxic fraction at a range of 6-10µg/ml being the Std A. Studies by (Cheung et al., 2005; 
Kumar et al., 2004; Rajagopal et al., 2003) demonstrated that Andrographolide, the major active 
diterpenoid of Andrograhis paniculata leaves exhibited specific tumouricidal activities on many 
cancer cell types.  
 
In this study, only five tumour cells viability were inhibited by the extract fractions with the 
exception of P815 which is less sensitive to Std A (the most potent cytotoxic fraction). This may 
suggest that Andrographolide (Std A) did not exhibit any tumouricidal activity on the growth of 
P815 tumour cells possibly due to the different pathway of mechanism of action of the other five 
tumour cells. 
 
Our findings offer support to the validity and in agreement with the traditional medicinal uses of 
this plant as well as the earlier studies on Andrographolide (A), the major constituent of the 
extract of Andrographis paniculata (Burm. f.) Nees is a potential cancer therapeutic agent 
(Cheung et al., 2005; Kumar et al., 2004; Rajagopal et al., 2003). 
 
Further studies are clearly needed to elucidate the anti-tumouricidal effects of Andrographolide 
(Std A), Dehydroandrographolide (Std D) as well as the crude plant extracts of Andrographis 
paniculata leaves which was reported earlier to contain three active components diterpene 
lactones Andrographolide as the major compound, Deoxandrographolide and 
Neoandrographolide. However, the most recent studies by Pramanick et al. (2005) and Shen et 
al. (2005) has isolated newer ent-labdane type diterpenoids from the leaves of Andrographis 
paniculata (Pramanick et al., 2005; Shen et al., 2005) which are now being investigated for their 
various pharmacological actions and bioactivities of these newly found constituents which may 
be present in small amounts but active and potent in nature. 
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10.1     Introduction 
 
10.1.1  General cytotoxicity on rat hepatocytes  
 
Cytotoxic drugs are used in the chemotherapies of cancer which interfere with cell proliferation 
during the process of cell division. Unfortunately, such drug action also affects the normal 
dividing cells, giving rise to untoward effects and complications such as immunosuppression and 
excessive hair loss (Tannock & Hill, 1998). Therefore, anti-tumour agent with specific toxicity 
targeting on tumour cells and at the same time without affecting the normal cells will become the 
ideal drug of choice in cancer therapies. 
 
Many compounds from natural sources are constantly being screened for cytotoxic activity 
against tumour cell lines and normal cells, with the interest to differentiate between the 
specificity and non specific tumour activites. The general cytotoxicity of the extract fractions on 
rat hepatocytes is discussed in this chapter on rat hepatocyte toxicity screening assay.   
 
 
Freshly isolated hepatocytes have high metabolic activity that make the intact liver a common 
target of toxicity. In vitro study on hepatocytes are usually used to determined whether anti-
tumour activity is specific or whether an extract is just generally toxic to most cell types. 
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10.2 Materials and Methods 
 
 
10.2.1 Plant materials 
 
The extract fractions of the Andrographis paniculata were previously described in Section 
5.3.2.3.2 and 5.3.2.3.3 of the Chapter 5. 
 
 
10.2.2 Biological materials 
 
All biological materials were provided by the Key Centre for Toxicity, RMIT. 
RPMI-1640 was obtained from Sigma Chemical Company (St Louis, MO., USA). 
Freshly isolated rat hepatocytes (hepatocytes cells were provided by Dr. Simone Yendle, the Key 
Centre for Toxicity, RMIT). 
 
10.2.3  General cytotoxicity assay 
 
10.2.3.1 Rat Hepatocyte Toxicity 
 
The evaluation of the general cytotoxicity of extracts against isolated rat hepatocytes HepG2 was 
carried out by the addition of blue dye of resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-oxide) 
sodium salt solution 0.01mg/ml in each well for the detection of cell viability. Extract fractions 
dissolved in 100% ethanol were serially diluted into final concentrations of 1, 3.3, 10, 33.3, 
100µg/ml in RPMI-1640 media containing 2mM glutamine, 10% heat inactivated foetal calf 
 278
serum (CSL, Parkville, Australia), 10mM 2-mercaptoethanol and 100µg/ml gentamicin sulfate) 
in a 96-well flat bottom cell culture sterile microtitre plate. Extract blank, ethanol solvent control 
and cell free wells were plated. Freshly isolated rat hepatocytes HepG2 (1 x 10
5 
cells/ml, 
provided by Associate Professor Paul Wright and Simone Yendle PhD, the Key Centre for 
Toxicity, RMIT) were added and the plate incubated for 48 hours at 37ºC, 5% CO2. Cell viability 
was assessed by the addition of blue dye of the resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-
oxide) C12H6NNaO4 (Sigma, USA) sodium salt solution 0.01mg/mL in each well, which is 
converted to pink in metabolically active cells and fluoresce. 6%w/v SDS (Sodium Dodecyl 
Sulfate) were added in final concentrations of 40µg/ml, 60µg/ml, 80µg/ml, 100µg/ml in four 
wells of extract free as a positive control and acts as the inhibitor of cancer cell lines. The 
fluorescence of the reaction product was measured using resazurin assay protocol at emission 
wavelength of 560nm and excitation wavelength of 590nm after 48 hours incubation (37ºC, 5% 
CO2) using the 96 wells fluorescence flat, pico green black plates. 
 
10.2.4 Data collection and statistical analysis 
 
Statistical Analysis was performed using Graph Pad Prism Version 4.0 for Windows (San Diego, 
CA, USA). Data was analysed by One Way Analysis of Variance (ANOVA) followed by 
Bonferroni Multiple Comparison Test for rat hepatocyte toxicity. Results are mean ± Standard 
Error of Mean (SEM), (*P<0.05, n=4). 
 
10.3 Results 
 
The general cytotoxicity of the extract fractions were evaluated by assessing the viability of the 
rat hepatocytes in the presence of two reference standards namely Andrographolide (Std A), 
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Dehydroandrographolide (Std D) and seven other Andrographis paniculata crude extract 
fractions. Results showed that significant toxicity was observed in all fractions but at varying 
degrees of cytotoxicity potency of the tested extract concentration at 100µg/ml (Figure 10.1). All 
the extract fractions displayed a concentration dependent effect on cell viability with the most 
cytotoxic of all the fraction extracts was Andrographolide (Std A) which has half effective dose 
IC50 value of 60µg/ml at 50% inhibition of rat hepatocyte viability (Table 10.2). At the 
concentration of 100µg/ml, the reference Std A, reducing rat hepatocyte viability by 68.78% ± 
0.84%. At the concentrations tested indicated that all the fractions are moderately and relatively 
non cytotoxic.  
 
Our results also demonstrated that the Brunei AP Ee ASE extract fraction at 100µg/ml reducing 
rat hepatocyte viability by 46.62% ± 4.95%. CXL Ee ASE extract fraction at 100µg/ml reducing 
rat hepatocyte viability by 11% ± 2.41% as illustrated in Table 10.1. Some extract fractions such 
as Std D (F2), Brunei AP Ee STIR (F4), CXL Ee ASE (F5), Brunei AP We ASE (F7), CXL We 
ASE (F8), and CRS Ee STIR (F9) exhibited inhibition on the percentage growth of the rat 
hepatocytes with varying degree of potency. Such finding demonstrated that for those fractions 
containing much lesser content of Andrographolide present in the extract fractions were 
relatively non-cytotoxic.   
 
This finding suggests that the Andrographis paniculata (Burm. f.) Nees from Brunei Darussalam 
may contain other active constituents apart from Andrgrapolide that may account for its 
moderate cytotoxicity. This requires further elucidation on the study of Andrographis paniculata 
source from countries with different climatic conditions and other factors that may affect the 
level of contents of constituents in the herb (Ngan et al., 1999). It has also been reported that 
geographical locations and seasons may explain the differences in the contents of the active 
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components in the plants (Hu & Wu, 1995). However, further studies are required to elucidate 
the different levels of contents and composition of constituents in Andrographis paniculata 
(Burm. f.) Nees obtained from other geographical locations in order to have a better 
understanding on this possible explanation. 
 
 
Table 10.1  % reducing of rat hepatocyte viability at extract concentration of 100µg/ml 
 
Crude Extract Fractions of  
Andrographis paniculata at 100µg/ml MEAN SEM 
F1 Std A  68.78 0.84% 
F2 Std D  14 3.38% 
F3 Brunei AP Ee ASE  46.62 4.95% 
F4 Brunei AP Ee STIR 17 3.54% 
F5 CXL  Ee ASE  11 2.41% 
F6 CXL  Ee STIR 16 2.58% 
F7 Brunei AP We ASE  2.40 0.40% 
F8 CXL We ASE  1.54 0.31% 
F9 CRS Ee STIR 1.69 0.40% 
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Figure 10.1. Effect of Andrographis paniculata extracts at varying concentrations (1, 3.3,  
10, 33.3, 100 µg/ml) on rat hepatocyte viability after 48 hours.  
Ethanol (1%v/v final concentration) used as a vehicle control (expressed as 100% 
viability). Data expressed as mean percent viability (relative to vehicle control) ± 
SEM (n=4). Data was analysed by One Way Analysis of Variance (ANOVA) 
followed by Bonferroni Multiple Comparison Test for rat hepatocyte toxicity.  
 282
 *Statistically significant P<0.05 when compared to vehicle control. 
Table 10.2 Effect of nine Andrographis paniculata fractions (1, 10, 100µg/ml) on rat 
hepatocytes viability.  
 
 
The half effective dose (IC50  values) of the Extract Fractions (µg/ml) in the inhibition of 
rat hepatocytes viability  
 
 
F1 Std A 60 
F2 Std D #No effect 
F3 Brunei AP Ee ASE 100 
F4 Brunei AP Ee STIR #No effect  
F5 CXL Ee ASE #No effect  
F6 CXL Ee STIR #No effect 
F7 Brunei We ASE #No effect 
F8 CXL We ASE #No effect 
F9 CRS Ee STIR   #No effect 
 
Results are mean ± SEM (n=4) expressed as a percentage of control viability.  
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# denotes that the other extract fractions showed no cytotoxicity towards the rat hepatocytes at 
the concentrations tested.  
10.4 Discussion 
 
General cytotoxicity of extracts was evaluated by assessing the viability of rat hepatocytes in the 
presence of Andrographolide, Dehydroandrographolide and the Andrographis paniculata  
extracts. The main findings of the present study showed that significant toxicity was only 
observed for the reference Std A at 100µg/ml. The most cytotoxic of all the tested fractions was 
reference Std A, reducing rat hepatocyte viability by 68.78% ± 0.84%. The other extract 
fractions were all relative non-cytotoxic. Solubility issues may also have affected the results of 
this assay, as the Andrographis paniculata extracts may contain substituents that were difficult to 
solubilise completely in the vehicle control.  
 
Study by Kapil et al., (1993) investigated the anti-hepatotoxic effects of major diterpenoids of 
Andrographis paniculata in hepatotoxicity induced in mice by carbon tetrachloride or ter-
butylhydroperoxide (tBHP) intoxication. The mice were pretreated with Andrographolide, 
Andrographiside and Neoandrographolide at 100 mg/kg, i.p. for 3 consecutive days with 
significant reduction in malondialdehyde formation, reduced glutathione (GSH) depletion and 
enzymatic leakage of glutamic-pyruvate transaminase (GPT) and alkaline phosphatase in either 
pretreated groups using the known hepatoprotective agent Silymarin as the positive control. 
Results showed that Andrographolide exhibited a lower protective potential than 
Andrographiside and Neoandrographolide, which the latter two were as effective as the control 
with respect to their effects on the formation of the degradation products of lipid peroxidation 
and release of GPT and alkaline phosphatase in the serum. Neoandrographolide restored the 
GSH status to normal. Study suggested that the greater protective antihepatotoxic effects of 
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Andrographiside and Neoandrographolide could be due to their glucoside groups which may act 
as strong and potent anti-oxidants (Kapil et al., 1993). 
The hepatoprotective effect of Andrographolide was studied by Handa and Sharma (1990) on 
acute hepatitis induced in rats by single dose of galactosamine (800 mg/kg, i.p.) or paracetamol 
(3g/kg, po). The hepatoprotective activity was monitored by estimating the serum transaminases 
(GOT and GPT), alkaline phosphatase and bilirubbin in serum, hepatic triglycerides, and by 
histopathological changes in the livers of experimental rats. The results confirmed that the  
in vivo hepatoprotective effect of Andrographolide against galactosamine or paracetamol-
induced hepatotoxicity were different in their primary mechanism of inducing hepatotoxicity 
which suggested that the protective mechanisms of Andrographolide which were non-specific in 
both intoxications may be responsible for the hepatoprotective activity of this major diterpenoid 
of Andrographis paniculata (Handa & Sharma, 1990a). In conjuction with this study, 
Andrographolide was found to normalize completely the Carbontetrachloride (CCl4)-induced 
increase in the pentobarbitone induced sleeping time of mice. In the previous earlier study, 
Choudhury and Poddar (1984) demonstrated that the kalmegh, the Andrographis paniculata leaf 
extracts had more protective action on Carbontetrachloride (CCl4)-induced hepatic toxicity than 
its bitter principle Andrographolide (Choudhury & Poddar, 1984). 
 
Freshly isolated hepatocytes have high metabolic activity that make the intact liver a common 
target of toxicity. In vitro study on hepatocytes are usually used to determined whether anti-
tumour activity is specific or whether an extract is just generally toxic to most cell types.  
 
The most cytotoxic of all the Andrographis paniculata extract fractions was Std A which has 
IC50 value of 60µg/ml at 50% inhibition of rat hepatocyte viability. At the concentration of Std A 
at 100µg/ml which reduced the rat hepatocyte viability by 68.78% ± 0.84%. In this study, all the 
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other fraction extracts and Std A did not exhibit any significant cytotoxicity at extract 
concentration less than 100µg/ml indicating that they are only moderate or  
relative non cytotoxic to hepatocytes. This is in agreement with the previous studies by Kumar et 
al., (2004) in the in vivo results from hollow fiber assay conducted in immunocompetent Swiss 
albino mice, demonstrated that Andrographolide significantly inhibited the cancer cell 
proliferation without showing any signs of cytoxicity in healthy normal mice treated with high 
doses of Andrographolide (Kumar et al., 2004). The findings demonstrated that Andrographolide 
displayed the most potent tumouricidal activity, yet was less cytotoxic in the rat hepatocyte 
assay, which may indicate that this extract potentially has specific anti-tumour activity. 
 
This finding offers support to the validity of the traditional medicinal uses of this plant as well as 
the earlier study on Andrographolide (A), the major active constituent of the extract of 
Andrographis paniculata (Burm. f.) Nees is non-cytotoxic and hepatoprotective (Handa & 
Sharma, 1990a).   
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11.1 Introduction 
 
The main objective of this thesis was to develop the strategic framework on TM/CAM for Brunei 
Darussalam in tandem with the global developments on TM/CAM. In conjunction with this 
objective, an interdisciplinary approach, as a case study, was also undertaken to investigate the 
genetic diversity, chemical profile, bioactivities and pharmacological actions of Andrographis 
paniculata (Burm. f.) Nees (HDM 15) from Brunei Darussalam involving different techniques in 
molecular biology, biochemistry and pharmacology for the systematic study of the tropical 
medicinal native plants of Brunei Darussalam. To the best of our knowledge, this is the first 
study on the Andrographis paniculata (Burm. f.) Nees (HDM 15) of Brunei Darussalam 
conducted. 
 
There have been several challenges for the study. Firstly, although there is a strong need from 
Brunei Darussalam government in promoting the safe use of traditional medicine, there has been 
little research done in terms of strategy and policy development in this area in Brunei 
Darussalam. Given the significant use of traditional medicine in the general population in this 
country, it is important to develop a framework on traditional medicine. After an extensive 
review of the developments of traditional medicine in other countries, regions or organizations, a 
framework has been proposed. The main feature of the framework is to encourage the 
formalisation of TM/CAM with the aim of achieving integrated health care systems and 
promoting the quality, safety and efficacy of TM/CAM interventions through the 
interdisciplinary approach in the research and development. In line with the concerted efforts 
worldwide are pivotal in supporting the WHO’s global strategy for TM/CAM. With such a 
strategy framework in place will benefit Brunei Darussalam in the actualisation of TM/CAM 
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practices as well as recognising the importance of the natural reserves of medicinal native plants 
available in the country, widely used by the local communities.  
 
The second challenge is on the study of tropical medicinal native plants of Brunei Darussalam 
with the need for new drug development in the treatment of certain disease conditions which 
have also been highlighted. Natural products have always been a potential source of new 
therapeutic agents in which the desire for the development of novel drugs warrant continued 
investigation. Given the complex nature of the research required for studying the medicinal 
native plants of Brunei Darussalam, a multi-disciplinary approach was taken by using various 
techniques to document the blue print for Andrographis paniculata (Burm. f.) Nees (HDM 15), a 
native medicinal plant grown in Brunei Darussalam. The techniques in this study have been 
shown to be useful and suitable for the phytochemical and biological profile of the activities of 
the crude plant extracts and their constituents. The laboratory investigations revealed that 
Andrographis paniculata from Brunei Darussalam exhibited a distinct genetic profile from the 
Andrographis paniculata of China. It has a wide range of anti-oxidant properties, 
pharmacological actions including anti-inflammatory and anti-tumour effects with relatively 
non-cytotoxicity on rat hepatocytes. Some of the pharmacological actions of Andrographis 
paniculata correlated with the active constituents Andrographolide (A) and 
Dehydroandrographolide (D). The findings have provided the first experimental evidence for 
tropical medicinal native plants of Brunei Darussalam, and also set up examples for studying 
other medicinal native plants in Brunei Darussalam. Given the rich native medicinal plant 
resources in Brunei Darussalam and the potential of understanding the pharmacological actions 
of native plants are of great significance in terms of health care and economic development of 
the region. Further work is clearly needed to the elucidation of potential targets of the active 
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components of the plants which can affect the ultimate outcomes on the quality, safety and 
efficacy of the plant.  
 
11.2 The studies on Andrographis paniculata (Burm. f.) Nees (HDM 15)  
– A Medicinal Native Plant of Brunei Darussalam 
 
This study was initiated using RAPD and PCR-RFLP of 5S-rRNA region of the phylogenetic 
diversity of nine accessions samples collected from the three districts namely Bandar Seri 
Begawan from the Brunei/Muara district (AP2, AP4, AP6, AP8, AP11, AP14, AP15), Kuala 
Belait district (K.B.), Temburong district (T) and Chuan Xin Lian (CXL) from China. The 
genetic comparison as demonstrated for Andrographis paniculata from Brunei Darussalam 
constituted as the first report on genetic diversity of related medicinal plants in Brunei 
Darussalam on the basis of RAPD analysis. The data obtained in this study reflected the utility of 
RAPD and PCR-RFLP in the analysis of genetic variability distribution within Andrographis 
paniculata. The finding of the close genetic distances between all the nine accessions from 
Brunei Darussalam and Chuan Xin Lian (CXL) are in agreement with the other studies on lotus 
(Campose et al., 1994), sweet potato (Cannoly et al., 1994), and Andrographis paniculata of 
India (Padmesh et al., 1999) which suggests that RAPD is more appropriate for the analysis of 
genetic diversity in closely related genotypes. This study provides a better understanding of 
genetic variation at the intraspecific level would help in identifying superior genotype(s) for 
cultivar development. The polymorphism obtained can be used as a marker for screening the 
genotypes. The genomic DNA fingerprinting by RAPD among fresh accessions from 
Andrographis species showed distinctive DNA fragments which may be used for the 
authentication, identification and quality assessment of the plant species or varieties. 
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The chromatographic analysis of Andrographis paniculata extract fractions using HPTLC and 
HPLC procedures (Jain et al., 2000) was intended to elucidate the levels of Andrographolide and 
Dehydroandrographolide contents in the Andrographis paniculata samples obtained from 
different districts of Brunei Darussalam and compared to the China samples. Difference in the 
contents of A and D in these samples were observed. The content of A (%w/w) in Temburong 
and Brunei AP samples were higher than those from CXL, K.B. and Chinese Reference samples. 
On the contrary, the content of D (%w/w) in Temburong and Brunei AP samples were lower 
than that in CXL, K.B. and Chinese Reference samples. When combining A and D contents, the 
ranking order were Temburong, CXL, Brunei AP, K.B. and Chinese Reference.  
 
Given that the different climatic, growing, storage conditions, freshness of the of herbal samples 
and the different post-harvesting processing may affect the contents of chemical components in 
the herbs (Hu & Wu, 1995; Ngan et al., 1999; Zhou, 1987), this may suggest why the content of 
A and D levels in Andrographis paniculata extracts are different from different region. 
Interestingly, the Andrographis paniculata extracts from different region for instance the Brunei 
samples were found to be higher in the Andrographolide content and lower in the 
Dehydroandrographolide may suggest that since the plant thrives best in the tropics and 
subtropical areas indicating that the climatic conditions may influence the levels of contents of 
this evergreen plant (Padmesh et al., 1999; Sabu, 2002). 
 
From the pharmacological and biological perspectives, the Andrographis paniculata which has 
been assessed and evaluated for its anti-oxidant, anti-tumour and anti-hepatotoxicity properties, 
as well as its pharmacological actions such as the effects against compound 48/80-induced 
histamine release in rat peritoneal mast cells, and iNOS mediated smooth muscle relaxations in 
rat aorta tissues and their bioactivities look promising. Study showed that the aqueous (We), 
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ethanol (Ee) and methanol (Me) extracts of Andrographis paniculata (Burm. f.) Nees of Brunei 
Darussalam exhibited some significant scavenging activities towards 1,1-diphenyl-2-
picryhydrazyl (DPPH), hydroxyl radical, hydrogen peroxide and nitric oxide in the cell-free 
systems with the exception of the aqueous extract which did not show any significant DPPH 
scavenging activity. Although it is not clear if Andrographis paniculata acts effectively in vivo 
as anti-allergies or anti-histaminic therapeutic agents since as it requires a relative higher dose 
(1mg/ml) for such effects in vitro as demonstrated in this study. The finding that the rat 
peritoneal mast cells is less responsive towards Andrographis paniculata extracts in this study is 
in close agreement with the previous study by (Gupta et al., 1998).  
 
The most significant finding is the demonstration that Andrographis paniculata possesses 
beneficial effects with Andrographolide possesses the most potent anti-tumourigenic activity and 
relatively non-cytotoxic to rat hepatocytes which is in agreement with the previous studies 
(Handa & Sharma, 1990a; Kapil et al., 1993; Rajagopal et al., 2003). Extract fractions studies 
have shown that this is due to the presence of Andrographolide which has varying potential 
pharmacological effects (Chiou et al., 2000).  
 
Andrographis paniculata leaves have been reported to contain three active components diterpene 
lactones Andrographolide as the major compound, Deoxandrographolide and 
Neoandrographolide. Recent studies by Pramanick et al. (2005) and Shen et al. (2005) has also 
isolated new ent-labdane type diterpenoids from the leaves of Andrographis paniculata 
(Pramanick et al., 2005; Shen et al., 2005) which are still undergoing various bioactivities 
testings. These active constituents may also be responsible for the pharmacological actions and 
bioactivities of Andrographis paniculata leaves. 
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The finding also suggests that Andrographis paniculata leaves may contain other active 
constituents other than Andrographolide with varying levels of %w/w content which may 
account for its varying potency of the anti-tumourigenic and cytotoxic activities. Preliminary 
results indicated that further anti-tumour and cytotoxicity tests on Andrographis paniculata is 
warranted which is required to be elucidated in the future studies to ensure the absolute safety of 
the leaves for long term consumption by the population.  
 
This finding offers support to the validity of the traditional medicinal uses of this plant as well as 
the earlier studies on Andrographolide (A), the major active constituent of the extract of 
Andrographis paniculata (Burm. f.) Nees is a potential anti-cancer therapeutic agent (Rajagopal 
et al., 2003).  
 
This study also provides a better understanding of genetic variation at the intraspecific level 
would help us in identifying the superior genotype(s) for cultivar development such as the higher 
level of active Andrographolide and lower level of the less active Dehydroandrographolide 
contents found in the Andrographis paniculata from Brunei Darussalam in particularly, the 
Temburong sample. It would be interesting to carry out future anti-tumour assay on this 
particular extract fraction. The isolation and chemical fingerprinting of this plant has not yet 
been achieved in our study, but it is hope that this will be pursued further in the near future. 
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11.3 Limitations of this thesis 
 
The limitations of this study which needs to be considered is that there are other chemical 
ingredients such as diterpene lactones active constituents other than Andrographolide such as 
Deoxyandrographolide and Neo-andrographolide and the recent studies by Pramanick et al., 
(2005) and Shen et al., (2005) isolated newer ent-labdane type diterpenoids from the leaves of 
Andrographis paniculata (Pramanick et al., 2005; Shen et al., 2005) which are also key players 
in the implication of the clinical benefits of Andrographis paniculata in total. It is also 
envisioned that Andrographis paniculata (Burm. f.) Nees will be the future potential anti-cancer 
pharmaceutical drug and ongoing studies are conducted to research into the other potent 
constituents and their pharmacological actions and bioactivities of this important medicinal plant. 
 
It has been demonstrated that Dehydroandrographolide is much lesser in potency than the rest of 
the active components when compared to Andrographolide as shown by previous studies. It is to 
be bear in mind that in most instances, Andrographis paniculata leaves are usually taken as a 
whole rather than as active constituents alone. The oral administration of the raw herbal leaves or 
powder by the communities at large in the dosage amount which may be much greater than the 
tested concentrations within this study may also play an important role in the clinical effects. It 
would be interesting to conduct further studies on the different doses of Andrographis paniculata 
taken by the community. The results of this future project may contribute to further 
understanding the mechanism of herbal remedies in totality.  
           
Although this project investigated only the individual dried plants of Andrographis species, some 
of the folklore herbal medicine may consist of brews which are mixtures of fresh plants directly 
source from the fields or gardens in their own countries or imported. Andrographis paniculata is 
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widely used by the local communities to treat a range of diseases such as hypertension and 
diabetes (Ahmad, 2004). The Andrographis paniculata leaves are usually consumed steeped in 
hot water for drinking. These mixtures may contain some chemical reactions by heat on boiling 
or brewing and the effect can be actually quite different from a single compound isolated from a 
dried plant or from its crude extract. There is also some evidence that customized TM/CAM 
might be more effective than standardized preparations (Bensoussan et al., 1998). The fact that 
what the public actually consume might not be the exact components that are investigated in the 
laboratory. Therefore, from the consumers’ perspective, totality plays a major part of the 
TM/CAM system of therapies. Further studies are needed to elucidate the actual mechanisms of 
actions of Andrographis paniculata on the selective analyses of the laboratory interventions 
conducted in this project. 
 
11.4 Future directions                                                            
 
Andrographis paniculata (Burm. f.) Nees grown in Brunei Darussalam is the first plant species 
being research at the University of the Royal Melbourne Institute of Technology. There is clearly 
a potential for using this approach to study other medicinal plants or natural products. There is 
also a clear need for the utilization of the research techniques employed and applies on other 
medicinal native plant species of Brunei Darussalam for the screening and hopefully resultant in 
the development of potential source of novel therapeutics. 
 
Future studies to be undertaken include understanding the species distribution, habitat, 
phenology of flowering and fruiting, cytology, breeding system and seed dormancy/germination 
of the species. To conduct further research on the quantification of the amount of intra and inter-
specificity genetic variability of Andrographis paniculata and its patterns of population 
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differentiation throughout the districts of Brunei Darussalam will be useful to gather more 
valuable scientific information on the profile of Andrographis paniculata. The significance of 
inbreeding and gene flow to the level and pattern of diversity in Andrographis paniculata need to 
be assessed as well as to test the hypothesis that genetic distance is considerably correlated with 
geographical distance and most importantly to identify superior genotype(s) with increased 
biomass and active component products i.e. Andrographolide synthesis.  
 
There is also a need to study whether the external factors such as seasons and climatic changes 
(temperate versus tropical), geographical location, soil types, agricultural conditions, and various 
other factors that may affect the composition of the secondary metabolites of Andrographis 
paniculata and their relative pharmacological effects and bioactivities. 
 
It would also be beneficial to conduct further studies on the Andrographis paniculata from other 
tropical and temperate regions and to assess their similarities and differences which may shed 
lights on the contents of its active ingredients and their clinical importance.   
 
Further studies on pharmacological actions of Andrographis paniculata in particular its anti-
tumour activities would be interesting, including the study on active ingredients of specific 
samples from Temburong region. Comparison studies on Andrographis paniculata and other 
medicinal plants with potential anti-cancer activity based on the similar anti-tumour assay should 
be encouraged. 
 
The current and additional research data will certainly expand our existing knowledge into the 
Brunei Darussalam medicinal native plants and promote an update of monographs on the local 
medicinal native plants of Brunei Darussalam as compiled and published by the Ministry of 
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Industry and Primary Resources, Brunei Darussalam to serve as the niche for future research and 
development of these important medicinal native plants. Fortunately in Brunei Darussalam, 
under the National Forestry Policy, this tropical rain forest is classified as virgin and primary 
forest which are designated as protected forest reserves and conservation forest for natural 
habitats, wildlife sanctuaries, and also for specific area of scientific research and development of 
potential therapeutic drugs. The availability of natural ingredients for herbal medicines is 
therefore abundant in the country.  
 
Finally, further research on the the potential tropical medicinal native plants in Brunei 
Darussalam will not only promote the development of the region but also may lead to the 
discovery of new therapeutic agents to benefit the general population in the world. In this regard, 
provisions on the future financial support for related projects are important to promote the 
evidence-based practice of traditional medicine in Brunei Darussalam. 
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Appendices 
 
Appendix I     Milestones of Andrographis paniculata (Burm. f.) Nees research areas 
Index Research studies References 
1 Antifertility effect of Andrographis paniculata (Nees) in male 
albino rat. 
Akbarsha, M. A., Manivannan, B., 
Hamid, K. S., & Vijayan, B. (1990) 
2 Double-blind, placebo-controlled, randomized, pilot clinical trial 
of immunoguard--a standardized fixed combination of 
Andrographis paniculata Nees, with eleutherococcus senticosus 
maxim, schizandra chinensis bail. And glycyrrhiza glabra l. 
Extracts in patients with familial mediterranean fever. 
Amaryan, G., Astvatsatryan, V., 
Gabrielyan, E., Panossian, A., 
Panosyan, V., & Wikman, G. 
(2003). 
3 Inhibitory effect of andrographolide from Andrographis 
paniculata on paf-induced platelet aggregation. 
Amroyan, E., Gabrielian, E., 
Panossian, A., Wikman, G., & 
Wagner, H. (1999). 
4 Suppression of no production in activated macrophages in vitro 
and ex vivo by neoandrographolide isolated from Andrographis 
paniculata. 
Batkhuu, J., Hattori, K., Takano, F., 
Fushiya, S., Oshiman, K., & 
Fujimiya, Y. (2002). 
5 Hypoglycaemic effects of Andrographis paniculata nees on non-
diabetic rabbits. 
Borhanuddin, M., Shamsuzzoha, M., 
& Hussain, A. H. (1994). 
6 Andrographis paniculata (Nees) induces relaxation of uterus by 
blocking voltage operated calcium channels and inhibits Ca(+2) 
influx. 
Burgos, R. A., Aguila, M. J., 
Santiesteban, E. T., Sanchez, N. S., 
& Hancke, J. L. (2001). 
7 Testicular toxicity assessment of Andrographis paniculata dried 
extract in rats. 
Burgos, R. A., Caballero, E. E., 
Sanchez, N. S., Schroeder, R. A., 
Wikman, G. K., & Hancke, J. L. 
(1997). 
8 Andrographis paniculata (Nees) selectively blocks voltage-
operated calcium channels in rat vas deferens. 
Burgos, R. A., Imilan, M., Sanchez, 
N. S., & Hancke, J. L. (2000). 
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9 Use of visual analogue scale measurements (vas) to assess the 
effectiveness of standardized Andrographis paniculata extract 
sha-10 in reducing the symptoms of common cold. A randomiz 
double blind-placebo study. 
Caceres, D., & J.L., H. a. (1999). 
10 Dehydroandrographolide succinic acid monoester as an inhibitor 
against the human immunodeficiency virus. 
Chang, R. S., Ding, L., Chen, G. Q., 
Pan, Q. C., Zhao, Z. L., & Smith, K. 
M. (1991). 
11 Andrographolide suppresses the expression of inducible nitric 
oxide synthase in macrophage and restores the vasoconstriction in 
rat aorta treated with lipopolysaccharide. 
Chiou, W. F., Lin, J. J., & Chen, C. 
F. (1998). 
12 In vivo and in vitro effects of kalmegh (Andrographis paniculata) 
extract and andrographolide on hepatic microsomal drug 
metabolizing enzymes. 
Choudhury, B. R., Haque, S. J., & 
Poddar, M. K. (1987). 
13 Andrographolide and kalmegh (Andrographis paniculata) extract: 
In vivo and in vitro effect on hepatic lipid peroxidation. 
Choudhury, B. R., & Poddar, M. K. 
(1984). 
14 Filaricidal properties of a wild herb, Andrographis paniculata. Dutta, A., & Sukul, N. C. (1982). 
15 The effect of Andrographis paniculata Nees in alleviating the 
myocardial ischemic reperfusion injury. 
Guo, Z. L., Zhao, H. Y., & Zheng, 
X. H. (1994). 
16 An experimental study of the mechanism of Andrographis 
paniculata Nees in alleviating the Ca
²+
)-overloading in the process 
of myocardial ischemic reperfusion. 
Guo, Z. L., Zhao, H. Y., & Zheng, 
X. H. (1995). 
17 Hepatoprotective activity of andrographolide against 
galactosamine & paracetamol intoxication in rats 
Handa, S. S., & Sharma, A. (1990a) 
18 Hepatoprotective activity of andrographolide from Andrographis 
paniculata against carbontetrachloride. 
Handa, S. S., & Sharma, A. (1990b). 
19 Antihepatotoxic effects of major diterpenoid constituents of 
Andrographis paniculata. 
Kapil, A., Koul, I. B., Banerjee, S. 
K., & Gupta, B. D. (1993). 
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20 Double-blind, placebo-controled pilot and phase iii study of 
activity of standardized Andrographis paniculata herba Nees 
extract fixed combination (kang jang) in the treatment of 
uncomplicated upper-respiratory tract infection. 
Melchior, J., & AA., S. (2000). 
21 The usage of Andrographis paniculata following extracorporeal 
shock wave lithotripsy (eswl) 
Muangman, V., Viseshsindh, V., 
Ratana-Olarn, K., & Buadilok, S. 
(1995). 
22 Andrographis paniculata in the symptomatic treatment of 
uncomplicated upper respiratory tract infection: Systematic 
review of randomized controlled trials. 
Poolsup, N., Suthisisang, C., 
Prathanturarug, S., Asawamekin, A., 
& Chanchareon, U. (2004). 
23 Anti-microbial activity of Andrographis paniculata. Prajjal, K., Singha, Roy, & Dey, S. 
(2003). 
24 Andropanolide and isoandrographolide, minor diterpenoids from 
Andrographis paniculata: Structure and x-ray crystallographic 
analysis. 
Pramanick, S., Banerjee, S., Achari, 
B., Das, B., Sr. Sen, A. K., 
Mukhopadhyay, S., et al. (2005). 
25 Immunostimulant agents from Andrographis paniculata. Puri, A., Saxena, R., Saxena, R. P., 
Saxena, K. C., Srivastava, V., & 
Tandon, J. S. (1993). 
26 Andrographolide, a potential cancer therapeutic agent isolated 
from Andrographis paniculata 
Rajagopal, S., Kumar, R. A., Deevi, 
D. S., Satyanarayana, C., & 
Rajagopalan, R. (2003). 
27 Hepatoprotective effects of Andrographis paniculata against 
carbon tetrachloride-induced liver damage. 
Rana, A. C., & Avadhoot, Y. (1991). 
28 Chemistry and pharmacology of Andrographis species. Saxena S., Jain D.C., & S., R. 
(1997). 
29 Ent-labdane diterpenoids from Andrographis paniculata. Shen, Y.-H., Li, R.-T., Xiao, W.-L., 
Xu, G., Lin, Z.-W., Zhao, Q.-S., et 
al. (2005). 
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30 Andrographolide prevents oxygen radical production by human 
neutrophils: Possible mechanism(s) involved in its anti-
inflammatory effect. 
Shen, Y. C., Chen, C. F., & Chiou, 
W. F. (2002). 
31 Choleretic effect of andrographolide in rats and guinea pigs. Shukla, B., & Visen, P. K. (1992). 
32 Modulatory influence of Andrographis paniculata on mouse 
hepatic and extrahepatic carcinogen metabolizing enzymes and 
anti-oxidant status 
Singh, R. P., Banerjee, S., & Rao, A. 
R. (2001). 
33 Anti-microbial activity of Andrographis paniculata. Singha, P. K., & Roy, S. (2003). 
34 Targeting of liposomal andrographolide to L. Donovani-infected 
macrophages in vivo 
Sinha, J., Mukhopadhyay, S., Das, 
N., & Basu, M. K. (2000) 
35 Cytotoxic diterpenoid constituents from Andrographis paniculata 
Nees leaves. 
Cytotoxic diterpenoid constituents 
from andrographis paniculata nees 
leaves. 
36 The screening of extracts from goniothalamus scortechinii, 
aralidium pinnatifidum and Andrographis paniculata for anti-
malarial activity using the lactate dehydrogenase assay. 
Siti Najila, M. J., Noor Rain, A., 
Mohamad Kamel, A. G., Syed Zahir, 
S. I., Khozirah, S., Lokman Hakim, 
S., et al. (2002). 
37 Efficacy of Andrographis paniculata Nees for pharyngotonsillitis 
in adults. 
Thamlikitkul, V., Dechatiwongse, 
T., Theerapong, S., Chantrakul, C., 
Boonroj, P., Punkrut, W., et al. 
(1991). 
38 Hepatoprotective and toxicological evaluation of Andrographis 
paniculata on severe liver damage 
Trivedi, N., & Rawal, U. M. (2000). 
39 Hepatoprotective and anti-oxidant property of Andrographis 
paniculata (Nees) in bhc induced liver damage in mice. 
Trivedi, N. P., & Rawal, U. M. 
(2001). 
40 Prevenion of atherosclerotic arterial stenosis and restenosis after 
angioplasty with Andrographis paniculata Nees and fish oil. 
Experimental studies of effects and mechanisms. 
Wang, D., & Zhao, H. (1994). 
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41 Antihyperglycemic effect of andrographolide in streptozotocin-
induced diabetic rats 
Yu, B. C., Hung, C. R., Chen, W. C., 
& Cheng, J. T. (2003). 
 
42 Cardiovascular activity of 14-deoxy-11,12-
didehydroandrographolide in the anaesthetised rat and isolated 
right atria. 
Zhang, C., Kuroyangi, M., & Tan, 
B. K. (1998). 
43 Mechanisms of cardiovascular activity of Andrographis 
paniculata in the anaesthetized rat 
Zhang, C. Y., & Tan, B. K. (1997). 
44 Anti-diabetic property of ethanolic extract of Andrographis 
paniculata in streptozotocin-diabetic rats. 
Zhang, X. F., & Tan, B. K. (2000b). 
45 Anti-hyperglycaemic and anti-oxidant properties of Andrographis 
paniculata in normal and diabetic rats 
Zhang, X. F., & Tan, B. K. (2000b). 
46 [study of Andrographis paniculata extracts on anti-platelet 
aggregation and release reaction and its mechanism] 
Zhang, Y. Z., Tang, J. Z., & Zhang, 
Y. J. (1994) 
47 Protective effects of Andrographis paniculata Nees on post-
infarction myocardium in experimental dogs 
Zhao, H. Y., & Fang, W. Y. (1990). 
48 Antithrombotic effects of Andrographis paniculata Nees in 
preventing myocardial infarction 
Zhao, H. Y., & Fang, W. Y. (1991). 
49 Antifertility effect of Andrographis paniculata in mice. Zoha, M. S., Hussain, A. H., & 
Choudhury, S. A. (1989). 
 
 
 
 
 
 
 
 
 319
Appendix II Chemicals and chemical suppliers 
APS Ajax Finechem, 9 Short Street, Auburn, NSW, Australia 
Calcium Chloride Dihydrate Ca Cl2. 2H2O, MW 147.02 (Analytical reagent) 
Magnesium Sulphate Hydrated Mg SO4.7H2O, MW 246.67 (Analytical reagent) 
Potassium Chloride KCl, MW 74.55 (Analytical reagent) 
Sodium Hydrogen Carbonate NaHCO3, MW 84.01, Assay 99.7, 100.3% 
NaH2PO4 0.41, MW 156.01 
BDH AnalaR Merck Pty Limited Chemicals (Australia), Kilsyth, VIC 313 , Australia 
Ascorbic acid 
1, 1-Diphenyl-2-picryhydrazyl (DPPH) 
Disodium ethylenediamine-tetra acetic acid [CH2N(CH2 COOH). CH2COONa]2 H2O, EDTA, 
Deoxyribose 
Ethanol, C2H5OH, absolute, BDHA, 99.7-100% v/v 
Ethylenediaminetetraacetic acid EDTA 
Horseradish peroxidase  
Hydrogen peroxide 
Iron (III) chloride 
Methanol CH3OH, absolute, 100% v/v, Density 0.79g/ml 
Methanol CH3OH, Hipersolv for HPLC 
Potassium dihydrogen orthophosphate KH2PO4, MW 136.09 
Potassium hydroxide KOH 
Sodium hydroxide NaOH 
Thiobarbituric acid TBA  
Thiochloroacetic acid TCA 
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BDL 
Heparin sodium injection 
Fluka Chemie GmbH, ch-9471 Buchs, Switzerland 
Di-sodium hydrogen phosphate dihydrate puriss.p.a.for HPLC, HNa2P.2H2O, MW 177.99, 
Assay 99% (T) 
1-octanesulfonic acid sodium salt monohydrate, C8H17 NaO3 S. H2O, MW 234.29 
ICN Biomedicals Inc 1263 South Chillicothe Road, Aurora, Ohio. 
Sodium dodecyl sulphate Ultra pure, MW 288.38  
Sigma-Aldrich Chemical Co., St. Louis, MO, USA 
Acetylcholine  
Boric acid, H3 BO3, MW 61.83  
Bovine serum albumin (BSA) 
Compound 48/80 
D-(+)-Glucose (Dextrose, Corn Sugar Anhydrous) C6H12O6, MW 180.2, > 99.5% (HPLC) 
Glucose 1%, MW 180.16 
Histamine injection  
L-Arginine Hydrochloride C6H14N4O2 .HCl, Sigma Ultra >99% (TLC) 
Lipopolysaccharide Escherichia Coli Serotype 0127: B8, L-3129, 
L-NAME 
L-(+)-Tartaric acid, C4H6O6, MW 150.09 
Lyophilized powder prepared by phenol extraction 
Magnesium Chloride Dihydrate, MW 95.21 
N-2-hydroxyethylpiperazine-N’-ethanesulfonic acid (HEPES 10), MW 238.31 
O-Phthalaldehide (OPA) 
Phenylephrine 
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Sodium Chloride NaCl, MW 58.44, 99.5% 
Sodium Hydroxide NaOH, MW 40.00, 98% 
Spermidine trihydrochloride,  
Sodium tartrate dibasic dihydrate minimum 99.0%  acid C4H4Na2O6.  2H2O, MW 230.08 
Tartaric acid, MW 150.1 
Invitrogen Corporation, Gibco, Auckland, NZ 
Trypan Blue Stain 0.4% 
Crown Science 
Whatman Filter paper No. 1, 150mm, Qualitative Circles, 150mm Dia Cat No 1001 150. 
Dionex Pty Ltd, Lanecove, 1595, NSW 
Dionex ASE Filter paper Part No. 056780 Grade D28, Size 30mm 
Chemsal Pty Limited, Lab Chem Class 6.1, Australia 
Celite (A Diatomite Product) 
E. Merck, Darmstardt, Germany 
HPTLC Aluminium sheets, silica gel, F254, precoated 
Kieselgel 60 (silica gel 60), particle size 0.040-0.063, 230-400 mesh ASTM  
Monash Animal Centre, Monash University, Clayton, VIC, Australia 
Spargue-Dawley rats, male, out bred 
Qiagen Pty Ltd, Clifton Hill, Victoria, Australia 
DNeasy Plant Mini Kit (50) 
DNeasy Plant Maxi Kit (250) 
Reagents for PCR amplification  
PCR buffer (Tris-HCl, KCl, gelatin)  
Invitrogen, Pty Ltd, Australia 
Taq DNA Polymerase Recombinant 
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Taq Polymerase Recombinant (500 units) 
Taq Polymerase Recombinant (250 units) 
MgCl2  
100 mM dNTP   Set (4x25µmol) 
100 mM dTTP 
100 Mm dGTP 
100 Mm dATP 
100 Mm dCTP 
deoxynucleotide triphosphate mixture (dNTPs),  
10-mer primers (Operon, Technologies, USA),  
1.5% Agarose gel for electrophoresis 
Loading Dye  
Marker/Ladder 
Polaroid 667 film 
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Appendix III Instrumentation and equipment 
Alltech Associate, Australia Brookhollow Ave Baulkham Hills, NSW 2153 
Alpha-bond C18 Column (300x3.9mm, I.D. 10 µm) Part No. 7701 
Beckman Coulter Inc., Fullerton, CA, USA 
Beckman J2-21 M/E High Speed Centrifuge 
Biofuge Heraeus Centrifuge in cold room. 
Buchi Laboratortechnik AG, Flawil, Switzerland 
Buchi RE 011 Rotavapor 
Buchi Rotavapor, Brinkman company, Westbury, NY, USA  
Brinkman Instruments Inc., Westbury, NY, USA 
CAMAG.Sonnenmattstr.11.CH-4132 Muttenz (Switzerland) 
CAMAG Linomat 5 
CAMAG Nanomat and Capillary Dispenser 
CAMAG Horizontal Developing Chamber 2  
Dionex Pty Ltd, Lanecove, 1595, NSW 
Dionex ASE (Accelerated Solvent Extraction) 100 Extraction System 
Dionex Corporation Filter sizes 25mm, 30mm, P/N 056781, Rev.1, GF/B Filter    
Dupont Supa Refrigerants, Asheville North Carolina USA 
Legaci Refrigeration System, Revco Freezer -80ºC, Quantum Scientific 
Dynavac FD 12 (Airvac Engineering Pty Ltd, Melbourne, Australia) 
Eppendorf  5415 C centrifuge 
HD Scientific (Hettich Zentrifugen) 
CFC Free Centrifuge 
Hitachi Ltd., Tokyo, Japan 
F-2000 Fluorescence Spectrophotometer 
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U-3200 UV-Vis Spectrophotometer 
IEC, Australia Industrial Equipment & Control Pty Ltd. 
pH meter Magnetic Stirrer Model 208-1 
Pierce Reacti-Therm Heating Module  
Reacti-Vap and Evaporating unit, Rockford, Illinos, USA 
Roche Diagnostic Australia Pty Ltd 31, Vic, Avenue 
Thermo Electron Corporation PX2 Thermal cycle 
Hot Plate Heater and Magnetic Stirrer 
Radiometer Analytical SA, Lyon, France 
PHM61 Laboratory pH Meter 
Shimazu Corporation, Kyoto, Japan 
Shimazu High Performance Liquid Chromatography system: 
Shimazu SPD-M10Avp system Photodiode Array Ultraviolet/Visible Detector 
SIL-10AD VP Shimazu Auto Injector 
LC-10AD AT VP Liquid Chromatograph 
FCV-10 AL. VP Leak 
DGU-14A Degasser 
RF-10A XL Fluorescence Detector 
CTO-10A VP Column oven 
SCL-10A VP System controller 
LC-10AT VP Liquid Chromatograph 
FRC-10A Fraction Collector 
STR ODS-II reverse-phase column (4.6mm I.D.x 150 mm length, Shimadzu) with Fluorescent 
Detector 
Microsoft Windows XP Pentium 4 
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Shimazu UV-160, UV-Visible recording Spectrophotometer 
Quincy, Mass, USA 
MacLab/4, Analog Digital Instruments Digitimer Ltd Multistim-system D330 
MacLab/4e 
Myograph Lab, Apple Computer Grass medical instrument, Model S88D 
Quantum Scientific 
Capsulefuge Tomy PMC-060 
 
 
 
 
 
